A world-class team of innovative researchers and caring physicians focused on solving some of the most complex problems in medicine...

Dr. Cindy Bailey
Chondrogen Patient
Knee Repair

Giuseppe Visani, M.D.
Hematology and Bone Marrow Transplantation
San Salvatore Hospital
Italy

Mark Vesely, M.D.
Interventional Cardiology
University of Maryland Medical Center

Hans Klingemann, M.D., Ph.D.
Oncology and Hematological Malignancies
Tufts Medical Center

Paul Martin, M.D.
Medical Oncology,
Hematopoietic Cell Transplantation
Fred Hutchinson Cancer Research Center

Jeff Szer, M.D.
Hematology and Bone Marrow Transplantation
Royal Melbourne Hospital
Australia

C. Thomas Vangsness, Jr., M.D.
Orthopedic Surgeon
University of Southern California

Hans Klingemann, M.D., Ph.D.
Oncology and Hematological Malignancies
Tufts Medical Center

C. Thomas Vangsness, Jr., M.D.
Orthopedic Surgeon
University of Southern California

Jeff Szer, M.D.
Hematology and Bone Marrow Transplantation
Royal Melbourne Hospital
Australia

C. Thomas Vangsness, Jr., M.D.
Orthopedic Surgeon
University of Southern California
…driven to help, where hope is needed most, in more than 250 leading centers across the country and around the world.

understanding

The power of comprehension.
The strength of compassion.
The resolve of commitment.
Right Now. Osiris is bringing new therapies to patients in need.

From commercializing the world's first stem cell product to the launch of our expanded access program for Prochymal, Osiris is leading the way.

- Founded Osiris
- Began mesenchymal stem cell preclinical development
- Initiated first Phase I human trial using MSCs
- Began MSC product manufacturing

1992

1997

1998

1999

2000

2003

2004

2005

2006

- Published key paper in Science demonstrating broad therapeutic utility of MSCs
- Initiated first Phase I/II trial for Prochymal in pediatric bone marrow transplant patients
- Partnered with JCR Pharmaceuticals to develop Prochymal for GvHD in Japan
- Demonstrated safety of Prochymal in adult and pediatric patients in early clinical trials
- Initiated Phase II trial evaluating Prochymal in acute GvHD
- Launched first stem cell product, Osteocel, for the repair of bone defects
- Received first Fast Track designation from FDA for a stem cell product
- Granted FDA Orphan Drug designation for Prochymal in GvHD
- Achieved a 77% complete remission rate in a Phase II trial for Prochymal in acute GvHD
- Initiated the first-ever FDA approved Phase III pivotal stem cell trial for steroid-refractory GvHD
- Completed initial public offering of OSIR on the NASDAQ
- Granted European GMP certification for Prochymal manufacturing process
- Improved Crohn’s disease patient outcomes in Phase II trial for Prochymal

Jin-Qiang Kuang, M.D.
Research Scientist, Discovery

Robert Newman, Ph.D.
Senior Manager, Biosurgery

Dayna Buskirk
Senior Director, Biosurgery

Tammy Oblander
Supervisor, Quality Control
• Granted Fast Track status by FDA for Prochymal in Crohn’s disease – Phase III clinical trial initiated
• Granted European Orphan Drug designation for Prochymal
• Improved heart attack patient outcomes in Phase I trial for Prochymal
• Partnered with Juvenile Diabetes Research Foundation for type 1 diabetes

2007

• Formed major alliance with Genzyme for the commercialization of Prochymal and Chondrogen
• Awarded Department of Defense contract for Prochymal for Acute Radiation Syndrome
• Demonstrated lasting benefit to patients receiving Prochymal in placebo-controlled heart attack trial
• Completed enrollment in first-ever Phase III stem cell trial for steroid-refractory GvHD
• Received approval from FDA and Health Canada for pediatric GvHD expanded access program
• Sold Osteocel business for $85M after generating revenues of over $40M

2008

• Achieved a 63% response rate when Prochymal is used as a rescue agent in children with end-stage GvHD
• Achieved significant improvement in response rates over standard of care for liver and gastrointestinal steroid-refractory GvHD
• Received approval from FDA for adult GvHD expanded access program
• Completed enrollment in Phase II type 1 diabetes trial
• Created a new Biosurgery division focused on developing high-end biologic products for use in surgical procedures

2009

• Demonstrated lasting benefit to patients receiving Prochymal in placebo-controlled heart attack trial
• Completed enrollment in first-ever Phase III stem cell trial for steroid-refractory GvHD
• Received approval from FDA for adult GvHD expanded access program
• Created a new Biosurgery division focused on developing high-end biologic products for use in surgical procedures

Robert Gagne
Prochymal Patient
Crohn’s Disease

Rod Monroy, Ph.D.
Senior Director,
Expanded Access Program

Dayna Buskirk
Senior Director,
Biosurgery

Doug Jacobstein, M.D.
Pediatric Gastroenterologist,
Medical Affairs

Right Now.
Smart, sustainable production

Osiris has developed a business model and manufacturing process that supports wide-scale adoption of this potentially game-changing technology. It starts with bone marrow taken from a healthy adult donor’s hip. We have a proprietary manufacturing process at commercial scale for the expansion of our stem cells that allows for the treatment of over 10,000 patients with product manufactured from a single bone marrow donation. It is a process that has been time tested and proven to deliver large-scale quantities of pharmaceutical-grade stem cells that have passed rigorous quality testing. Our products can then be stored frozen for long periods of time and immediately administered when needed via a standard intravenous infusion or direct injection.
These stem cells have the natural ability to detect injury and respond accordingly, diminishing inflammation and promoting repair.

**Infants**

Infants respond to injury in an almost miraculous way. MSCs are present in very large numbers, resulting in tremendous regenerative capabilities, a controlled inflammatory response, and little fibrosis or scarring.

**Adults**

As we age, the number of MSCs in the body declines, and an adult’s response to injury is very different from that of an infant. Adults have limited regenerative capabilities, pronounced inflammatory responses, and increased scarring.

**With MSCs**

Osiris’ mesenchymal stem cell therapies increase the number of MSCs available for healing and change the way that we respond to injury. Increasing the number of high-quality MSCs reduces inflammation, increases the tissue regenerative capabilities of the body, and reduces the amount of scarring that typically occurs following injury.
Throughout all of this, Yasmeen has been so strong, and we are so proud of our little girl... Thank you for never giving up.

March 16, 2010

Dear Osiris,

Our daughter Yasmeen was diagnosed with leukemia in October 2005 at the tender age of two years old. It was a parent’s worst fear, but we were determined to meet it head-on, and began chemotherapy immediately. For the most part, Yasmeen did well.

However, we were given the bad news that her cancer returned in November 2007. Her oncologist told us that a bone marrow transplant would give Yasmeen the best possible chance of beating the cancer. Yasmeen had a bone marrow transplant in March 2008. She did well initially, but other issues developed during her recovery. We were then informed that she was in need of another bone marrow transplant. She had her second transplant in May 2009. Throughout all of this, Yasmeen has been so strong, and we are so proud of our little girl.

During her second transplant, Yasmeen developed severe GvHD. Her skin was peeling and her intestines were hemorrhaging. She had to be transferred to the ICU, and we hoped and prayed for a miracle.

Our doctors tried everything, but nothing seemed to help.

Finally, one of them recommended that we try Prochymal, which we did.

We were very scared and had many questions... about everything. But we started to see results right away. Soon, the bleeding stopped and she was able to leave the ICU. Before long, Yasmeen was back to working on crafts, like a six-year-old should.

Today Yasmeen is home with us, and we will soon be celebrating her 7th birthday. We are so grateful to all of the doctors and other medical staff, to the donors, and to Osiris for being there when we needed you most and for understanding just how precious Yasmeen is to us.

Thank you for never giving up,
Ivan and Judy

Commitment to Compassion

In 2007, Osiris initiated a compassionate use program for children with life-threatening GvHD. The program provides Prochymal to children who are in desperate need of help. In late 2008, the United States FDA granted Osiris Expanded Access status for Prochymal, making it easier and faster for these children to receive therapy when they need it most. Osiris is treating children just like Yasmeen across the country and around the world.

Right Now:
DEAR SHAREHOLDERS,

“Things didn’t work out as we had hoped. Things went wrong no matter how hard we tried. Problems arose that seemed so overwhelming, we didn’t know what else to do.”

These are the feelings the parents of children with GvHD face every day. They fight back thoughts of helplessness and despair as they battle together with their child for life itself. But how they respond in the face of unimaginable adversity is, in a word, inspiring.

Seeing that the road ahead will be hard, they drive on with unshakeable determination. Throughout the pain, they never lose focus. Presented with the risks, they respond with courage.

Yasmeen’s story is one of many powerful examples. It seems so unfair that a child should have to endure so much—first, by surviving leukemia that couldn’t be cured with chemotherapy alone, then to suffer through not one, but two bone marrow transplants, only to develop life-threatening GvHD. But with the strength of her mom and dad, the skill of her outstanding team of doctors and nurses, and her own everlasting will, Yasmeen overcame it all.

These are the people we are privileged to help, the experiences we are honored to share, and the lessons that shape our thoughts and actions. These are the lives we are fighting for. For them, this is not a game to be won or lost, nor is it a hypothesis to be tested. For them, this is everything.

We are on a mission. It is simple and clear, yet holds the power to change the face of modern medicine. We are committed to obtaining the first full approval for a stem cell therapy. We understand it is not easy and that there can be no shortcuts along the way. But we also understand what is at stake.

We thank you, our shareholders, for sharing our vision and for standing with us as we fight for what matters most—the patients and families we serve.

Sincerely,

C. Randal Mills, Ph.D.
President and Chief Executive Officer

Peter Friedli
Chairman of the Board

Micah Fleming
Prochymal Patient
GvHD
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-K

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934:

For the fiscal year ended December 31, 2009

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934:

For the transition period from _______ to _______

Commission file number 001-32966

Osiris Therapeutics, Inc.
(Exact name of registrant as specified in its charter)

Delaware 71-0881115
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)

7015 Albert Einstein Drive, Columbia, Maryland 21046-1707
(Address of principal executive offices) (Zip Code)

443-545-1800
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class Name of Each Exchange on with Registered

Common Stock, $0.001 par value NASDAQ Global Market

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities
Act. Yes ☒ No ☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of
the Act. Yes ☒ No ☐

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of
the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if
any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
and post such files). Yes ☒ No ☐

Indicate by check mark whether disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained
herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller
reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐ Accelerated filer ☒ Non-accelerated filer ☐ Smaller reporting company ☐
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

On June 30, 2009, the last business day of the registrant’s most recently completed second fiscal quarter, the
aggregate market value of voting Common Stock held by non-affiliates of registrant, based upon the last sale price of the
Common Stock reported on the NASDAQ Global Market was approximately $300,876,000.

The number of shares of the registrant’s Common Stock outstanding as of March 10, 2010 is 32,775,331.

Documents Incorporated by Reference:

Portions of the Registrant’s definitive proxy statement for its 2010 Annual Meeting of Stockholders (the “Proxy
Statement”) to be filed no later than 120 days after the close of the fiscal year are incorporated herein by reference in
Part III.
# INDEX

## PART I

<table>
<thead>
<tr>
<th>Item</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Item 1. Business</td>
<td>3</td>
</tr>
<tr>
<td>Item 1A. Risk Factors</td>
<td>29</td>
</tr>
<tr>
<td>Item 1B. Unresolved Staff Comments</td>
<td>48</td>
</tr>
<tr>
<td>Item 2. Properties</td>
<td>48</td>
</tr>
<tr>
<td>Item 3. Legal Proceedings</td>
<td>48</td>
</tr>
<tr>
<td>Item 4. Removed and Reserved</td>
<td>48</td>
</tr>
</tbody>
</table>

## PART II

<table>
<thead>
<tr>
<th>Item</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Item 5. Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</td>
<td>49</td>
</tr>
<tr>
<td>Item 6. Selected Financial Data</td>
<td>51</td>
</tr>
<tr>
<td>Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations</td>
<td>52</td>
</tr>
<tr>
<td>Item 7A. Quantitative and Qualitative Disclosures About Market Risk</td>
<td>65</td>
</tr>
<tr>
<td>Item 8. Financial Statements and Supplementary Data</td>
<td>66</td>
</tr>
<tr>
<td>Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</td>
<td>102</td>
</tr>
<tr>
<td>Item 9A. Controls and Procedures</td>
<td>102</td>
</tr>
<tr>
<td>Item 9B. Other Information</td>
<td>102</td>
</tr>
</tbody>
</table>

## PART III

<table>
<thead>
<tr>
<th>Item</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Item 10. Directors, Executive Officers and Corporate Governance</td>
<td>102</td>
</tr>
<tr>
<td>Item 11. Executive Compensation</td>
<td>102</td>
</tr>
<tr>
<td>Item 13. Certain Relationships and Related Transactions, and Director Independence</td>
<td>103</td>
</tr>
<tr>
<td>Item 14. Principal Accounting Fees and Services</td>
<td>103</td>
</tr>
</tbody>
</table>

## PART IV

<table>
<thead>
<tr>
<th>Item</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Item 15. Exhibits, Financial Statement Schedules</td>
<td>103</td>
</tr>
</tbody>
</table>
PART I

ITEM 1. Business.

CAUTIONARY STATEMENTS ABOUT FORWARD-LOOKING INFORMATION

This Annual Report on Form 10-K includes “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. Statements included or incorporated herein which are not historical facts are forward looking statements. When used in this Annual Report, the words estimates, expects, anticipates, projects, plans, intends, believes, forecasts and variations of such words or similar expressions are intended to identify forward-looking statements, but these terms are not the exclusive means of identifying forward looking statements.

Forward looking statements reflect management’s current views with respect to future events and performance and are based on currently available information and management’s assumptions regarding future events. While management believes that its assumptions are reasonable, forward-looking statements are subject to various known and unknown risks and uncertainties and actual results may differ materially from those expressed or implied herein. In connection with the “safe harbor provisions” of the Private Securities Litigation Reform Act of 1995, the Company notes that certain factors, among others, which could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein are discussed in greater detail under Item 7; “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Item 1A “Risk Factors,” and may be discussed elsewhere herein or in other documents we file with the Securities and Exchange Commission, or SEC. Examples of forward-looking statements may include, without limitation, statements regarding any of the following: our product development efforts; our clinical trials and anticipated regulatory requirements, and our ability to successfully navigate these requirements; the success of our product candidates in development; status of the regulatory process for our biologic drug candidates; implementation of our corporate strategy; our financial performance; our product research and development activities and projected expenditures, including our anticipated timeline and clinical strategy for mesenchymal stem cells (MSCs) and biologic drug candidates (including Prochymal® and Chondrogen®); our cash needs; patents, trademarks and other proprietary rights; the safety and ability of our potential products to treat disease; our ability to supply a sufficient amount of our product candidates and, if approved, products to meet demand; our costs to comply with governmental regulations; our relationship with collaborating partners; our ability to maintain and benefit from our collaborative arrangements; our ability to benefit from government contracts; our plans for sales and marketing; our plans regarding facilities; types of regulatory frameworks we expect will be applicable to our potential products; and results of our scientific research.

Readers are cautioned that all forward-looking statements attributable to us or persons acting on our behalf apply only as of the date of this Annual Report and are expressly qualified in their entirety by the cautionary statements included herein. We undertake no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances and do not intend to do so.

When we use the terms “Osiris,” “we,” “us,” and “our” we mean Osiris Therapeutics, Inc., a Delaware corporation.

Company Overview

We are a leading stem cell therapeutic company headquartered in Columbia, Maryland and focused on developing and marketing products to treat serious medical conditions in the inflammatory, autoimmune, orthopedic, and cardiovascular areas. We were incorporated in Delaware in April 2002. Our predecessor company was organized in 1992. Our lead biologic drug candidate, Prochymal®, is
being evaluated in Phase III clinical trials for four indications, including acute and steroid refractory graft versus host disease (“GvHD”), Crohn’s disease and for the repair of gastrointestinal injury resulting from radiation exposure, and is the only stem cell therapeutic currently granted both Orphan Drug and Fast Track status by the United States Food and Drug Administration (“FDA”). Prochymal is also being developed for the repair of heart tissue following a heart attack, and for protection of pancreatic islet cells in patients with type 1 diabetes. Our pipeline of internally developed biologic drug candidates under evaluation also includes Chondrogen® for osteoarthritis in the knee.

In the fourth quarter of 2008, we entered into a collaboration agreement with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen. Under the terms of the agreement, we retained the rights to commercialize Prochymal and Chondrogen in the United States and Canada and Genzyme has been granted exclusive rights to commercialize Prochymal and Chondrogen in all other countries, except with respect to GvHD in Japan, where Prochymal has previously been licensed to another pharmaceutical company. Under the agreement, we were paid $130 million for these rights. The agreement also provides for contingent milestone payments of up to $1.25 billion in the aggregate in addition to royalties on any sales by Genzyme to be paid by Genzyme to us.

We have also partnered with Genzyme Corporation to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. In January 2008 we were awarded a contract from the U.S. Department of Defense, pursuant to which we, in partnership with Genzyme, are seeking to develop and stockpile Prochymal for the repair of gastrointestinal injury resulting from acute radiation exposure. Additionally, we have partnered with the Juvenile Diabetes Research Foundation (“JDRF”) for the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes mellitus.

In April 2008, we committed to a plan to sell our assets related to Osteocel®, a product that we had produced and marketed since July 2005, for regenerating bone in orthopedic indications. On May 8, 2008, we entered into an Asset Purchase Agreement to sell our entire product line relating to the processing, manufacturing, marketing and selling of Osteocel to NuVasive, Inc. The total proceeds from the sale of Osteocel were $85.0 million, all of which has been received by us. The assets and operations related to Osteocel are reported as discontinued operations in the financial statements included in Item 8 to this Annual Report on Form 10-K for all periods.

In August 2009, we announced the creation of a new Biosurgery Division focused on developing and marketing high-end biological products for use in surgical procedures. We intend to build on the success of our first generation implantable product, Osteocel which generated over $40 million of revenue for us before being sold for $85.0 million in 2008. We presently plan to introduce the first product of the Biosurgery division during 2010 and expect to treat this as an operating segment beginning in fiscal 2010.

We are a fully integrated company, having developed capabilities in research, development, manufacturing, marketing and distribution of stem cell products. We have developed an extensive intellectual property portfolio to protect our technology including 49 U.S. and 278 foreign patents owned or licensed. We have 22 U.S. patent applications pending and 80 foreign patent applications pending.

Our two biologic drug candidates utilize human mesenchymal stem cells, or MSCs. MSCs can selectively differentiate, based on the tissue environment, into various tissue lineages, such as bone, muscle, fat, tendon, ligament, cartilage and bone marrow stroma. In addition, MSCs have anti-inflammatory properties and can prevent fibrosis or scarring. These characteristics give MSCs the
potential to treat a wide variety of medical conditions. We believe that our biologic drug candidates have advantages over other stem cell therapeutics in development for the following reasons:

- **Stem Cell Source.** Our stem cells are obtained from adult bone marrow, a readily available source. The cells are drawn from the hips of volunteer donors between the ages of 18 and 30 years, using a simple needle and syringe aspiration. Because the cells are obtained from consenting adult donors, we are able to largely avoid the ethical controversy surrounding embryonic and fetal stem cell research.

- **Ability to Mass Produce.** Through our proprietary manufacturing methods, we can grow MSCs in a controlled fashion to produce up to 10,000 treatments of our biologic drug candidates from a single bone marrow donation. Our ability to produce a large quantity of treatments from one donation provides us with manufacturing efficiencies and product consistency that are essential to commercialization.

- **Universal Compatibility.** Many stem cell therapies under development can elicit a rejection response in the recipient and therefore require donor-to-recipient matching or potentially harmful immunosuppression. This greatly reduces manufacturing efficiencies and creates a risk of mismatch which can result in an acute inflammatory response leading to serious medical complications and can even be fatal. Based on our clinical experience, we believe that our biologic drug candidates are not rejected by the patient’s immune system and so, like type O negative blood, do not require matching. This universal compatibility allows us to produce a standardized product available to all patients in almost any medical setting.

- **Treatment on Demand.** Our biologic drug candidates can be stored frozen at end-user medical facilities until they are needed. We anticipate that medical facilities will be able to prescribe and dispense these products in much the same way as conventional drugs. In contrast, other stem cell technologies under development require weeks to prepare after a patient’s need is identified. This is a key feature of our technology, as many patients in the critical care setting require prompt treatment.

The following table summarizes key information about our biologic drug candidates.

<table>
<thead>
<tr>
<th>Drug Candidate</th>
<th>Indication</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prochymal</strong></td>
<td>Steroid Refractory Acute GvHD</td>
<td>Phase III</td>
</tr>
<tr>
<td></td>
<td>First Line Treatment of Acute GvHD</td>
<td>Phase III</td>
</tr>
<tr>
<td></td>
<td>Treatment-Resistant Acute GvHD</td>
<td>Expanded Access</td>
</tr>
<tr>
<td></td>
<td>Biologics Refractory Crohn's Disease</td>
<td>Phase III</td>
</tr>
<tr>
<td></td>
<td>Type I Diabetes Mellitus</td>
<td>Phase II</td>
</tr>
<tr>
<td></td>
<td>Acute Myocardial Infarction</td>
<td>Phase II</td>
</tr>
<tr>
<td></td>
<td>Pulmonary Disease</td>
<td>Phase II</td>
</tr>
<tr>
<td></td>
<td>Acute Radiation Syndrome</td>
<td>Phase III (Animal Rule)</td>
</tr>
<tr>
<td><strong>Chondrogen</strong></td>
<td>Osteoarthritis &amp; Cartilage Protection</td>
<td>Phase II</td>
</tr>
</tbody>
</table>

**Prochymal**, our lead biologic drug candidate, is being evaluated in Phase III clinical trials for four indications including the first line treatment of acute graft versus host disease (“GvHD”), steroid refractory acute GvHD, biologics refractory Crohn’s disease and for the repair of gastrointestinal injury resulting from radiation exposure. Prochymal is the only stem cell therapeutic currently designated by the FDA as both an Orphan Drug and Fast Track product.

**Prochymal for Treatment-Resistant GvHD**

GvHD is a life threatening immune system reaction that commonly affects one or more of the skin, gastrointestinal tract, and liver in patients who have received a bone marrow transplant. Although
in the U.S. there are no drugs approved for treating GvHD, the disease is commonly treated off-label with steroids. GvHD that does not respond to this treatment is known as steroid refractory GvHD. A large majority of steroid refractory GvHD patients die within six months. In a Phase II trial for treatment refractory GvHD, we enrolled patients that did not respond to treatment with steroids and at least one second line therapy. Of these patients, all responded to treatment with Prochymal, and 59% achieved complete resolution of their disease. Prochymal has been granted Fast Track status by FDA as well as Orphan Drug status by FDA and the European Medicines Agency for GvHD.

In May 2008, we received clearance from the FDA to initiate an expanded access treatment program making Prochymal available to children with life threatening GvHD. Under the program, children, 2 months to 17 years of age, with Grades B-D acute GvHD that hasn’t responded to steroids are eligible for treatment. Upon completion of enrollment of the Phase III trials evaluating Prochymal in adults with GvHD, the expanded access program was broadened to include patients 18 to 70 years of age. The expanded access programs for Prochymal in treating adult and pediatric patients with refractory GvHD are ongoing.

In February 2010, we reported the results of a study evaluating Prochymal as a rescue therapy in 59 pediatric patients with severe, treatment-resistant acute GvHD. The trial enrolled patients with Grades B-D acute GvHD who had failed steroids and other immunosuppressive agents. Patients in the study received two intravenous infusions of Prochymal per week for a total of four weeks. Patients who experienced a partial response by day 28 were eligible for continued treatment. GvHD assessments were used in the study to detect improvements in patients treated with Prochymal. At study entry, 90% of children had Grade C/D GvHD, the most severe forms of GvHD and were unresponsive to an average of three lines of therapy. Overall response to treatment with Prochymal at 28 days was 63%. Response to Prochymal at day 28 significantly improved survival over those patients who progressed (78% vs. 9%, p<0.05). Patients in the trial were treated at 33 pediatric transplant centers across the U.S., Canada, Europe and Australia.

In September 2009, we announced the preliminary results for the two Prochymal Phase III GvHD trials described below. While the trials did not reach significance in their primary endpoints, the studies did reveal several important findings:

- The primary endpoint for the steroid-refractory GvHD trial (durable complete response) for the per protocol population approached statistical significance (40% Prochymal vs. 28%, standard of care, p=0.08, n=179);
- Prochymal significantly improved response in steroid-refractory liver (76% vs. 47%, p=0.03) and gastrointestinal GvHD (82% vs. 68%, p=0.03);
- In the sickest patients—those with GvHD affecting all three organs, skin, liver and gastrointestinal tract—treatment with Prochymal resulted in a 63% overall response rate, while none of the placebo-treated patients responded (p<0.05);
- Children receiving Prochymal had an overall response rate of 64% compared to 36% in patients receiving placebo; and
- In children with steroid-refractory GvHD, Prochymal more than doubled complete response rates (64% vs. 29%) and reduced disease progression by half (21% vs. 43%).

**Phase III Clinical Trial—Steroid Refractory Acute GvHD**

Our Phase III trial evaluated the safety and efficacy of Prochymal in conjunction with standard of care for the treatment of patients who had failed to respond to corticosteroid treatment for acute GvHD. This clinical trial is a double-blind, placebo-controlled study. Patients six months to 70 years of age were randomized to receive Prochymal or placebo at a 2:1 ratio in addition to standard of care.
The trial enrolled 260 patients and treated 244 patients from 72 leading bone marrow transplant centers in the United States, Canada, Europe and Australia.

The primary endpoint, durable complete response, for the per-protocol population in the Phase III trial evaluating Prochymal in steroid-refractory GvHD approached but did not reach statistical significance, with 40% of patients receiving Prochymal, as compared to 28% of placebo patients, achieving a durable complete response. The per-protocol patient population refers to the group of patients that met all of the study protocol requirements, such as inclusion and exclusion criteria. The addition of Prochymal to standard of care significantly improved response in steroid-refractory liver (76% vs. 47%, p=0.03) and gastrointestinal (82% vs. 68%, p=0.03) GvHD. In the sickest patients—those with GvHD affecting all three organs—skin, liver and gastrointestinal tract—treatment with Prochymal resulted in a 63% overall response rate, while none of the placebo-treated patients responded (p<0.05). Prochymal also demonstrated a positive safety profile relative to placebo.

The pediatric subset in the Phase III trial evaluating Prochymal in steroid-refractory acute GvHD was also evaluated. Those pediatric patients receiving Prochymal had an overall response rate of 64%, compared to 36% in pediatric patients receiving placebo. Prochymal patients exhibited a complete response rate more than double that of placebo patients (64% vs. 29%) and exhibited a reduction in disease progression by half (21% vs. 43%). Survival was also improved in those patients receiving Prochymal, as 79% of pediatric patients receiving Prochymal survived thru day 100 versus 50% of those receiving placebo.

**Phase III Clinical Trial—First Line Treatment of Acute GvHD.**

Our previous Phase II trial for treatment of newly diagnosed acute GvHD indicated that patients were twice as likely to have total clinical resolution of their disease when Prochymal was added to steroid therapy, compared to reported results for treatment with steroids alone. Twenty-nine of 31 patients, or 94%, responded in the Phase II trial, after receiving two infusions of Prochymal, with 24 patients, or 77% achieving a complete response, meaning the patients had experienced total clinical resolution of the disease. At six months, 61% of all patients treated with Prochymal still had a durable response requiring no additional immunosuppressive therapy, clinical intervention, or increased steroid use. Of these, 95% were alive at six months.

The Phase III trial to evaluate Prochymal as a first line treatment for GvHD is a randomized, double blind, placebo controlled study that completed enrollment with 192 patients from 52 leading transplant centers across the United States, Canada and Australia. Patients received a total of six infusions during the first four weeks of the study. The trial did not meet its primary endpoint. However, the majority of patients enrolled in this trial were suffering from skin GvHD, which responded significantly better to steroids than had previously been reported in controlled trials. This high response rate to standard of care diminished the potential for Prochymal to demonstrate an effect.

**Phase III Clinical Trial—Biologics Refractory Crohn’s Disease.**

Based on our clinical observations of the effects of Prochymal on the gastrointestinal symptoms of patients with GvHD, we are developing Prochymal for the treatment of Crohn’s disease. Crohn’s disease is a chronic condition that results in inflammation of the gastrointestinal tract. We completed patient enrollment in a Phase II trial for Crohn’s disease under a separate Investigational New Drug application (“IND”). We received Fast Track designation from the FDA for the development of Prochymal for patients with moderate to severe Biologics Refractory Crohn’s Disease.

Patients were enrolled in a Phase III trial evaluating Prochymal for the treatment of moderate to severe Crohn’s disease that is refractory to biological therapy. The placebo-controlled, double-blind study was designed to enroll 270 patients, 18 to 70 years of age, with a Crohn’s Disease Activity Index ("CDAI") greater than 250. The primary endpoint of this trial is the proportion of patients with CDAI of less than 150 (clinical remission) at day 28. Patients were enrolled at approximately 60 leading centers in the United States and Canada.
Enrollment in the Phase III trial was ended at 207 patients after the trial’s final interim analysis showed that one of the two Prochymal dose arms had crossed a futility boundary. The current standard for determining response of Crohn’s patients is largely subjective, and therefore, there may have been response bias resulting in significantly higher than expected placebo response rates.

**Phase II Clinical Trial—Acute Myocardial Infarction.**

Prochymal is also being evaluated as a therapy to improve heart function in patients who have suffered a heart attack. Based on statistics published in 2005 by the American Stroke Association and the American Heart Association, approximately 700,000 individuals in the United States each year experience their first heart attack. According to these same statistics, approximately 20% of these patients suffer extensive damage to their heart muscle leading to heart failure within six years. In preclinical studies in animal models, Prochymal targeted the damaged area of the heart following a single intravenous infusion. These studies also indicate that Prochymal prevents scar formation that typically occurs after a heart attack and improves cardiac function eight to ten weeks after its administration.

Positive two-year data was reported for a Phase I clinical trial evaluating the safety and efficacy of the intravenous administration of Prochymal in patients who experienced their first acute myocardial infarction (“AMI”). In the 53-patient, double-blind, placebo-controlled trial, patients receiving the therapy had significantly lower rates of adverse events, such as cardiac arrhythmias, as well as significant improvements in heart, lung and global function. Administration of Prochymal was found to be well tolerated at all dose levels. Based on these positive findings, we have received approval from the FDA to initiate a Phase II trial. In December 2009, results from the study were published in the *Journal of the American College of Cardiology*.

A Phase II double-blind, placebo-controlled trial to evaluate the safety and efficacy of Prochymal in conjunction with standard of care to improve heart function in patients who experience a first heart attack is currently enrolling patients. The trial is being conducted at leading institutions and academic research centers in the United States and Canada. Target enrollment is 220 patients and those participating will be randomized to Prochymal or placebo at a 2:1 ratio.

**Phase II Clinical Trial—Early Onset Type 1 Diabetes Mellitus.**

In early 2010, enrollment was completed for 63 patients in our Phase II, double-blind, placebo-controlled study evaluating Prochymal for the treatment of early onset type 1 diabetes in individuals 12 to 35 years old. We believe that based upon their mechanism of action, MSCs may home to the pancreas and inhibit the local immune and inflammatory responses, preventing the destruction of pancreatic islets and promoting the repair of pancreatic tissue damage. Patients were enrolled within 2 to 16 weeks of being diagnosed with type 1 diabetes and received three infusions of Prochymal over the course of 60 days. The primary efficacy endpoint, the measurement of C-peptide produced after glucose stimulation, will be measured at one year. We have entered into a collaborative agreement with the Juvenile Diabetes Research Foundation (“JDRF”) for this study. This agreement provides for JDRF to fund $4.0 million of clinical study costs. To date, we received $3.5 million from JDRF to fund clinical costs, and expect to receive the remaining $500 thousand during 2010.

**Phase II Clinical Trial—Chronic Obstructive Pulmonary Disease**

Enrollment in the 62-patient Phase II clinical trial evaluating the safety and efficacy of Prochymal in conjunction with standard of care for improving pulmonary function in patients with moderate to severe Chronic Obstructive Pulmonary Disease (“COPD”) was completed in the second half of 2008. Patients in the double-blind, placebo-controlled study were randomized to either Prochymal or placebo at a 1:1 ratio and received 4 infusions over the course of 90 days. Measurements used in the trial to
detect potential improvements in subjects treated with Prochymal include pulmonary function tests, exercise capability, systemic inflammation and quality of life assessments. In addition, exacerbations and hospitalizations due to COPD will be monitored for both safety and efficacy. Patients will be evaluated over the course of two years following initial Prochymal or placebo infusion.

At the six-month interim analysis, the trial met its primary goal of demonstrating the safety of Prochymal in patients with compromised pulmonary function. Prochymal significantly decreased systemic inflammation in patients when compared to those receiving placebo, as determined by C-reactive protein (CRP). Despite this reduction in inflammation, however, pulmonary function in patients receiving Prochymal was not significantly improved compared to those receiving placebo.

**Phase III Clinical Trial—Animal Rule—Acute Radiation Syndrome.**

In 2007, we partnered with Genzyme Corporation to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. In January 2008, we were awarded a contract from the United States Department of Defense (“DoD”) for the development and stockpiling of Prochymal for the treatment of acute radiation syndrome (“ARS”). Assuming FDA approval of Prochymal for ARS, the DoD may exercise purchase options for up to 20,000 doses of Prochymal at a price of $10,000 per dose.

**Chondrogen** is our biologic drug candidate for the treatment of osteoarthritis and the reduction of pain in the knee. In 2006, we completed enrollment of a randomized double-blind, placebo controlled Phase I/II clinical trial evaluating Chondrogen for safety and preliminary efficacy based upon regeneration of meniscus at six-months. In November 2007, we reported one-year data for the Phase I/II Chondrogen trial. The data continued to show improvements in joint condition that correlated with a clinically and statistically significant improvement in pain in patients with osteoarthritis (OA) who received Chondrogen as compared to those treated with the control, hyaluronic acid (HA). Patients receiving the control were 3.5 times more likely to experience degenerative bone changes associated with OA as compared to those receiving Chondrogen. The effects were dose dependent and pain scores improved from six months to one year following treatment, suggesting that Chondrogen caused a biological modification of patients’ OA.

We expended approximately $63.3 million in fiscal 2009, $69.9 million in fiscal 2008, and $47.1 million in fiscal 2007, on research and development. Our research and development expenditures in 2007 were entirely sponsored by us. In fiscal 2009, we were reimbursed for $3.0 million of research and development expenditures through our contract with DoD and earned $1.5 million in funding from JDRF. In fiscal 2008, we were reimbursed for $2.5 million of research and development expenditures through our contract with DoD and received $2.0 million in funding from JDRF. For more detailed financial information, including information regarding our revenues, profit and loss, and total assets and research and development costs and expenses for the past three fiscal years, see our Financial Statements included in Item 8 to this Annual Report on Form 10-K for fiscal year 2009.

**Scientific Background**

Stem cells are a special class of cells that can self-replicate and differentiate into multiple tissue types. Different populations of stem cells, also called progenitor or precursor cells, reside within the body. These cells are generally classified according to their differentiation potential, or ability to become distinct cell types. Embryonic stem cells are recognized as being totipotent, or unlimited, in terms of the number of different cell types they can become. Other stem cells are either multipotent, meaning capable of becoming two or more cell types, or unipotent, meaning preprogrammed for a single final cell type. Multipotent stem cells include the hematopoietic stem cells responsible for generating cells associated with the circulatory and immune systems, mesenchymal stem cells.
responsively for the formation of connective tissue cells, and neuronal stem cells dedicated to producing the different nervous system cell types. Stem cells participate in embryological and fetal development and orchestrate tissue repair following disease or injury in the adult. Though the precise mechanism of their activity has not yet been determined, experimental work has provided empirical evidence of the therapeutic benefit of various types of stem cells administered to animal and human subjects.

The embryonic stem cell ("ESC"), has the greatest differentiation potential and is capable of developing into all cell types found within the human body. ESCs must be harvested from human embryos, giving rise to ethical controversies surrounding the procurement of ESCs, which have hindered progress in ESC research. Also, technical difficulties in purifying and growing ESCs have prevented widespread experimental work capable of withstanding academic or regulatory scrutiny.

In adults, two major classes of stem cells exist in bone marrow: hematopoietic stem cells and mesenchymal stem cells. Throughout life, hematopoietic stem cells, ("HSCs"), located within the bone marrow give rise to most types of blood cells. HSC transplantation has served as the basis for a number of aggressive treatments for various types of cancer. However, therapies based on HSCs are largely limited to hematological disorders because HSCs can only differentiate into blood cells.

In contrast to HSCs, mesenchymal stem cells, ("MSCs"), are progenitor cells that differentiate into various connective tissues, such as bone, muscle, fat, tendon, ligament, cartilage and bone marrow stroma when they receive appropriate biochemical and biomechanical signals. Other biochemical stimuli cause MSCs to mobilize to areas of injury or inflammatory disease. Once there, MSCs coordinate tissue regeneration at a local level by producing tissue growth factors and by interacting with local cells to reduce inflammation and scarring. Importantly, MSCs do not express certain markers on the surface of cells, known as HLA class II antigens, which are responsible for recognition of the cells by the immune system. Also, the cell surface markers, CD40, CD80 and CD86, which are essential for activation of immune cells, are not present on MSCs. These characteristics allow MSCs to:

- be transplanted into an unmatched patient without giving rise to an immune response;
- regenerate connective tissues like bone and cartilage;
- act as a potent anti-inflammatory agent; and
- exhibit anti-fibrotic activity to limit tissue damage.

MSCs and HSCs are most readily isolated from bone marrow. Because MSCs represent a small fraction of bone marrow cells, they require amplification to be clinically useful. We have developed and optimized a proprietary process for isolating and expanding these cells using standardized cell culture methodologies. We can grow MSCs in a controlled fashion to produce up to 10,000 treatments of our biologic drug candidates from a single bone marrow donation.

Stem cells can be derived from either the patient, referred to as an autologous source, or from a donor, referred to as an allogeneic source. For many cell therapies, allogeneic sourcing is not possible due to the immune response that typically occurs following the injection of unrelated cells. The non-immunogenic nature of MSCs permits allogeneic cell sourcing and carries significant advantages over autologous sourcing. Allogeneic cell sourcing from a healthy donor population allows for specific quality control measures to select therapeutically optimal stem cells. For example, if a patient's cells are of poor quality due to advanced age, disease or metabolic state, the resulting product will likely be of similarly poor quality. We believe that allogeneic sources used in large scale production will enable us to utilize quality control practices to ensure that product potency is reproducible from treatment to treatment. We have developed quality standards for our biologic drug candidates, including potency assays directed to the specific indications for use. No patients participating in our clinical trials or who have used Osteocel to date have experienced an immunogenic response.
Strategy

We are striving to be the first company to receive FDA marketing approval of a stem cell drug and to become the world’s leading provider of stem cell therapies.

Successfully commercialize our lead stem cell therapy, Prochymal. We completed the enrollment of the first worldwide Phase III stem cell clinical trial in the fourth quarter of 2008, enrolling 244 patients at 72 leading bone marrow transplant centers across the United States, Canada, United Kingdom, Spain, Italy, Australia, Germany and Switzerland. Assuming marketing approval, we plan to develop a sales and marketing organization to promote Prochymal initially for the treatment of the orphan indication of refractory GvHD. Based on the small number of bone marrow transplantation hospitals treating patients with GvHD in the United States and Canada and the lack of effective treatments for this population, we believe we can successfully market Prochymal with a small, specialized sales force.

Expand our pipeline of biologic drug candidates where our stem cell technology has a therapeutic potential. We are continuously investing in our biologic drug candidate pipeline by evaluating our therapies in additional diseases and disorders where we believe MSCs may have therapeutic benefit. This will allow us to maintain our position as the leader in cellular therapeutics.

Exploit our MSC technology, manufacturing ability and proprietary know-how to advance our pipeline. We intend to leverage our preclinical research, safety data and manufacturing ability to rapidly and efficiently grow our biologic drug candidate pipeline. Because we utilize MSCs as the active agent for all of our biologic drug candidates, we believe the accumulated safety data will reduce the time and cost associated with early stage clinical trials for new indications.

Internally develop and commercialize future biologic drug candidates. We believe that we have the requisite experience to develop and commercialize any future biologic drug candidates without the help of a strategic partner. Due to our experience with Osteocel and our current pipeline candidates, we believe we have gained the clinical, regulatory, manufacturing and commercial capabilities to successfully develop and commercialize biologic drug candidates and novel tissue products.

Clinical Programs

Prochymal

Prochymal is our biologic drug candidate that is being used to treat medical conditions in a variety of indications. Prochymal is being evaluated in Phase III clinical trials for four indications, including first line and steroid refractory acute GvHD, Crohn's disease and for the repair of gastrointestinal injury resulting from radiation exposure, and is the only stem cell therapeutic currently designated by the FDA as both an Orphan Drug and Fast Track product. Prochymal is also being developed for the repair of heart tissue following a heart attack and for the protection of pancreatic islet cells in patients with type 1 diabetes, for the treatment of Chronic Obstructive Pulmonary Disease (“COPD”).

Graft versus Host Disease

GvHD is a life threatening immune system reaction that commonly affects one or more of the skin, gastrointestinal tract, and liver in patients who have received a bone marrow transplant. We estimate that there are approximately 3,000 instances of GvHD in the United States each year.

Bone marrow transplantation is a treatment of last resort for patients with certain cancers and some genetic diseases. This procedure can result in a particularly serious type of rejection referred to as acute GvHD. This condition gets its name because the bone marrow transplant, or the graft, begins to attack the recipient, or the host. As noted in an article published in the journal Biology of Blood and Marrow Transplantation in 2005, acute GvHD is one of the most common complications of allogeneic bone marrow or hematopoietic stem cell transplantation, affecting approximately 50% of transplant
patients. Acute GvHD is graded for prognostic and treatment purposes on a four grade scale, with Grade I considered mild, Grade II moderate, and Grades III-IV considered severe and life-threatening. The onset of GvHD in patients who have received a bone marrow transplant leads to a poor prognosis because of the already weakened state of these patients. According to a 2002 article published in *Biology of Blood and Marrow Transplantation*, the estimated one-year survival rate for patients with acute GvHD decreases drastically with increasing disease severity, as illustrated below:

<table>
<thead>
<tr>
<th>Acute GvHD</th>
<th>Estimated One Year Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade I</td>
<td>65%</td>
</tr>
<tr>
<td>Grade II</td>
<td>60%</td>
</tr>
<tr>
<td>Grade III</td>
<td>39%</td>
</tr>
<tr>
<td>Grade IV</td>
<td>22%</td>
</tr>
</tbody>
</table>

Typically, patients are treated aggressively with steroids when their GvHD reaches Grade II. A 2001 article published in the journal *Blood* noted that approximately 50% of these patients will not respond to treatment with steroids and approximately 50-80% of steroid refractory GvHD patients die of the disease.

The current treatments available for acute GvHD are inadequate in two primary ways. First, mortality in patients with acute GvHD is unacceptably high. Second, most treatments for acute GvHD suppress or destroy the immune system. This can lead to a number of debilitating side effects, including severe and life threatening infection. Unlike steroids or other immunosuppressant drugs, which have a systemic effect, Prochymal’s mechanism of action is designed to specifically target areas of inflammation. Therefore, we believe the use of Prochymal will result in a higher survival rate.

We are conducting two Phase III trials for acute GvHD and have been granted Fast Track status by FDA for both. The first Phase III trial investigated Prochymal in patients with steroid refractory acute GvHD. Seventy two sites in the United States, Canada, Europe and Australia participated in this trial and the trial enrolled 260 patients and treated 244 patients. The primary endpoint of this first Phase III trial, durable complete response approached statistical significance with 40% of patients receiving Prochymal and 28% of placebo patients achieving a durable complete response.

The second Phase III trial is evaluating Prochymal as a first line treatment for acute GvHD and is taking place in 52 leading centers in the United States and Canada. We completed enrollment of 192 patients who received a total of six infusions during the first four weeks of the study. The trial did not meet its primary endpoint. The majority of patients enrolled in this trial were suffering from skin GvHD, which responded significantly better to steroids than had previously been reported in controlled trials. This high response rate to standard of care diminished the potential for Prochymal to demonstrate an effect.

We recently reported data from a 59-patient trial evaluating Prochymal as a rescue therapy in pediatric patients with severe, treatment-resistant acute GvHD. The trial enrolled patients with grades B-D acute GvHD who had failed steroids and other immunosuppressive agents. Patients who experienced a partial response by day 28 were eligible for continued treatment. GvHD assessments were used in the study to detect improvements in patients treated with Prochymal. At study entry, 90% of children had Grade C/D GvHD, the most severe forms of GvHD, and were unresponsive to an average of three lines of therapy. Overall response to treatment with Prochymal at 28 days was 63%. Response to Prochymal at day 28 significantly improved survival over those patients who progressed (78% vs. 9%, p<0.05). Patients in the trial were treated at 33 pediatric transplant centers across the U.S., Canada, Europe and Australia. There were no infusional toxicities associated with the administration of Prochymal.
We completed a Phase II trial evaluating Prochymal as a first-line treatment in combination with steroids, for patients diagnosed with Grade II-IV acute GvHD. A total of 32 patients were enrolled and 31 patients were treated with two infusions of Prochymal, administered 72 hours apart. The treatment commenced within 48 hours of GvHD diagnosis. In this study, we were evaluating safety, dose and response to treatment by day 28. When Prochymal was added to steroid therapy, patients were twice as likely to have total clinical resolution of their disease compared to reported results for treatment with steroids only. Twenty-nine (29) of 31 patients, or 94%, responded after receiving two infusions of Prochymal, with 24 patients, or 77%, achieving a complete response, meaning the patients had experienced total clinical resolution of the disease. At six months, 61% of all patients treated with Prochymal still had a durable response requiring no additional use. Of these, 95% were alive at six months.

In 2003 we completed a Phase I trial to determine the safety of Prochymal in patients who received hematopoietic stem cell transplants. The trial investigated patient response to three different doses of Prochymal. No safety concerns related to the use of Prochymal were observed in the 46 subjects who were evaluated.

We obtained both Fast Track and Orphan Drug designation in 2005 for the use of Prochymal in GvHD patients. The FDA grants Fast Track designation to investigational drugs that have the potential to treat life-threatening diseases with unmet medical needs. Our Biologic License Application will be eligible for an expedited review process by the FDA as a result of this designation. Orphan Drug designation offers several benefits including eligibility for grants to fund studies, up to seven years of marketing exclusivity and a waiver of the Biologic License Application fee of approximately $900,000. Prochymal is the only stem cell therapy currently designated by the FDA as both an Orphan Drug and Fast Track product candidate.

Crohn’s Disease

Based on our clinical observations of the effects of Prochymal on the gastrointestinal symptoms of patients with GvHD, we are developing Prochymal for the treatment of Crohn’s disease. Crohn’s disease is a chronic, life-long condition that features relapsing inflammation of the gastrointestinal tract. Severe Crohn’s disease can cause intractable diarrhea and abdominal pain, undesirable changes in lifestyle, hospitalization, and unwanted side effects from required medications. Approximately 60% of Crohn’s disease patients require at least one surgery to remove an affected portion of their intestine at some time during their lifetime, according to a 2002 article in the journal *Alimentary Pharmacology & Therapeutics*. This article further notes that there are over 500,000 cases of diagnosed Crohn’s disease in the United States, and at any given time approximately 10% of these cases have a severe exacerbation or relapse that does not respond to traditional immunosuppressive treatments, including biologics. Standard treatments of steroids and other immune suppressants often cause secondary health problems. According to a 2003 article in the *British Journal of Clinical Pharmacology*, with current medical therapies about 50% of patients with severe Crohn’s disease will relapse within one year.

We completed a Phase II trial in 2006 studying Prochymal as a treatment for moderate to severe Crohn’s disease that is refractory to steroids and other immune suppressants. We enrolled ten patients in this study and communicated the results during the October 2006 annual meeting of the American College of Gastroenterology. The trial was a prospective, randomized, open label trial, conducted at 4 leading centers in the United States. Patients with moderate to severe Crohn’s disease, defined as having a Crohn’s Disease Activity Index (“CDAI”) of at least 220, who had previously failed treatment with steroids and other immunosuppressive agents, were given two infusions of Prochymal seven days apart. A total of ten patients were treated and nine patients were evaluated through the 28 day follow-up. One patient elected to exit the trial prior to completion. Patients were assigned to one of two treatment groups and received Prochymal on an outpatient basis. In addition to safety parameters, patients were evaluated for changes in CDAI and improvement in the Inflammatory Bowel Disease.
Questionnaire (“IBDQ”). Prior to entering the trial, patients who had been treated with infliximab (Remicade® or other biological agents were required to complete a washout period of 90 days to preclude the possibility that response was the result of a previous treatment.

Entering this trial, the average CDAI score at baseline was 341. Patients entering this study had suffered from Crohn’s disease for an average of 14.2 years, and 80% of the patients required prior surgical intervention to treat their Crohn’s disease. In the study, one-third of the patients had a reduction of CDAI of greater than 100 points within 14 days of treatment. Each of these responders had failed previous treatment with infliximab. Mean IBDQ scores improved significantly from baseline to day 28 (113 to 146, p=0.008). One-third of the patients reported IBDQ scores of at least 170, indicating they had achieved clinical remission of their disease. Although not reaching statistical significance, there appeared to be correlation between dose and response. Patients receiving the high dose had a 72-point greater reduction in CDAI than those receiving low dose (CDAI reduction of 137 vs. 65). There were no infusional toxicities, and no treatment-related severe adverse events.

As a result of the encouraging data of the Phase II trial, we initiated a Phase III trial evaluating Prochymal for the treatment of moderate to severe Crohn’s disease that is refractory to biological therapy. The placebo-controlled, double-blind study was designed to enroll 270 patients, 18 to 70 years of age with a CDAI greater than 250. The primary endpoint of this trial is the proportion of patients with CDAI of less than 150 (clinical remission) at day 28. Patients were enrolled at approximately 60 leading centers in the U.S. and Canada.

On March 27, 2009, we announced that we had elected to end enrollment at 207 patients in this Phase III clinical trial because we believe that there was a design flaw in the trial resulting in significantly higher than expected placebo response rates. The decision was made after the trial’s final scheduled interim analysis showed that one of the two Prochymal dose arms had crossed a futility boundary. The dose arm was unlikely to achieve the primary endpoint of remission because of the high placebo response rate. This analysis continued to show no serious safety concerns with the therapy and safety was not a factor in the decision to stop enrollment. After careful discussions with the FDA, we elected to discontinue enrollment rather than attempt to re-power the trial. We will keep the trial blinded and expect to use the data in the design of future trials for the treatment of Crohn’s disease. The Prochymal Crohn’s program consisted of two separate but related trials. The first trial, described above, evaluates patients’ initial response to two dose levels of Prochymal as compared to placebo. This trial was originally designed to enroll 270 patients. Patients responding to the initial therapy were then eligible to participate in a second, longer-term trial evaluating Prochymal as a maintenance therapy. Because the current standard for determining response of Crohn’s patients is largely subjective, there may have been response bias in order to meet the eligibility requirements for continuation of therapy in the longer-term maintenance trial. Accordingly, enrollment in the second trial has also ended.

**Acute Myocardial Infarction**

We are also evaluating Prochymal as a therapy to improve heart function in patients who have suffered a heart attack. Preclinical studies indicate that Prochymal prevents scar formation that typically occurs after a heart attack and improves cardiac function eight to ten weeks after its administration. As discussed further below, we completed enrollment in a Phase I clinical trial for Prochymal in 2006. This trial is designed to evaluate the safety and efficacy of Prochymal to restore heart function in patients experiencing a first time heart attack.

A heart attack, or acute myocardial infarction (“AMI”), occurs when coronary arteries become blocked with fatty deposits, depriving the heart muscle of oxygen and nutrients. Based on statistics published in 2005 by the American Stroke Association and the American Heart Association, in the United States approximately 700,000 individuals each year experience their first heart attack. According to these same statistics, approximately 20% of patients experiencing their first heart attack suffer extensive damage to their heart muscle, leading to heart failure within six years. Furthermore, we
believe the statistics indicate that despite improvements in the standard of care, this progression from myocardial infarction to heart failure remains largely unavoidable in patients with AMIs.

Prochymal is being developed for the treatment of heart muscle damage following AMI. Its primary indication is to treat post-AMI complications and prevent the formation of scar tissue and associated cardiac dysfunction. Our preclinical studies indicate that the mechanism by which Prochymal improves myocardial function includes the prevention of pathological scarring of the heart muscle and the formation of new blood vessels. We are developing Prochymal as a therapy to be delivered through a standard intravenous line up to 10 days post-myocardial infarction.

In preclinical studies, Prochymal selectively targeted the damaged area of the heart when a single infusion was administered. These studies also indicated that Prochymal has the effect of retarding or stopping the progression of further cardiac tissue deterioration and limiting the damage caused by an AMI. Significant improvements in cardiac function as demonstrated by increased ejection fraction, reduced end diastolic pressures, and reduced wall stress were observed eight to ten weeks after administration of Prochymal. A preclinical study was performed to determine if an intravenous infusion of MSCs following myocardial infarction would result in an improvement in cardiac function. Significant improvement in cardiac function as indicated by left ventricular ejection fraction (LVEF) was observed three months after infarct in those animals receiving intravenous delivery of MSCs compared to control animals. MSCs were detected in the damaged area of the heart muscle of Prochymal treated animals, but not in the remote, undamaged regions.

In March 2006, we completed enrollment of a 53-patient Phase I randomized, double blind, placebo controlled clinical study to evaluate Prochymal in patients following AMI. The trial was designed to investigate patient response to three different doses of Prochymal versus placebo. Exploratory efficacy endpoints included overall improvement in the function and remodeling of the heart muscle six months after treatment. A safety evaluation for each subject was conducted two years after the subject was enrolled in the trial.

In March 2007, we reported six-month results in this trial. Heart attack patients receiving Prochymal had significantly lower rates of adverse events, such as cardiac arrhythmias, as well as significant improvements in heart, lung and global function. Administration of Prochymal was found to be well tolerated at all dose levels. Patients in the Prochymal group were four times less likely to experience an arrhythmic event compared to those receiving placebo (9% vs. 37%, p=0.025). The percentage of patients who experienced clinically significant premature ventricular contractions was significantly less after receiving Prochymal as compared to placebo at the one month (6% vs. 32%, p < 0.05) and two month (9% vs. 38%, p < 0.05) time points. Patients with anterior wall myocardial infarctions had a statistically significant 7.0 point (24%) improvement in ejection fraction at three months and a 7.3 point (25%) improvement at six months over baseline (p<0.05). In comparison, placebo patients in this group did not have a significant increase. Patients receiving Prochymal had significantly improved pulmonary function as measured by improvement in FEV1% predicted values (17 point Prochymal vs. 6 point placebo, p<0.05). FEV1 or forced expired volume in one second is the amount of air that can be exhaled in a patient’s first second of expiration. Comparing the patient’s FEV1 reading with normal predicted values (FEV1% predicted) provides a measure of the severity of pulmonary disease. Significantly more patients who received Prochymal experienced improvement in their overall condition at six months as compared to those receiving placebo (42% vs. 11%, p=0.027).

In February 2008, we reported one-year results in the Phase I trial. The trial continued to demonstrate Prochymal’s strong safety profile as well as continued statistically significant improvement in heart function. One year magnetic resonance imaging (MRI) data on LVEF was collected and patients treated with Prochymal showed a statistically significant 5.2 point increase over baseline (p=0.021). Patients receiving placebo showed only a 1.8-point improvement over baseline, which was not statistically significant. Patients with more severe myocardial infarction, defined as a baseline LVEF of 45% or less, demonstrated even greater effects. The Prochymal treatment group showed a 6.5-point
improvement one year post-treatment, compared to a 1.9-point increase in the placebo group. Prochymal treated patients continued to experience fewer adverse events at a rate of 6.1 per patient, compared to 8.0 per patient in the placebo group. This one-year interim analysis was performed as a part of the full two-year follow-up, and as a result, contains only limited data.

Data from the final two-year time point was reported in February 2009 and indicated a continuing benefit from treatment with Prochymal. The trial met its primary endpoint demonstrating the safety of Prochymal in the acute myocardial infarction setting. Patients receiving Prochymal continued to experience fewer adverse events at a rate of 6.1 per patient, compared to 8.0 per patient in the placebo group. This effect was maintained for the duration of the study, with 47.4% of placebo patients experiencing cardiac arrhythmia compared to only 11.8% of Prochymal patients ($p=0.006$). Ventricular arrhythmias are associated with tissue damage and scar formation in the heart resulting from infarction and can be a sign of poorer prognosis. Two year MRI demonstrated that there was statistically significant improvement in LVEF over baseline, 6.6 point in Prochymal relative to a 3.9 point improvement in placebo. For patients with more severe myocardial infarction, defined as a baseline LVEF of 45% or less, even greater effects were observed. The Prochymal group showed a significant 9.5 point improvement over baseline two years post-treatment ($p < 0.05$). This compares favorably to the 3.1 point increase observed for the placebo group. No serious adverse events were attributed to Prochymal, and all-cause hospitalizations trended lower in the Prochymal group (38.2%) as compared to the placebo group (47.4%).

Based upon the positive results from the Phase I trial, we received approval from the FDA to initiate a Phase II trial. The Phase II double-blind, placebo-controlled trial will evaluate the safety and efficacy of Prochymal in conjunction with standard of care for improving heart function in patients who experienced a first heart attack. This trial focuses on patients who have suffered a severe myocardial infarction, defined as LVEF between 30% and 45% at baseline. The target enrollment is 220 patients. Patients are randomized to either Prochymal or placebo at 1:1. Efficacy endpoints determined from cardiac MRI include end systolic volume, LVEF and the ability of Prochymal to preserve functional heart tissue, or limit scar formation following a heart attack. In addition, functional and quality of life assessments are being performed.

**Type 1 Diabetes Mellitus**

We are also investigating Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes mellitus. Type 1 diabetes, commonly known as juvenile diabetes or insulin-dependent diabetes, is an autoimmune disorder that attacks and destroys insulin producing islet cells in the pancreas causing glucose accumulation in the blood. As a result, those suffering from type 1 diabetes must take insulin to regulate blood sugar levels. Over time, poorly controlled diabetes can lead to serious health conditions, including heart disease, stroke, blindness, amputations, kidney disease and nerve damage. Currently, there are no preventative measures for type 1 diabetes. In preclinical research, both animal and human bone marrow-derived mesenchymal stem cells (MSCs) were shown to preserve beta cell function in animal models of diabetes.

In October 2007, we reported the initiation of a Phase II trial evaluating the safety and efficacy of Prochymal in conjunction with standard of care in preserving insulin production in patients recently diagnosed with type 1 diabetes mellitus. The trial is double-blind, placebo-controlled and we completed enrollment of the 63 patients in early 2010. Patients in the study received three intravenous infusions of Prochymal over the course of sixty days. The primary endpoint of the trial is the measurement of C-peptide produced during a Mixed Meal Tolerance Test in patients treated with Prochymal, compared to those receiving placebo. This test is frequently used in diabetic patients to determine how much insulin is being produced by the pancreas in response to glucose stimulation. The patients in the trial will be followed for safety and efficacy for two years.
Chondrogen

Chondrogen is our biologic drug candidate for regeneration of meniscus, a type of cartilage that cushions the knee joint. There are currently no FDA approved products available to regenerate meniscal tissue. In several preclinical studies, Chondrogen, a preparation of adult mesenchymal stem cells formulated for direct injection into the knee, regenerated meniscus and prevented osteoarthritis in animal models. As described further below, at the end of the first quarter of 2006 we completed enrollment in a Phase I/II clinical trial for Chondrogen, designed to evaluate the safety and preliminary efficacy in patients following surgery to remove torn meniscus.

The meniscus is a crescent-shaped cushion in the knee joint that protects cartilage and enables the knee to move smoothly. Injury and tears to the meniscus are common and can be traumatic, arising from sports injury for example, or degenerative, due to daily wear and tear. An injured or torn meniscus is painful and typically requires surgical intervention. The current standard of care for significant injuries is partial meniscectomy surgery, in which the damaged portion of the meniscus is permanently removed. According to a 2005 article in the American Journal of Sports Medicine, approximately 1.0 million people have surgery to remove damaged or torn meniscus in the United States each year. As noted in a 1999 article in the journal Sports Medicine, patients who have had this procedure are 10 to 15 times more likely to develop osteoarthritis, a highly debilitating orthopedic condition. As a result, a significant medical need exists for a product that can regenerate the meniscal tissue removed during surgery and prevent cartilage degeneration.

At the end of the first quarter of 2006, we completed a randomized double-blind, placebo controlled Phase I/II clinical trial evaluating Chondrogen for safety and preliminary efficacy based upon regeneration of meniscus at six-months. We plan on evaluating each patient for safety two years after the patient enrolled in the trial. Participants in the trial received one of two doses of Chondrogen or placebo, and a total of 55 patients were treated. At the one-year time point, Chondrogen met its primary endpoint of demonstrating product safety. An initial review of the data showed that Chondrogen was well tolerated, was not associated with serious adverse events, did not result in any adverse hematological events, and did not result in the formation of any unwanted or ectopic tissue. There was no significant change in the volume of meniscus on MRI at six-months in patients that received Chondrogen compared to those patients receiving placebo. However, about 30% of patients treated with Chondrogen demonstrated an improvement in their baseline cartilage or joint condition, while no patients in the placebo group demonstrated similar improvement.

In November 2007, we reported one-year data for the Phase I/II Chondrogen trial. The data continued to show improvements in joint condition that correlated with a clinically and statistically significant improvement in pain in patients with osteoarthritis (“OA”) who received Chondrogen as compared to those treated with the control, hyaluronic acid (“HA”). Patients receiving the control were 3.5 times more likely to experience degenerative bone changes associated with OA as compared to those receiving Chondrogen. The effects were dose dependent and pain scores improved from six months to one year following treatment, suggesting Chondrogen caused a biological modification of patients’ OA. Patients will be followed for safety and additional preliminary efficacy, such as cartilage damage and changes in the meniscus for two years under the current study protocol.

Collaborations

Genzyme Corporation—Collaboration Agreements

Prochymal and Chondrogen Development and Commercialization

In October 2008, we entered into a collaboration agreement with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen. Under the terms of the agreement, we retain the right to commercialize Prochymal and Chondrogen in the United States and Canada and
Genzyme is provided the right to commercialize the treatments in all other countries, except with respect to GvHD in Japan where JCR Pharmaceuticals Co., Ltd. has these rights. This collaboration agreement also provides for contingent milestone payments to us of up to $1.25 billion, in addition to royalties on any sales by Genzyme, as described below.

The Collaboration Agreement also provides for upfront non-contingent, non-refundable payments to us of $130.0 million ($75.0 million of which was received in November 2008 and $55.0 million was received on July 1, 2009), and up to $500 million in development and regulatory milestone payments for Prochymal related to GvHD, Crohn’s disease and other potential additional indications that we and Genzyme develop together. Based upon sales in Genzyme territories, we are eligible to receive up to $250 million in sales milestones for Prochymal as follows: $100 million payable when annual sales reach $500 million in the Genzyme territories and $150 million payable when annual sales reach $1 billion.

Upon receipt of the results of the planned Phase II clinical trial for Chondrogen, Genzyme may elect to opt-out of further Chondrogen development, at which point all rights to Chondrogen revert back to us with no further obligation by either company. If Genzyme elects to continue with Chondrogen development, we are eligible to receive up to $100 million in development and regulatory milestones based on the achievement of certain clinical trial results and regulatory approvals. Based on sales in Genzyme territories, we are eligible to receive up to $400 million in sales milestones for Chondrogen.

We are also eligible to receive significant escalating royalties on sales of Prochymal and Chondrogen within the Genzyme territories.

We are obligated to complete the on-going clinical trials for Prochymal and Chondrogen at our own cost and will also be responsible for the costs of any new clinical trials for agreed upon indications through Phase II trials. The costs for any subsequent Phase III clinical trials will be borne 60% by us and 40% by Genzyme.

Genzyme has also agreed to provide launch support to us for the sales and marketing of Prochymal in the United States and Canada upon receipt of marketing approval from regulatory authorities. We will pay Genzyme royalties for these services in amounts that we presently estimate to approximate their fair value.

Prochymal Development to Treat Acute Radiation Syndrome

In July 2007, we entered into an agreement with Genzyme for collaboration in the preparation and execution of development and purchase agreements with United States and Allied government agencies for countermeasures to nuclear terrorism and other radiological emergencies. In January 2008, we were awarded a contract from the United States Department of Defense (“DoD”) for the development and stockpiling of Prochymal for the treatment of Acute Radiation Syndrome (“ARS”). Under the terms of the contract, the DoD will provide technology and product development funding to us up to $24.7 million. The contract further provides for additional funding for activities leading to FDA approval of Prochymal for ARS and the scaling up of manufacturing processes, and provides the DoD with successive options for the purchase of up to 20,000 doses of Prochymal in the aggregate. The total value of the contract, assuming FDA approval and the exercise by the DoD of all of its options to purchase doses of Prochymal at $10,000 per dose, is up to $224.7 million. We will carry out this contract in partnership with Genzyme, with us contributing Prochymal and our corresponding safety and advocacy database to the effort, and with Genzyme lending its mass product development and large scale commercialization expertise. Our agreement with Genzyme provides for Genzyme to receive a royalty of 15% of net product sales, limited to those sales made under contracts with United States or Allied government agencies for emergency preparedness.
Juvenile Diabetes Research Foundation—Collaborative Agreement

In October 2007, we entered into a collaborative agreement with the Juvenile Diabetes Research Foundation (“JDRF”) for the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes. Under the terms of the agreement, JDRF has agreed to fund $4.0 million of the research costs, payable to us based upon the achievement of established milestones. We received $1.5 million in funding from JDRF during 2009 and $2.0 million in funding from JDRF during 2008, and expect to receive the remaining $0.5 million during 2010. We are recognizing the revenue from the JDRF agreement over the estimated schedule of completing this research.

JCR Pharmaceuticals Co., Ltd.—License Agreement

In August 2003, we entered into a license agreement with JCR Pharmaceuticals Co., Ltd. (“JCR”), pursuant to which we granted to JCR an exclusive right in Japan to our MSC technology for use in connection with the use of hematopoietic stem cells derived from peripheral blood, cord blood or bone marrow in the treatment of hematological malignancies.

The license agreement provided for a payment by JCR to us of an up-front license fee of $3.0 million and payment of an additional $0.5 million upon a certain technology transfer. In addition, if and when marketing approval is obtained in Japan, JCR is required to pay up to $7.0 million in pre-commercialization milestones per product and certain amounts for pre-determined thresholds of cumulative net sales. Lastly, JCR has an obligation to pay royalties to us, with such amount dependent upon the cumulative net sales. We received a $0.5 million milestone payment in 2007 when JCR filed an IND in Japan.

Under the terms of the collaborative arrangement, JCR will bear all costs associated with bringing the drug to market in Japan. JCR is obligated to use its reasonable best efforts to develop and commercialize in Japan products covered under the terms of the license, including conducting clinical trials and procuring regulatory and other approvals. The license expires with respect to specific products on the later of 15 years from the date of the first sale of the product in Japan or the date on which our last patent in Japan covering that product expires. Also, the license and the collaboration can be terminated unilaterally by JCR upon 180 days notice to us or by mutual agreement between us and JCR.

In conjunction with this collaboration, JCR made a $3.0 million investment in our preferred stock, which converted at the closing of our initial public offering into 136,363 shares of our common stock.

Intellectual Property

Our broad intellectual property portfolio originates from our pioneering scientific efforts. We have established a considerable patent position in adult stem cell technology and actively seek to protect proprietary technologies that we consider important to our business, including compositions of matter as well as methods of manufacture and methods of use. We believe that one particularly strong aspect of our patent estate is a claim that relates to the isolated mesenchymal stem cell regardless of its origin, type of expansion or ultimate use. Other layers of our patent protection relate to the application of our stem cell technologies to various organs (e.g. heart, lungs) and therapeutic areas (e.g. autoimmune disorders, inflammatory disorders). Additionally we own IP related to purified compositions of MSCs and the methods that we believe are necessary to manufacture a safe product. We currently own or have exclusive licenses to 49 issued U.S. patents, and 278 foreign patents. We have 22 U.S. patent applications pending and 80 foreign patent applications pending. We are committed to protecting our intellectual property position by continuously monitoring the competitive landscape and are prepared to act aggressively in the event that our strong market position is ever threatened by an infringing product.
We also rely upon trade secrets to protect our proprietary information. Through our experience with MSCs and MSC-based product development, we have developed expertise and know-how in this field. We manufacture clinical grade MSCs in-house and contract for the production through contract manufacturers. To protect this know-how, our policies require confidentiality agreements with our employees, consultants, contractors, manufacturers, outside collaborators, sponsored researchers, and advisors. These agreements generally provide for protection of confidential information, restrictions on the use of materials and assignment of inventions conceived during the course of performance for us. These agreements might not effectively prevent disclosure of our confidential information.

We were founded on the basis of MSC technology obtained from Case Western Reserve University ("CWRU"). In January 1993, we entered into a Technology Transfer and License Agreement with CWRU, which was subsequently amended in October 1999 and twice in October 2003. Pursuant to this license agreement certain patents were assigned to us and others were exclusively licensed to us, with the right to grant sublicenses. The exclusive license is subject to any rights of a governmental agency based on research funding by such an agency, and to CWRU’s retained rights under the patents for non-clinical research, testing or educational purposes of CWRU.

With respect to the patents licensed to us, we are obligated to pay royalties to CWRU based on sales of products covered by granted licensed patents, and such royalties commence with respect to each such product on the third anniversary of the initial sale thereof. We are also obligated to pay minimum royalties under the agreement with CWRU and remain responsible for patent costs. The license is terminable by CWRU in the event that there is a material breach by us. Otherwise the license is for the life of the patents. Under certain circumstances, we are obligated to negotiate in good faith with a third party a sublicense under patents licensed from CWRU and under patents and know-how owned by us that are reasonably required by the third party to exercise the granted sublicense. We are not obligated to grant such a sublicense where it would have a potential adverse effect on a product being researched, developed or commercialized by us or by a licensee or sublicensee of ours.

Under terms of a Marketing, Collaboration and License Agreement with Lonza, we have licensed our MSC technology to Lonza to sell MSCs, the MSC descendants, cells produced from MSCs and materials used with MSCs for commercial and non-commercial research purposes. Under the terms of this agreement, Lonza is specifically precluded from selling the licensed products for use in humans. We receive royalties on any sales under this agreement.

Patent life determination depends on the date of filing of the application and other factors promulgated under patent law and regulatory laws including, for example, the United States Drug Price Competition and Patent Term Restoration Act of 1984, known as the Hatch-Waxman Act. The patent term restoration period is generally one-half the time between the effective date of an Investigational New Drug Application ("IND") and the submission date of a New Drug Application or NDA, plus the time between the submission date of an ("NDA") and the approval of the drug. Only the earliest patent applicable to an approved drug is eligible for the extension. The United States Patent and Trademark Office, in consultation with the FDA, reviews and approves applications for patent term extension. We expect to apply for patent term extensions where eligible to bolster market exclusivity beyond nominal patent expiration dates.

Manufacturing

Production of Biologic Drug Candidates

One way in which we believe that we have differentiated ourselves from other stem cell companies through proprietary manufacturing methods that allow for the controlled growth of MSCs to produce up to 10,000 treatments of our biologic drug candidates from a single bone marrow donation. This is in
contrast to most other stem cell technologies that are able to make only a single treatment from each
donation.

We have been manufacturing MSCs for over ten years. The first material manufactured in-house
was released in 1999. Since that time manufacturing has continued to expand to support our clinical
trials. The current manufacturing process utilizes cell factories, a closed system of surfaces on which the
cells adhere, for stem cell expansion. We have developed this technology into a reproducible process
that can be scaled up and transferred to additional sites. A second manufacturing site was successfully
qualified in 2003. In addition, JCR Pharmaceuticals, our partner in Japan, has successfully implemented
our manufacturing technology in Japan. We and our contract manufacturers believe that we perform all
of our manufacturing activities in compliance with the FDA's current Good Manufacturing Practice
requirements.

Our manufacturing process begins with the collection of bone marrow aspirate from qualified
volunteer donors, 18-30 years of age. Prior to donation, these individuals are screened and tested for a
battery of diseases including HIV and hepatitis according to the FDA's donor suitability guidance. We
purchase bone marrow aspirate from commercial sources. Since the mesenchymal stem cell is extremely
rare, accounting for only one in every 100,000 cells in bone marrow, an initial purification process is
required. Upon arrival at our facilities, MSCs are isolated and selectively removed from the bone
marrow through a multi-step process. A beneficial feature of our stem cells is that they adhere to the
surface of the cell factory and the other remaining cell populations that do not adhere are washed away
throughout the process. Our stem cells are then expanded, harvested, packaged and cryopreserved as
an in-process intermediate, and we conduct a second battery of quality testing. Each packaged
intermediate is further expanded and formulated to produce the final product. Sterility and quality
testing completes the process. This well-defined process has allowed for the development of a supply
chain where material specifications have been established and vendors have been qualified.

The final product will be configured to allow for ease of storage, distribution and use in the clinic.
We expect the product will be provided in ready-to-use patient dose quantities, shipped from the
distribution center on dry ice, and stored in the freezer at the pharmacy.

Production of Osteocel

In July 2008, we sold our Osteocel business to NuVasive, Inc. and concurrently entered into a
Manufacturing Agreement under which we continued to manufacture Osteocel for the exclusive sale to
NuVasive through March 2009.

Osteocel is a matrix of viable cancellous bone containing primary or unexpanded MSCs. Unlike
our biologic drug candidates, the stem cells and cancellous bone used in Osteocel are obtained from
organ and tissue donors. Additionally, the production of Osteocel is different from our biologic drug
candidates in that it does not feature the expansion of MSCs. The processing of Osteocel is in many
ways more like the process of organ donation than standard tissue processing.

Sales, Marketing and Distribution

We intend to self-commercialize all of our biologic drug candidates in the United States and
Canada upon FDA approval through the creation of sales and marketing capabilities in existing and
new indications. In addition, under our collaborative agreement with Genzyme Corporation, Genzyme
has agreed to provide us with launch support of our biologic drug candidates for a two-year period
commencing approximately six months before the anticipated receipt of marketing approval from the
FDA. Genzyme has expertise and extensive resources in the successful launch, sales and marketing of
cellular therapies. We have also entered into a collaborative arrangement with JCR Pharmaceuticals
Co., Ltd. for the distribution of Prochymal for GvHD in Japan following marketing approval.
Our biologic drug candidates are stored at -140 degrees Celsius. Generally, we do not believe this will pose a significant problem for end-users as most hospitals and medical centers have freezers with these storage capabilities readily available. However, some facilities may not have this type of storage available and this may limit distribution. In an effort to mitigate this, we are performing studies to store the product at higher temperatures.

Upon FDA approval of Prochymal for GvHD indications, we expect to focus our sales and marketing efforts on the approximately 210 transplantation hospitals in the United States that are registered with the International Bone Marrow Transplantation Registry. We expect to employ a number of sales representatives, initially targeting the most active transplantation centers in a region. An important component of the sales strategy will be to gain the support of key opinion leaders, facilitating the adoption of Prochymal as the treatment strategy for GvHD. We have entered into a license agreement with JCR Pharmaceuticals that grants it the exclusive right to distribute Prochymal for the treatment of GvHD in Japan when it has been approved for marketing in that country.

**Competition**

Our industry is subject to rapid and intense technological change. We face, and will continue to face, intense competition from pharmaceutical, biopharmaceutical and biotechnology companies, as well as numerous academic and research institutions and governmental agencies engaged in drug discovery activities or funding, both in the United States and abroad. Some of these competitors are pursuing the development of drugs and other therapies that target the same diseases and conditions that we target in our commercial, clinical and preclinical programs.

Many of the companies competing against us have financial and other resources substantially greater than our own. In addition, many of our competitors have significantly greater experience in testing pharmaceutical and other therapeutic products, obtaining FDA and other regulatory approvals of products, and marketing and selling those products. Accordingly, our competitors may succeed more rapidly than we will in obtaining FDA approval for products and achieving widespread market acceptance. If we obtain necessary regulatory approval and commence significant commercial sales of our products, we will also be competing with respect to manufacturing efficiency and marketing capabilities, areas in which we have limited or no commercial-scale experience.

Our two biologic drug candidates, if approved, would compete with several marketed products and other future biologic drug candidates. For our existing product and each of our clinical-stage biologic drug candidates, the primary competitors include:

- **Prochymal.** If approved, Prochymal will likely be the first drug indicated for the treatment of acute GvHD. The competitive landscape in Crohn’s disease is more crowded and, if approved, Prochymal will compete with Johnson & Johnson’s Remicade®, Abbott’s HUMIRA®, Biogen’s Tysabri® and UCB’s Cimzia®.

- **Chondrogen.** If approved, Chondrogen will compete with pain relievers such as acetaminophen, nonsteroidal anti-inflammatory drugs intra-articular injection of corticosteroid or hyaluronic acid. However, none of these have proven disease-modifying, which is one of the goals of the Chondrogen development program.

We may face competition in the future from other companies that are researching and developing stem cell therapies. We are aware of many companies working in this area, including: Aastrom Biosciences, Advanced Cell Technology, Athuersys, Cellerant Therapeutics, Cognate Therapeutics, Cytori Therapeutics, Gamida Cell, Geron, Angioblast, Mesoblast, MultiCell Technologies, Neuronyx, Theradigm, ViaCell and StemCells.

We expect to compete based upon, among other things, our intellectual property portfolio and the efficacy of our products. Our ability to compete successfully will depend on our continued ability to
attract and retain skilled and experienced scientific, clinical development and executive personnel, to identify and develop viable biologic drug candidates and to exploit these products and compounds commercially before others are able to develop competitive products.

In addition, our stem cell therapies may be expensive as compared to other therapies and this may make it more difficult for us to compete with other pharmaceuticals.

Government Regulation

Regulation by governmental authorities in the United States and other countries is a significant factor in the development, manufacture, commercialization and reimbursement of our products and services. Virtually all of the products we develop will require marketing approval, or licensure, by governmental agencies prior to commercialization. In particular, human therapeutic products are subject to rigorous preclinical and clinical testing and other approval procedures of the U.S. Food and Drug Administration, or FDA, and similar regulatory authorities in other countries. Various governmental statutes and regulations also govern or influence testing, manufacturing, safety, labeling, storage and record keeping related to such products and their marketing. State, local and other authorities may also regulate pharmaceutical manufacturing facilities. The process of obtaining these approvals and the subsequent compliance with appropriate statutes and regulations require the expenditure of substantial time and money, and there can be no guarantee that approvals will be granted.

FDA Approval Process

Our biologic drug candidates will require approval from the FDA and corresponding agencies in other countries before they can be marketed. The FDA regulates human therapeutic products in one of three broad categories: biologics, drugs, or medical devices. Our biologic drug candidates will be regulated as biological products. The FDA generally requires the following steps for pre-market approval or licensure of a new biological product or new drug product:

- preclinical laboratory and animal tests conducted in compliance with the FDA's Good Laboratory Practice, or GLP, requirements to assess a drug’s biological activity and to identify potential safety problems, and to characterize and document the product’s chemistry, manufacturing controls, formulation, and stability;
- submission to the FDA of an Investigational New Drug ("IND") application, which must become effective before clinical testing in humans can begin;
- obtaining approval of Institutional Review Boards ("IRBs") of research institutions or other clinical sites to introduce the biologic drug candidate into humans in clinical trials;
- adequate and well-controlled human clinical trials to establish the safety and efficacy of the product for its intended indication conducted in compliance with the FDA's Good Clinical Practice, ("GCP") requirements;
- compliance with current Good Manufacturing Practices ("cGMP") regulations and standards;
- submission to the FDA of a Biologics License Application, or BLA, or New Drug Application, or NDA, for marketing that includes adequate results of preclinical testing and clinical trials;
- FDA review of the marketing application in order to determine, among other things, whether the product is safe, effective and potent for its intended uses; and
- obtaining FDA approval of the BLA including inspection and approval of the product manufacturing facility as compliant with cGMP requirements, prior to any commercial sale or shipment of the pharmaceutical agent.
Typically, clinical testing involves a three-phase process although the phases may overlap. In Phase I, clinical trials are conducted with a small number of healthy volunteers or patients and are designed to provide information about product safety and to evaluate the pattern of drug distribution and metabolism within the body. In Phase II, clinical trials are conducted with groups of patients afflicted with a specific disease in order to determine preliminary efficacy, optimal dosages and expanded evidence of safety. In some cases, an initial trial is conducted in diseased patients to assess both preliminary efficacy and preliminary safety and patterns of drug metabolism and distribution, in which case it is referred to as a Phase I/II trial. Phase III clinical trials are generally large-scale, multicenter, comparative trials conducted with patients afflicted with a target disease in order to provide statistically valid proof of efficacy, as well as safety and potency. In some circumstances, the FDA may require Phase IV or post-marketing trials if it feels that additional information needs to be collected about the drug after it is on the market. During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data and clinical trial investigators. An agency may, at its discretion, re-evaluate, alter, suspend, or terminate the testing based upon the data which have been accumulated to that point and its assessment of the risk/benefit ratio to the patient. Monitoring all aspects of the study to minimize risks is a continuing process. All adverse events must be reported to the FDA.

The results of the preclinical and clinical testing on a non-biologic drug and certain diagnostic drugs are submitted to the FDA in the NDA or BLA. In the case of vaccines or gene and cell therapies, the results of clinical trials are submitted as a BLA. In responding to the submission of a BLA or NDA, the FDA may grant marketing authority, request additional clinical data or deny approval if the FDA determines that the application does not satisfy its regulatory approval criteria. FDA review of a BLA or NDA typically takes one to three years, but may last longer, especially if the FDA asks for more information or clarification of information already provided. Further clinical trials may be required to gain approval to promote the use of the product for any additional indications. Such additional indications are obtained through the approval of a supplemental BLA or NDA.

The process of obtaining regulatory approval is lengthy, uncertain, and requires the expenditure of substantial resources. Each NDA or BLA must be accompanied by a user fee, pursuant to the requirements of the Prescription Drug User Fee Act (“PDUFA”) and its amendments. The FDA adjusts the PDUFA user fees on an annual basis. According to the FDA's fee schedule, effective through September 30, 2008, the user fee for an application requiring clinical data, such as an NDA or BLA, is $1,178,000. PDUFA also imposes an annual product fee for prescription drugs and biologics ($65,030), and an annual establishment fee ($392,700) on facilities used to manufacture prescription drugs and biologics. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs or BLAs for products designated as orphan drugs, unless the drug also includes a non-orphan indication, and if a contract manufacturer is used, the contract manufacturer is responsible for the establishment fee.

Before approving an NDA or BLA, all facilities and manufacturing techniques used for the manufacture of products must comply with applicable FDA regulations governing cGMP. A local field division of the FDA is responsible for completing this inspection and providing recommendation for or against approval. This effort is intended to assure appropriate facility and process design to avoid potentially lengthy delays in product approvals due to inspection deficiencies. Similarly, before approving a new drug or biologics application, the FDA may also conduct pre-licensing inspections of a company, its contract research organizations and/or its clinical trial sites to ensure that clinical, safety, quality control and other regulated activities are compliant with GCP. To assure such cGMP and GCP compliance, the applicants must incur significant time, money and effort in the area of training, record keeping, production, and quality control. Following approval, the manufacture, holding, and distribution of a product must continue to devote significant resources to maintain full compliance in these areas.
After FDA approval has been obtained, the FDA will require post-marketing reporting to monitor the side effects of the drug. Further studies may be required to provide additional data on the product’s risks, benefits, and optimal use, and will be required to gain approval for the use of the product as a treatment for clinical indications other than those for which the product was initially tested. Results of post-marketing programs may limit or expand the further marketing of the product. Further, if there are any modifications to the drug, including changes in indication, labeling, or a change in the manufacturing process or manufacturing facility, an NDA or BLA supplement may be required to be submitted to the FDA.

Additionally, after the FDA has authorized a drug product to enter commercial distribution, numerous regulatory requirements apply. These include, among others, the cGMPs, which require manufacturers to follow extensive design, testing, control, documentation and other quality assurance procedures during the manufacturing process; labeling regulations; the FDA’s general prohibition against promoting drug products for unapproved or off-label uses; and adverse event reporting regulations, which require that manufacturers report to the FDA if their drug may have caused or contributed to a death or serious injury. The FDA has broad post-market and regulatory and enforcement powers. Failure to comply with the applicable U.S. drug regulatory requirements could result in, among other things, warning letters, fines, injunctions, consent decrees, civil penalties, refunds, recalls or seizures of products (which would result in the cessation or reduction of production volume), total or partial suspension of production, withdrawals or suspensions of current product applications, and criminal prosecution. Adverse events related to a drug product in any existing or future markets could cause regulatory authorities to withdraw market approval for such product.

Fast Track and Orphan Drug Designations

Congress enacted the Food and Drug Administration Modernization Act of 1997 in part to ensure the availability of safe and effective drugs, biologics, and medical devices by expediting the FDA review process for new products. The Modernization Act establishes a statutory program for the approval of Fast Track products, including biologics. A Fast Track product is defined as a new drug or biologic intended for the treatment of a serious or life-threatening condition that demonstrates the potential to address unmet medical needs for this condition. Under the Fast Track program, the sponsor of a new drug or biologic may request the FDA to designate the drug or biologic as a Fast Track product at any time during the clinical development of the product. This designation assures access to FDA personnel for consultation throughout the development process and provides an opportunity to request priority review of a marketing application providing a six-month review timeline for the designated product. If a preliminary review of the clinical data suggests that a Fast Track product may be effective, the FDA may initiate review of sections of a marketing application for a Fast Track product before the sponsor completes the application. This rolling review is available if the applicant provides a schedule for submission of remaining information and pays applicable user fees. However, the time periods specified under PDUFA concerning timing goals to which the FDA has committed in reviewing an application do not begin until the sponsor submits the complete application. During the first quarter of 2005 the FDA designated Prochymal as a Fast Track product for the treatment of GvHD. Prochymal also received Fast Track designation from the FDA in January 2007 for the treatment of refractory Crohn’s disease. We cannot predict whether this designation will impact the timing or likelihood of FDA approval of Prochymal.

The Orphan Drug Act provides incentives to manufacturers to develop and market drugs for rare diseases and conditions affecting fewer than 200,000 persons in the United States at the time of application for Orphan Drug designation. The first developer to receive FDA marketing approval for an Orphan Drug is entitled to a seven year exclusive marketing period in the United States for that product as well as a waiver of the BLA user fee. However, a drug that the FDA considers to be clinically superior to, or different from, another approved orphan drug, even though for the same
indication, may also obtain approval in the United States during the seven year exclusive marketing period. The FDA granted Orphan Drug designation for Prochymal during the last quarter of 2005.

Legislation similar to the Orphan Drug Act has been enacted in countries other than the United States, including the European Union. The orphan legislation in the European Union is available for therapies addressing conditions that affect five or fewer out of 10,000 persons. The marketing exclusivity period is for ten years, although that period can be reduced to six years if, at the end of the fifth year, available evidence establishes that the product is sufficiently profitable not to justify maintenance of market exclusivity.

Privacy Law

Federal and state laws govern our ability to obtain and, in some cases, to use and disclose data we need to conduct research activities. Through the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) Congress required the Department of Health and Human Services to issue a series of regulations establishing standards for the electronic transmission of certain health information. Among these regulations were standards for the privacy of individually identifiable health information. Most health care providers were required to comply with the Privacy Rule as of April 14, 2003.

HIPAA does not preempt, or override, state privacy laws that provide even more protection for individuals’ health information. These laws’ requirements could further complicate our ability to obtain necessary research data from our collaborators. In addition, certain state privacy and genetic testing laws may directly regulate our research activities, affecting the manner in which we use and disclose individuals’ health information, potentially increasing our cost of doing business, and exposing us to liability claims. In addition, patients and research collaborators may have contractual rights that further limit our ability to use and disclose individually identifiable health information. Claims that we have violated individuals’ privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.

Other Regulations

In addition to privacy law requirements and regulations enforced by the FDA, we also are subject to various local, state and federal laws and regulations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals and the use and disposal of hazardous or potentially hazardous substances, including chemicals, micro-organisms and various radioactive compounds used in connection with our research and development activities. These laws include, but are not limited to, the Occupational Safety and Health Act, the Toxic Test Substances Control Act and the Resource Conservation and Recovery Act. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards prescribed by state and federal regulations, we cannot assure you that accidental contamination or injury to employees and third parties from these materials will not occur. We may not have adequate insurance to cover claims arising from our use and disposal of these hazardous substances.

Foreign Regulation

We will most likely have to obtain approval for the manufacturing and marketing of each of our products from regulatory authorities in foreign countries prior to the commencement of marketing of the product in those countries. The approval procedure varies among countries, may involve additional preclinical testing and clinical trials, and the time required may differ from that required for FDA approval or licensure. Although there is now a centralized European Union approval mechanism in place, this applies only to certain specific medicinal product categories. In respect of all other medicinal products, each European country may impose certain of its own procedures and requirements in

26
addition to those requirements set out in the appropriate legislation, many of which could be
time-consuming and expensive. Although data requirements presently exist for gene therapy and
somatic cell therapy medicinal products, additional European approval standards for cellular therapy
are still under development, and consequently approval of cell therapy products in Europe may require
additional data that we may not be able to satisfy.

Employees

As of December 31, 2009, our headcount was 57 full-time employees. Of this total, 42 were
engaged in research and development and clinical trials for our Biologic Drug products and 15 were
engaged in administration, facilities and finance. All of our employees have entered into non-disclosure
agreements with us regarding our intellectual property, trade secrets and other confidential or
proprietary information. None of our employees are represented by a labor union or covered under a
collective bargaining agreement, and we have not experienced any work stoppages.

Executive Officers of the Registrant

Executive officers are appointed annually by the Board of Directors and, subject to the terms of
any applicable employment agreement, serve at the discretion of the Board of Directors. Information
regarding our executive officers is as follows:

<table>
<thead>
<tr>
<th>Name</th>
<th>Age</th>
<th>Position</th>
<th>Other Offices or Positions Held During the Past Five Years</th>
</tr>
</thead>
<tbody>
<tr>
<td>C. Randal Mills, Ph.D.</td>
<td>38</td>
<td>President and Chief Executive Officer (since July 2004)</td>
<td>Dr. Mills is also a member of the Board of Directors. Prior to joining Osiris, Dr. Mills was an executive officer of Regeneration Technologies, Inc. (NASDAQ—RTIX). Dr. Mills served in several leadership positions at RTI from its formation in 1998 until 2004, including Vice President of Business Development and Vice President of Operation and R&amp;D, and is credited with several key initiatives, including the development and commercialization of RTI's core technology, BioCleanse.</td>
</tr>
<tr>
<td>Lode Debrabandere, Ph.D.</td>
<td>44</td>
<td>Senior Vice President, Therapeutics (since July 2006)</td>
<td>Prior to joining Osiris, Dr. Debrabandere served for over four years with Bristol-Myers Squibb as Vice President for Strategic Marketing for Neuroscience and Infectious Diseases. He led the Neuroscience Unit and was the Global Brand Leader for Abilify™. Previously, Dr. Debrabandere led the Marketing department of UCB Pharma Inc., focusing in the areas of allergy/respiratory (Zyrtec™) and neurology (Keppra™).</td>
</tr>
<tr>
<td>Name</td>
<td>Age</td>
<td>Position</td>
<td>Other Offices or Positions Held During the Past Five Years</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----</td>
<td>-----------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Michelle LeRoux Williams, Ph.D.</td>
<td>35</td>
<td>Chief Scientific Officer</td>
<td>Dr. Williams joined Osiris in 2001 as the Director of Orthopedics and was responsible for the development of Osteocel from the initial concept through product launch in 2005. Dr. Williams also advanced the Chondrogen program from preclinical testing through the Phase I/II clinical trial. Prior to joining Osiris, Dr. Williams completed an NIH postdoctoral fellowship in tissue engineering at Columbia University, evaluating cellular constructs for the repair and regeneration of cartilage in arthritis patients.</td>
</tr>
<tr>
<td>Philip R. Jacoby, Jr.</td>
<td>57</td>
<td>Chief Financial Officer and Corporate Secretary</td>
<td>Mr. Jacoby has over 30 years of financial and management experience with public and privately held companies. Mr. Jacoby joined Osiris in April 2005 as our Corporate Controller and principal accounting officer in preparation for our initial public offering. Prior to joining Osiris, Mr. Jacoby was the Vice President and Corporate Controller for FTI Consulting, Inc. (NYSE—FCN) from 1999 through the first quarter of 2005.</td>
</tr>
</tbody>
</table>

Available Information

Our website address is www.osiris.com. Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 are available on our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the U.S. Securities and Exchange Commission, or SEC. The public may read and copy these materials at the SEC’s Public Reference Room at 100 F Street, NE, Washington, D.C. 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains a website that contains such reports, proxy and information statements and other information, and the Internet address is http://www.sec.gov. Information contained on our website is not and should not be deemed a part of this annual report or any other report or filing filed with the SEC.
ITEM 1A. Risk Factors.

Risks Related To Our Business

We have a history of operating losses and may not achieve or sustain profitability.

Until fiscal 2009, we incurred losses in each year since our inception, and may incur additional losses over the next several years. As of December 31, 2009, we had an accumulated deficit of $260.3 million. These losses resulted principally from costs incurred in our research and development programs and from our general and administrative expenses. These losses, among other things, have had and will continue to have an adverse effect on our stockholders’ equity, total assets and working capital.

We expect to continue to incur significant operating expenses in the foreseeable future as we seek to:

- complete our Phase III clinical trials for Prochymal for GvHD and Crohn’s disease;
- complete our Phase II clinical trial for Prochymal for cardiac indications, and, if supported by the Phase II clinical trial, initiate Phase III clinical trials;
- complete our Phase II clinical trial for Prochymal for type 1 diabetes, and, if supported by the Phase II clinical trial, initiate Phase III clinical trials;
- complete our animal studies for Prochymal for acute radiation syndrome, and, if supported by the preclinical studies, initiate further studies;
- maintain, expand and protect our intellectual property portfolio; and
- add operational, financial, accounting, facilities engineering and information systems personnel, consistent with expanding our operations and our status as a public company.

In addition, during 2008 we sold our Osteocel business unit, including our only commercially available product. While we expect to achieve commercialization of at least some of our other products, there can be no assurances when, or if, we will be able to do so.

The extent of our future operating losses or profits is highly uncertain, and we may not achieve or sustain profitability. If we are unable to achieve and then maintain profitability, the market value of our common stock will decline and you could lose part or all of your investment.

The current credit and financial market conditions may exacerbate certain risk affecting our business.

We rely upon third parties for certain aspects of our business, including collaboration partners, wholesale distributors, contract clinical trial providers, contact manufacturers and third-party suppliers. Because of the recent tightening of global credit and the volatility in the financial markets, there may be a delay or disruption in the performance or satisfaction of commitments to us by these third parties, which could adversely affect our business.

If we are not able to recruit and retain qualified management and scientific personnel, we may fail in developing our technologies and biologic drug candidates.

Our future success depends to a significant extent on the skills, experience and efforts of the principal members of our scientific, management and sales personnel. These members include C. Randal Mills, Ph.D., Michelle L. Williams, Ph.D., Philip R. Jacoby, Jr., and Lode Debrabandere Ph.D. The loss of any or all of these individuals could harm our business and might significantly delay or prevent the achievement of research, development or business objectives. We have entered into employment agreements with Dr. Mills and Dr. Debrabandere. The existence of an employment agreement does not, however, guarantee retention of these employees, and we may not be
able to retain those individuals for the duration of or beyond the end of their respective terms. Except for Dr. Mills and Dr. Debrabandere, none of our employees is employed for a specified term. Competition for personnel is intense. We may be unable to retain our current personnel or attract or integrate other qualified management and scientific personnel in the future.

If the potential of our stem cell therapies to treat diseases is not realized, the value of our technology and our development programs could be significantly reduced.

The potential of our stem cell therapies to treat diseases is currently being explored by us. We have not proven in clinical trials that our stem cell therapies will be a safe and effective treatment for any disease. Our stem cell therapies are susceptible to various risks, including undesirable and unintended side effects, unintended immune system responses, inadequate therapeutic efficacy or other characteristics that may prevent or limit their marketing approval or commercial use. We have not yet completed all of the testing necessary to allow us to make a determination that serious unintended consequences will not occur. If the potential of our stem cell therapies to treat disease is not realized, the value of our technology and our development programs could be significantly reduced. Because our biologic drug candidates are based on MSCs, any negative developments regarding the therapeutic potential or side effects of MSCs could have a material adverse effect on our business, financial condition and results of operations.

Our product development programs are based on novel technologies and are inherently risky.

We are subject to the risks of failure inherent in the development of products based on new technologies. The novel nature of our therapeutics creates significant challenges in regards to product development and optimization, manufacturing, government regulation, third-party reimbursement and market acceptance. For example, the FDA has relatively limited experience with stem cell therapies. None has been approved by the FDA for commercial sale, and the pathway to regulatory approval for our biologic drug candidates may accordingly be more complex and lengthy. Additionally, stem cells are subject to donor-to-donor variability, which can make standardization more difficult. As a result, the development and commercialization pathway for our therapies may be subject to increased uncertainty, as compared to the pathway for new conventional drugs.

There are no FDA approved treatments for some of the disease indications we are pursuing. This could complicate and delay FDA approval of our biologic drug candidates.

There are no drugs or therapies currently approved with stated indications for the first-line treatment of acute GvHD or the treatment of steroid refractory GvHD. As a result, the clinical efficacy endpoints, or the criteria to measure the intended results of treatment, for our biologic drug candidate Prochymal for the treatment of GvHD may be difficult to determine. In addition, patients battling GvHD and who, therefore, are candidates for treatment with Prochymal, are typically very ill as a result of an underlying genetic or oncologic condition. Due to the graveness of their underlying disease and the very serious complications and disorders that often accompany acute GvHD, many of these patients will die from causes other than GvHD prior to the completion of the study even if their GvHD responds favorably to treatment with Prochymal. The resulting reduction in the number of patients available for evaluation at the end of the study may make it more difficult for us to demonstrate efficacy, as necessary to obtain FDA approval to market Prochymal for commercial sale.

There are also no drugs or therapies currently approved with stated indications for the repair of heart muscle following heart attack. As a result, the clinical endpoints for our biologic drug candidate Prochymal for cardiac indications may be difficult to determine. In the case of Prochymal for the treatment of Crohn’s disease, there are other products approved for the treatment of this disease, so it is expected that the clinical efficacy endpoints for Prochymal for this indication will be established by comparison with these already approved treatments. In order to obtain FDA approval for any
indication, we will have to demonstrate, among other things, that our biologic drug candidate is safe and effective for that indication. The results of our clinical trials must be statistically significant, meaning that there must be sufficient data to indicate that it is unlikely the outcome occurred by chance. These challenges may prevent us from developing and commercializing products on a timely or profitable basis, or at all.

*Our biologic drug candidates represent new classes of therapy that the marketplace may not understand or accept.*

Even if we successfully develop and obtain regulatory approval for our biologic drug candidates, the market may not understand or accept them. We are developing biologic drug candidates that represent novel treatments and will compete with a number of more conventional products and therapies manufactured and marketed by others, including major pharmaceutical companies. The degree of market acceptance of any of our developed and potential products will depend on a number of factors, including:

- the clinical safety and effectiveness of our products and their perceived advantage over alternative treatment methods;
- our ability to demonstrate that Prochymal can have a clinically significant effect, initially on steroid refractory GvHD and acute GvHD, and then also the other indications for which we seek approval;
- our ability to separate ourselves from the ethical controversies associated with stem cell drug candidates derived from human embryonic or fetal tissue;
- ethical controversies that may arise regarding the use of stem cells or human tissue of any kind, including adult stem cells, adult bone marrow and other adult tissues derived from donors;
- adverse events involving our biologic drug candidates or the products or product candidates of others that are stem cell based;
- our ability to supply a sufficient amount of our product to meet regular and repeated demand in order to develop a core group of medical professionals familiar with and committed to the use of our products; and
- the cost of our products and the reimbursement policies of government and third-party payors.

If the health care community does not accept our potential products for any of the foregoing reasons, or for any other reason, it could affect our sales, having a material adverse effect on our business, financial condition and results of operations.

*The successful commercialization of our biologic drug candidates, or any of our other potential stem cell therapeutics, will depend on obtaining reimbursement from third-party payors.*

If we successfully develop and obtain necessary regulatory approvals, we intend to sell our biologic drug candidates initially in the United States and Canada. In the United States, the market for any pharmaceutical product is affected by the availability of reimbursement from third-party payors, such as government health administration authorities, private health insurers, health maintenance organizations and pharmacy benefit management companies. Stem cell therapies like Prochymal and Chondrogen may be expensive compared with standard pharmaceuticals, due to the higher cost and complexity associated with the research, development and production of stem cell therapies, the small size and large geographic diversity of the target patient population for some indications, and the complexity associated with distribution of stem cell therapies which require special handling, storage and shipment procedures and protocols. This, in turn, may make it more difficult for us to obtain adequate reimbursement from third-party payors, particularly if we cannot demonstrate a favorable cost-benefit
relationship. Third-party payors may also deny coverage or offer inadequate levels of reimbursement for our potential products if they determine that the product has not received appropriate clearances from the FDA or other government regulators or is experimental, unnecessary or inappropriate. For example, patients battling GvHD and who, therefore, are candidates for treatment with Prochymal, are typically very ill as a result of an underlying genetic or oncologic condition. Because these patients have a low probability of survival (whether or not their GvHD is successfully treated), third-party payors may resist reimbursing the cost of treatment.

In some of the other countries in which we or other entities with which we collaborate, including Genzyme Corporation, may seek to market our products, the pricing of prescription pharmaceutical products and services and the level of government reimbursement are subject to governmental control. In these countries, pricing negotiations with governmental authorities can take six to twelve months or longer after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we or our collaborators may be required to conduct one or more clinical trials that compare the cost effectiveness of our biologic drug candidates or products to other available therapies. Conducting one or more additional clinical trials would be expensive and result in delays in commercialization of our products.

Managing and reducing health care costs has been a general concern of federal and state governments in the United States and of foreign governments. Although we do not believe that any recently enacted or presently proposed legislation should impact our business, we might be subject to future regulations or other cost-control initiatives that materially restrict the price we receive for our products. In addition, third-party payors are increasingly challenging the price and cost-effectiveness of medical products and services, and many limit reimbursement for newly approved health care products. In particular, third-party payors may limit the indications for which they will reimburse patients who use any products that we may develop. Cost control initiatives could decrease the price for products that we may develop, which would result in lower product revenues to us.

*Our dependence upon a limited supply of bone marrow donors and biologics growth media may impact our ability to produce sufficient quantities of our biologic drug candidates as necessary to complete our clinical trials, and if our trials are successful, to meet product demand.*

The population of acceptable bone marrow donors is limited to volunteers between the ages of 18 and 30. In addition, potential donors are prescreened for a variety of health conditions and are only allowed to donate bone marrow a total of six times in their lifetime, further limiting the total number of potential donors. The amount of bone marrow donated may be insufficient for us to mass produce our biologic drug candidates. In addition, the expansion of MSCs through our proprietary manufacturing methods utilizes biologic growth media which may be in limited supply. Future government regulation or health concerns may also reduce the number of donors or otherwise limit the amount of bone marrow available to us. If we cannot secure quantities of bone marrow or biologic growth media sufficient to meet the manufacturing demands for our clinical trials, we might not be able to complete our clinical trials and obtain marketing approval for our biologic drug candidates. Moreover, even if our clinical trials are successful and we obtain marketing approval for our biologic drug candidates, our inability to secure enough bone marrow to meet product demand would limit our potential revenues.

*Our biologic drug candidates are derived from human bone marrow sources and therefore have the potential for disease transmission.*

The utilization of donated bone marrow creates the potential for transmission of communicable disease, including but not limited to human immunodeficiency virus (“HIV”) viral hepatitis, syphilis, Creutzfeldt-Jakob disease, or the human form of “mad cow” disease, and other viral, fungal or bacterial pathogens. Although we are required to comply with federal and state regulations intended to
prevent communicable disease transmission, and our suppliers of adult human bone and bone marrow
are also required to comply with such regulations in connection with their collection, storage and
supply to us:

- we or our suppliers may fail to comply with such regulations;
- even with compliance, our products might nevertheless be viewed by the public as being
  associated with transmission of disease; and
- a patient that contracts an infectious disease might assert that the use of our products resulted
  in disease transmission, even if the patient became infected through another source.

Any actual or alleged transmission of communicable disease could result in patient claims,
litigation, distraction of management’s attention and potentially increased expenses. Further, any failure
in screening, whether by us or other manufacturers of similar products, could adversely affect our
reputation, the support we receive from the medical community and overall demand for our products.
As a result, such actions or claims, whether or not directed at us, could have a material adverse effect
on our reputation with our customers and our ability to market our products, which could have a
material adverse effect on our business, financial condition and results of operations.

We may not be able to manufacture our biologic drug candidates in quantities sufficient for later stage clinical
studies or for commercial sale.

If we successfully obtain marketing approval for one of our biologic drug candidates, we may not
be able to produce sufficient quantities of the product at an acceptable cost. Commercial-scale
production of therapies made from live human mesenchymal stem cells involves production in small
batches and strict adherence to complex manufacturing and storage protocols and procedures. Our
biologic drug candidates are inherently more difficult to manufacture at commercial-scale than chemical
pharmaceuticals, which are manufactured using precise chemical formulations and operational methods.

We use third-party collaborators to help us develop and commercialize our products, and our ability to
commercialize such products may be impaired or delayed if collaborations are unsuccessful.

We have arrangements in place with third-party collaborators as a means to help us with research
and development efforts or marketing and distribution. For example:

- we are party to a Collaboration Agreement with Genzyme Corporation for the development and
  commercialization of Prochymal and Chondrogen outside the United States and Canada for
certain indications, and with the potential for the development and commercialization of these
product candidates for additional indications in the future;
- we have a collaboration with JCR Pharmaceuticals Co., Ltd. granting to JCR an exclusive right
to Prochymal for the treatment of GvHD in Japan; and
- we have a collaboration with Genzyme Corporation to develop effective countermeasures to
nuclear terrorism and other radiological emergencies. The initial focus of the collaboration is to
develop Prochymal to treat the potentially lethal complications of acute radiation syndrome.

We may enter into additional collaborations in the future. We are dependent upon the success of
our current and any future collaborators in performing their responsibilities in connection with the
relevant collaboration. If we fail to maintain these collaborative relationships for any reason, we would
need to undertake on our own and at our own expense, or find other collaborators, to perform the
activities we currently anticipate will be performed by our collaborators. This would substantially
increase our cash requirements. We may not have the capability or financial capacity to undertake these
activities on our own, or we may not be able to find other collaborators on acceptable terms, or at all.
This may limit the programs we are able to pursue and result in significant delays in the development, sale and manufacture of our products, and may have a material adverse effect on our business.

We are subject to a number of risks associated with our dependence upon our collaborative relationships, including:

- our collaborators may not cooperate with us or perform their obligations under our agreements with them;
- we cannot control the quality, amount and timing of our collaborators’ resources that will be devoted to performing their responsibilities under our agreements with them, and our collaborators may choose to pursue alternative technologies in preference to those being developed in collaboration with us;
- refusal to or failure of our collaborators to perform their responsibilities in a timely manner, including breach;
- the right of the collaborator to terminate its collaboration agreement with us for reasons outside our control, and in some cases on limited notice;
- business combinations and changes in a collaborator’s business strategy may adversely affect the party’s willingness or ability to complete its obligations;
- loss of significant rights to our collaborative parties if we fail to meet our obligations;
- disagreements as to ownership of clinical trial results or regulatory approvals;
- withdrawal of support by a collaborator following development or acquisition by the collaborator of competing products; and
- disagreements with a collaborator regarding the collaboration agreement or ownership of intellectual property or other proprietary rights.

Due to these factors and other possible events, we could suffer delays in the research, development or commercialization of our products or we may become involved in litigation or arbitration, which would be time consuming and expensive.

Two of our most significant collaborative arrangements are with Genzyme Corporation, and our ultimate success may depend upon performance on the part of Genzyme and the success of these collaborations.

We are party to two collaborative arrangements with Genzyme, one for the development and commercialization of Prochymal and Chondrogen outside the United States and Canada for certain indications, and the other to develop effective countermeasures to nuclear terrorism and other radiological emergencies. These collaborations are subject to all of the risks and uncertainties applicable to collaborative arrangements generally, including those described above. In addition, these collaborations are subject to a number of risks and uncertainties specific to the transactions and the parties.

Under our collaborative arrangement with Genzyme for commercialization of Prochymal and Chondrogen outside the United States, Genzyme agreed to make two up front payments to us totaling $130.0 million, which have been received. In addition, we have the opportunity to earn up to an additional $1.25 billion in milestone payments pursuant to this collaboration. Receipt of these additional milestone payments is conditioned upon the achievement of the applicable development, regulatory and sales milestones, all of which are subject to all of the risks and uncertainties otherwise applicable to our business, including the success of Prochymal and Chondrogen. Genzyme has the right to terminate the collaboration at any time after July 1, 2009. Genzyme also has the right to “opt-out” of further participation with regard to Chondrogen development, whereupon all rights to Chondrogen
will revert to us, but our opportunity to earn Chondrogen-related development, regulatory and sales milestones of up to approximately $500.0 million will cease. The success of this collaboration for us will in part be dependent upon Genzyme, including determinations regarding the exercise of its termination and opt-out rights, and its success in obtaining timely regulatory approvals for the marketing of products outside of the United States, and ability to generate sales sufficient to trigger milestone and royalty payments to us.

Under our collaborative arrangement with Genzyme for the development of effective countermeasures to nuclear terrorism and other radiological emergencies, we were awarded in January 2008 a contract from the U.S. Department of Defense to develop and supply Prochymal for ARS. We are carrying out this contract in partnership with Genzyme, with us contributing Prochymal and our corresponding safety and advocacy database to the effort, and with Genzyme lending its mass product development and large scale commercialization expertise.

Genzyme has significantly greater resources than we do, and these collaborations are not as core to its business, as they are to ours. We are dependent upon Genzyme’s continued performance under these collaborations, and any determination by Genzyme not to proceed or perform, or any material adverse event that affects Genzyme’s ability or desire to perform, under either of these collaborations may have a material adverse effect on our business.

We are currently dependent upon third-parties for services and raw materials needed for the manufacture of our biologic drug candidates, and if these products are successfully commercialized, may become dependent upon third-parties for their distribution. If any of these third parties fail or are unable to perform in a timely manner, our ability to manufacture and deliver could be compromised.

In order to produce our biologic drug candidates for use in clinical studies, and to produce any of our biologic drug candidates that may be approved for commercial sale, we require biological media, reagents and other highly specialized materials. This is in addition to the bone marrow aspirate used in the manufacture of our biologic drug candidates. These items must be manufactured and supplied to us in sufficient quantities and in compliance with cGMP. To meet these requirements, we have entered into supply agreements with firms that manufacture these components to cGMP standards. Our requirements for these items are expected to increase if and when we transition to the manufacture of commercial quantities of our biologic drug candidates.

In addition, as we proceed with our clinical trial efforts, we must be able to demonstrate to the FDA that we can manufacture our biologic drug candidates with consistent characteristics. Accordingly, we are materially dependent on these suppliers for supply of cGMP-grade components of consistent quality. Our ability to complete ongoing clinical trials may be negatively affected in the event that we are forced to seek and validate a replacement source for any of these critical components. If we are not able to obtain adequate supplies of these items of consistent quality from our third-party suppliers, it will also be more difficult to manufacture commercial quantities of our biologic drug candidates that are approved for commercial sale.

In addition, if commercial sale of our biologic drug candidates is approved, we intend to rely on third parties for their distribution. Proper shipping and distribution requires compliance with specific storage and shipment procedures. Failure to comply with these procedures or the occurrence of inadvertent damage to the shipping container will necessitate return and replacement, potentially resulting in additional cost and causing us to fail to meet supply requirements.
Use of third-party manufacturers may increase the risk that we will not have adequate quantities of our biologic drug candidates.

We use third-party manufacturers to supply our biologic drug candidates for clinical trials. Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured such components ourselves, including:

- reliance on the third party for regulatory compliance and quality assurance;
- the possible breach of the manufacturing agreement by the third party; and
- the possible termination or nonrenewal of the agreement by the third party, based on its own business priorities, at a time that is costly or inconvenient for us.

Our contract manufacturers are subject to all of the risks and uncertainties that we have when we manufacture on our own. Similar to us, they are subject to ongoing, periodic, unannounced inspection by the FDA and corresponding state and foreign agencies or their designees to ensure strict compliance with cGMP regulations and other governmental regulations and corresponding foreign standards. However, we do not control compliance by our contract manufacturers with these regulations and standards. Our present or future manufacturers might not be able to comply with these regulatory requirements. If our third-party manufacturers fail to comply with applicable regulations, the FDA or other regulatory authorities could impose sanctions on us, including fines, injunctions, civil penalties, denial of marketing approval of our biologic drug candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of biologic drug candidates or our other products, operating restrictions and criminal prosecutions. Any of these actions could significantly and adversely affect supplies of our biologic drug candidates or other products and could have a material adverse effect on our business, financial condition and results of operations.

We have contracted with Lonza to manufacture quantities of our stem cell drug candidates for our clinical trials. If Lonza is unable to increase production sufficiently, we may also not be able to meet anticipated market demand in the future.

If our processing and storage facility or our clinical manufacturing facilities are damaged or destroyed, our business and prospects would be negatively affected.

If our processing and storage facility or the equipment in the facility were to be significantly damaged or destroyed, we could suffer a loss of some or all of the stored units of our biologic drug candidates and it would force us to halt our clinical trial processes.

We lease approximately 61,203 square feet of space in Columbia, Maryland that houses essentially all of our corporate operations. Currently, we maintain insurance coverage totaling $19.4 million against damage to our property and equipment, an additional $4.0 million to cover business interruption and extra expenses, and $5.6 million to cover R&D restoration expenses. If we have underestimated our insurance needs, we will not have sufficient insurance to cover losses above and beyond the limits on our policies.
*Ethical and other concerns surrounding the use of stem cell therapy or human tissue may negatively affect public perception of us or our products or biologic drug candidates, or may negatively affect regulatory approval of our products or biologic drug candidates, thereby reducing demand for our products and adversely affecting the market price for our common stock.*

The commercial success of our biologic drug candidates will depend in part on general public acceptance of the use of stem cell therapy for the prevention or treatment of human diseases. The use of embryonic stem cells and fetal tissue for research and stem cell therapy has been the subject of substantial national and international debate regarding related ethical, legal and social issues. In the U.S., for example, until March 2009, federal government funding of embryonic stem cell research was limited to specifically identified cell lines and was not otherwise available. We do not use embryonic stem cells or fetal tissue, but the public may not be able to, or may fail to, differentiate our use of adult stem cells from the use by others of embryonic stem cells or fetal tissue. This could result in a negative perception of our company or our products or biologic drug candidates.

We may obtain stem cells from volunteer adult bone marrow donors from non-profit organizations that collect and process tissue donations. Bone marrow donors receive payment, but ethical concerns have been raised by some about the use of donated human tissue in a for-profit setting, as we are doing.

Future adverse events in the field of stem cell therapy or changes in public policy could also result in greater governmental regulation of our biologic drug candidates and potential regulatory delays relating to their testing or approval.

*We may eventually compete with other companies for product sales. Many of these competitors have greater resources or capabilities than we have, or may succeed in developing better products or in developing products more quickly than we do, and we may not compete successfully with them.*

In the marketplace, we compete or may eventually compete with other companies and organizations that are marketing or developing therapies for our targeted disease indications, based on traditional pharmaceutical, medical device or other, non-cellular therapy and technologies. These include: Novartis, the manufacturer of Neoral® for the prevention of organ rejection in transplant patients, which would compete with Prochymal for the treatment of GvHD; and Johnson & Johnson, the manufacturer of Remicade®, and Abbott, the manufacturer of Humira®, which would compete with Prochymal for the treatment of Crohn’s disease. In addition to those listed above, we have other potential competitors developing a variety of therapeutics.

We also face competition in the cell therapy field from academic institutions and governmental agencies. Many of our current and potential competitors have greater financial and human resources than we have, including more experience in research and development and more established sales, marketing and distribution capabilities.

We anticipate that competition in our industry will increase. In addition, the health care industry is characterized by rapid technological change, resulting in new product introductions and other technological advancements. Our competitors may develop and market products that render products now or in the future under development by us, or any products manufactured or marketed by us, non-competitive or otherwise obsolete.

*The use of our stem cell therapies in human subjects may expose us to product liability claims, and we may not be able to obtain adequate insurance.*

We face an inherent risk of product liability claims. None of our products have been widely used over an extended period of time, and therefore our safety data are limited. We derive the raw materials for our products from human donor sources, the manufacturing process is complex, and the handling
requirements are specific, all of which increase the likelihood of quality failures and subsequent product liability claims. We will need to increase our insurance coverage if and when we begin commercializing our biologic drug candidates. We may not be able to obtain or maintain product liability insurance on acceptable terms with adequate coverage or at all. If we are unable to obtain insurance, or if claims against us substantially exceed our coverage, then our business could be adversely impacted. Whether or not we are ultimately successful in any product liability litigation, such litigation could consume substantial amounts of our financial and managerial resources and could result in, among other things:

- significant awards against us;
- substantial litigation costs;
- recall of the product;
- injury to our reputation;
- withdrawal of clinical trial participants; or,
- adverse regulatory action.

Any of these results could have a material adverse effect on our business, financial condition and results of operations.

By completing the sale of our Osteocel business, we sold the assets that produce our only currently commercialized product.

Pursuant to the asset purchase agreement with NuVasive, Inc., we sold our entire product line relating to the processing, manufacturing, marketing and selling of Osteocel and Osteocel XO. Although we generate revenues from a variety of other sources, including collaborative agreements and a government contract, the Osteocel business that we sold to Nuvasive included our only commercially available product.

Our long term business prospects will depend primarily on the success of our biologic drug candidates business.

Although we expect to continue to manufacture tissue based surgical biologic products in the future, our biologic drug candidate business will be the primary focus of our business. Our long term business prospects will, therefore, be dependent almost solely on the success of our biologic drug candidate business. This business is based on novel technologies and involves significant risks and challenges in regards to product development and optimization, manufacturing, government regulation, intellectual property, third-party reimbursement and market acceptance, among the other risks disclosed by us.

Risks Related to Intellectual Property

If our patent position does not adequately protect our products, others could compete against us more directly, which would harm our business and have a material adverse effect on our financial condition and results of operations.

Our success depends, in large part, on our ability to obtain and maintain intellectual property protection for our biologic drug candidates. The patent position of biotechnology companies is generally highly uncertain, involves complex legal and factual questions and has been the subject of much litigation. Neither the U.S. Patent and Trademark Office nor the courts has a consistent policy regarding the breadth of claims allowed or the degree of protection afforded under many biotechnology patents.
The claims of our existing U.S. patents and those that may issue in the future, or those licensed to us, may not confer on us significant commercial protection against competing products. Third parties may challenge, narrow, invalidate, design around, or circumvent any patents owned, assigned or licensed to us and those that we may obtain in the future. Our patents on MSC technology, in particular, cover mesenchymal stem cells and the therapeutic uses thereof. Patents with such claims tend to be more vulnerable to challenge by other parties than patents with extremely narrow claims. Also, our pending patent applications may not issue, may issue with substantially narrower claims than currently pending claims, or we may not receive any additional patents. Further, the laws of foreign countries may not protect our intellectual property rights to the same extent as do the laws of the United States. Our patents might not contain claims that are sufficiently broad to prevent others from utilizing our technologies. Consequently, our competitors may independently develop competing products that do not infringe our patents or other intellectual property.

Because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any of our products can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantages of the patent. For instance, one of our patents related to our MSC technology will expire in 2013 if no extensions are applied for and received. To the extent our biologic drug candidates based on that technology are not commercialized ahead of this date, to the extent we have no other patent protection on such products, or to the extent that regulatory or patent extensions are not granted, those products would not have the robust protection we currently expect to enjoy. The background technologies used in the development of our biologic drug candidates are known in the scientific community, and it is possible to duplicate the methods we use to create our biologic drug candidates.

If certain license agreements are terminated, our market exclusivity could be adversely affected.

We are a party to various agreements that give us rights to use specified technologies applicable to research, development and commercialization of our product candidates. If these agreements are voided or terminated, our product development, research and commercialization efforts may be altered or delayed. Certain aspects of our technology rely on patented inventions developed using university or other third party resources. The universities or third parties may have certain rights, as defined by law or applicable agreements, in such patents, and may choose to exercise such rights. If we fail to comply with any terms or provisions of these agreements, our rights could be terminated. Currently, we are in compliance with the terms of all agreements, and we do not have any reason to believe that our rights might be terminated.

If we are unable to protect the confidentiality of our proprietary information, trade secrets and know-how, our competitive position would be impaired and our business, financial condition and results of operations could be adversely affected.

Some aspects of our technology, especially regarding manufacturing processes, are unpatented and maintained by us as trade secrets. In an effort to protect these trade secrets, we require our employees, consultants, collaborators and advisors to execute confidential disclosure agreements before the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual’s relationship with us be kept confidential and not disclosed to third parties. These agreements, however, may not provide us with adequate protection against improper use or disclosure of confidential information, and these agreements may be breached. A breach of confidentiality could affect our competitive position. In addition, in some situations, these agreements may conflict with, or be subject to, the rights of third parties with whom our employees, consultants, collaborators or advisors have previous employment or consulting relationships. Also, others may independently develop
substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets.

Adequate remedies may not exist in the event of unauthorized use or disclosure of our confidential information. The disclosure of our trade secrets would impair our competitive position and could have a material adverse effect on our business, financial condition and results of operations.

**If we infringe or are alleged to infringe intellectual property rights of third parties, it will adversely affect our business, financial condition and results of operations.**

Our research, development and commercialization activities, including any biologic drug candidates or products resulting from these activities, may infringe or be alleged to infringe patents owned by third parties and to which we do not hold licenses or other rights. There may be applications that have been filed but not published that, when issued, could be asserted against us. These third parties could bring claims against us that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, we could be enjoined from certain activities including a stop or delay in research, development, manufacturing or sales activities related to the product or biologic drug candidate that is the subject of the suit.

As a result of patent infringement claims, or in order to avoid potential claims, we may choose or be required to seek a license from the third party. These licenses may not be available on acceptable terms, or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms. All of the issues described above could also impact our collaborators, which would also impact the success of the collaboration and therefore us.

There has been substantial litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical and biotechnology industries. In addition to infringement claims against us, we may become a party to other patent litigation and other proceedings, including interference and reexamination proceedings declared by the United States Patent and Trademark Office and opposition proceedings before the patent offices for other countries (e.g. the European Patent Office) or similar adversarial proceedings, regarding intellectual property rights with respect to our products and technology. For example, a patent that was granted to us in Europe for human mesenchymal stem cells in the cardiac context was opposed in the European Patent Office by two different companies. In 2008 we prevailed in an opposition before the European Patent Office against one patent related to the cardiac indications of Prochymal. Though we were successful in that particular case, the outcome of any future patent controversies is uncertain. The cost to us of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace and, as a result, on our business, financial condition and results of operations. To the extent that our employees, consultants or contractors use intellectual property owned by others, disputes may arise as to the rights related to or resulting from the use of such intellectual property.
We may become involved in lawsuits to protect or enforce our patents or the patents of our collaborators or licensors, which could be expensive and time consuming.

Litigation may be necessary to enforce patents issued or licensed to us, to protect trade secrets or know-how, or to determine the scope and validity of the proprietary rights. Litigation, opposition or interference proceedings could result in substantial additional costs and diversion of management focus. If we are ultimately unable to protect our technology, trade secrets or know-how, we may be unable to operate profitably.

Competitors may infringe our patents or the patents of our collaborators or licensors. As a result, we may be required to file infringement claims to protect our proprietary rights. This can be expensive, particularly for a company of our size, and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is invalid or is unenforceable, or may refuse to enjoin the other party from using the technology at issue. An adverse determination of any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly. Interference proceedings brought by the U.S. Patent and Trademark Office may be necessary to determine the priority of inventions with respect to our patent applications or those of our collaborators or licensors. Litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distraction to our management. We may not be able, alone or with our collaborators and licensors, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States.

Furthermore, though we would see protective orders where appropriate, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If investors perceive these results to be negative, the market price for our common stock could be significantly harmed.

The biotechnology industry, including our fields of therapeutic interest, is highly competitive and subject to significant and rapid technological change. Accordingly, our success will depend, in part, on our ability to respond quickly to such change through the development and introduction of new products. Our ability to compete successfully against currently existing and future alternatives to our product candidates and systems and competitors who compete directly with us in the biopharmaceutical industry will depend, in part, on our ability to: attract and retain skilled scientific and research personnel; develop technologically superior products; develop competitively priced products; obtain patent or other required regulatory approvals for our products; and be early entrants to the market; manufacture, market and sell our products, independently or through collaborations. If a third party were to commercialize a competitive product, there is no assurance that we would have a basis for initiating patent infringement proceedings or that, if initiated, we would prevail in such proceedings.

Risks Related to Regulatory Approval and Other Government Regulations

If we are not able to successfully develop and commercialize our biologic drug candidates and obtain the necessary regulatory approvals, we may not generate sufficient revenues to continue our business operations.

In order to generate sales revenue from our biologic drug candidates, we must conduct extensive preclinical studies and clinical trials to demonstrate that our biologic drug candidates are safe and effective and obtain required regulatory approvals. Our early stage biologic drug candidates may fail to perform as we expect. Moreover, our biologic drug candidates in later stages of development may fail to show the desired safety and efficacy traits despite having progressed successfully through preclinical or initial clinical testing. We will need to devote significant additional research and development, financial resources and personnel to develop commercially viable products and obtain the necessary regulatory approvals.
If our biologic drug candidates do not prove to be safe and efficacious in clinical trials, we will not obtain the required regulatory approvals. If we fail to obtain such approvals, we may not generate sufficient revenues to continue our business operations.

Even if we obtain regulatory approval of a product, that approval may be subject to limitations on the indicated uses for which it may be marketed. Even after granting regulatory approval, the FDA and regulatory agencies in other countries continue to review and inspect marketed products, manufacturers and manufacturing facilities, which may create additional regulatory burdens. Later discovery of previously unknown problems with a product, manufacturer or facility, may result in restrictions on the product or manufacturer, including a withdrawal of the product from the market. Further, regulatory agencies may establish additional regulations that could prevent or delay regulatory approval of our products.

We cannot market and sell our biologic drug candidates in the United States or in other countries if we fail to obtain the necessary regulatory approvals or licensure.

We cannot sell our biologic drug candidates until regulatory agencies grant marketing approval, or licensure. The process of obtaining regulatory approval is lengthy, expensive and uncertain. It is likely to take several years to obtain the required regulatory approvals for our lead stem cell biologic drug candidate, Prochymal, or we may never gain the necessary approvals. Any difficulties that we encounter in obtaining regulatory approval may have a substantial adverse impact on our operations and cause our stock price to decline significantly. Moreover, because our biologic drug candidates are all based on a single platform technology, MSCs, any adverse events in our clinical trials for one of our biologic drug candidates could negatively impact the clinical trials and approval process for our other biologic drug candidates.

To obtain marketing approvals in the United States for MSC products, for instance, we must, among other requirements, complete carefully controlled and well-designed clinical trials sufficient to demonstrate to the FDA that the biologic drug candidate is safe and effective for each disease for which we seek approval. Several factors could prevent completion or cause significant delay of these trials, including an inability to enroll the required number of patients or failure to demonstrate adequately that MSCs are safe, effective and potent for use in humans. Negative or inconclusive results from or adverse medical events during a clinical trial could cause the clinical trial to be repeated or a program to be terminated, even if other studies or trials relating to the program are successful. The FDA can place a clinical trial on hold if, among other reasons, it finds that patients enrolled in the trial are or would be exposed to an unreasonable and significant risk of illness or injury. If safety concerns develop, we or the FDA could stop our trials before completion. Some participants in our MSC clinical trial have experienced serious adverse events, seven of which have been determined to be possibly related to MSCs and one of which has been determined to be probably related. A serious adverse event is an event that results in significant medical consequences, such as hospitalization, disability or death, and must be reported to the FDA. We cannot assure you that safety concerns regarding MSCs will not develop.

The pathway to regulatory approval for MSCs may be more complex and lengthy than for approval of a new conventional drug. Similarly, to obtain approval to market our stem cell products outside of the United States, we, together with our collaborative partners, will need to submit clinical data concerning our products and receive regulatory approval from governmental agencies, which in certain countries includes approval of the price we intend to charge for our product. We may encounter delays or rejections if changes occur in regulatory agency policies during the period in which we develop a biologic drug candidate or during the period required for review of any application for regulatory agency approval. If we are not able to obtain regulatory approvals for use of our biologic drug candidates under development, we will not be able to commercialize such products, and therefore may not be able to generate sufficient revenues to support our business.
If we are not able to conduct our clinical trials properly and on schedule, marketing approval by FDA and other regulatory authorities may be delayed or denied.

The completion of our clinical trials may be delayed or terminated for many reasons, including, but not limited to, if:

- the FDA does not grant permission to proceed and places the trial on clinical hold;
- subjects do not enroll in our trials at the rate we expect;
- subjects experience an unacceptable rate or severity of adverse side effects;
- third-party clinical investigators do not perform our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, Good Clinical Practice and regulatory requirements, or other third parties do not perform data collection and analysis in a timely or accurate manner;
- inspections of clinical trial sites by the FDA or Institutional Review Boards (IRBs) of research institutions participating in our clinical trials find regulatory violations that require us to undertake corrective action, suspend or terminate one or more sites, or prohibit us from using some or all of the data in support of our marketing applications; or
- one or more IRBs suspends or terminates the trial at an investigational site, precludes enrollment of additional subjects, or withdraws its approval of the trial.

Our development costs will increase if we have material delays in our clinical trials, or if we are required to modify, suspend, terminate or repeat a clinical trial. If we are unable to conduct our clinical trials properly and on schedule, marketing approval may be delayed or denied by the FDA.

We may not be able to secure and maintain research institutions to conduct our clinical trials.

We rely on research institutions to conduct our clinical trials. Specifically, the limited number of bone marrow transplant centers further heightens our dependence on such research institutions for our Phase III trials. Our reliance upon research institutions, including hospitals and clinics, provides us with less control over the timing and cost of clinical trials and the ability to recruit subjects. If we are unable to reach agreement with suitable research institutions on acceptable terms, or if any resulting agreement is terminated, we may be unable to quickly replace the research institution with another qualified institution on acceptable terms. We may not be able to secure and maintain suitable research institutions to conduct our clinical trials.

Final marketing approval of our biologic drug candidates by the FDA or other regulatory authorities for commercial use may be delayed, limited, or denied, any of which would adversely affect our ability to generate operating revenues.

Any of the following factors may cause final marketing approval for our biologic drug candidates to be delayed, limited or denied:

- our biologic drug candidates require significant clinical testing to demonstrate safety and effectiveness before applications for marketing approval can be filed with the FDA;
- data obtained from preclinical and nonclinical animal testing and clinical trials can be interpreted in different ways, and the FDA may not agree with our interpretations;
- it may take many years to complete the testing of our biologic drug candidates, and failure can occur at any stage of the process;
- negative or inconclusive results or adverse side effects during a clinical trial could cause us to delay or terminate development efforts for a biologic drug candidate; or,
commercialization may be delayed if the FDA requires us to expand the size and scope of the clinical trials.

If marketing approval for our biologic drug candidates is delayed, limited or denied, our ability to market products, and our ability to generate product sales, would be adversely affected.

Producing and marketing an approved drug or other medical product is subject to significant and costly post-approval regulation.

Even if approved for commercial sale, it is likely that Prochymal will receive conditional approval by the FDA, and we will be required to conduct Phase IV clinical trials to obtain full approval. Even if we obtain full approval of a product, that approval is subject to limitations on the indicated uses for which we can market it. After granting marketing approval, the FDA and regulatory agencies in other countries continue to review and inspect marketed products, manufacturers and manufacturing facilities, creating additional regulatory burdens. Later discovery of previously unknown problems with a product, manufacturer or facility may result in restrictions on the product or manufacturer, including a withdrawal of the product from the market. Further, regulatory agencies may establish additional regulations that could prevent or delay marketing approval of our products.

Our business involves the use of hazardous materials that could expose us to environmental and other liability.

We have facilities in Maryland that are subject to various local, state and federal laws and regulations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals and the use and disposal of hazardous or potentially hazardous substances, including chemicals, micro-organisms and various radioactive compounds used in connection with our research and development activities. In the United States, these laws include the Occupational Safety and Health Act, the Toxic Test Substances Control Act and the Resource Conservation and Recovery Act. We cannot assure you that accidental contamination or injury to our employees and third parties from hazardous materials will not occur. We do not have insurance to cover claims arising from our use and disposal of these hazardous substances other than limited clean-up expense coverage for environmental contamination due to an otherwise insured peril, such as fire.

We may not be able to obtain or maintain Orphan Drug designation for our biologic drug candidates.

Some jurisdictions, including the European Union and the United States, may designate drugs for relatively small patient populations as orphan drugs. Although the FDA and its European counterpart, the European Medicines Agency (“EMEA”) have designated Prochymal for the treatment of steroid refractory GvHD as an orphan drug, none of our other biologic drug candidates have received such designation. Orphan Drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process, but does make the product eligible for orphan drug exclusivity, reduced filing fees and specific tax credits. Generally, if a company receives the first marketing approval for a product with an Orphan Drug designation in the clinical indication for which it has such designation, the product is entitled to orphan drug exclusivity. Orphan drug exclusivity means that the health authorities will not approve another application to market the same drug for the same indication, except in limited circumstances, for a period of up to seven years in the United States and ten years in Europe. This exclusivity, however, could block the approval of our biologic drug candidates if a competitor obtains marketing approval before us. Even if we obtain orphan drug exclusivity for any of our biologic drug candidates, we may not be able to maintain it. For example, if a competitive product is shown to be clinically superior to our product, any orphan drug exclusivity we have will not block the approval of such competitive product.
The Fast Track designation for development of any of our products may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood the biologic drug candidate will receive marketing approval.

If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for FDA Fast Track designation for a particular indication. Marketing applications filed by sponsors of products in Fast Track development may qualify for priority review under the policies and procedures offered by the FDA, but the Fast Track designation does not assure any such qualification. Although we have obtained a Fast Track designation from the FDA for Prochymal for the treatment of GvHD and treatment refractory Crohn’s disease, receipt of Fast Track designation may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures. In addition, the FDA may withdraw our Fast Track designation at any time. If we lose our Fast Track designation, the approval process may be delayed. In addition, our Fast Track designation does not guarantee that we will qualify for or be able to take advantage of the expedited review procedures and does not increase the likelihood that Prochymal will receive regulatory approval for the treatments of steroid refractory GvHD or Crohn’s disease.

Risks Related to Government Contracts

Federal government spending priority or our relationships with the federal government may change in a manner that harms our business or prospects.

Our ability to successfully pursue and perform under development and purchase agreements with United States and Allied governmental agencies for countermeasures to nuclear terrorism and other radiological emergencies, including the contract awarded to us by the DoD for the development and stockpiling of Prochymal for the treatment of ARS, depends upon continued federal government expenditures on defense, emergency preparedness and other programs. These expenditures will likely fluctuate over time. While spending authorizations for defense and emergency preparedness related programs by the government have increased in recent years, and in particular after the 2001 terrorist attacks, future levels of expenditures and authorizations for these programs may decrease, remain constant or shift to program areas inapplicable to us. Our business, prospects, financial condition and/or operating results could be materially harmed by budgetary constraints affecting federal government spending generally, or specific departments or agencies in particular, and by changes in fiscal policies or available funding, or by changes in federal government programs or requirements or delays in government appropriations process. In addition, our business, prospects, financial condition and/or operating results could be materially harmed if we are suspended or disbarred from contracting with the federal government or a significant governmental agency, or our reputation or relationship with governmental entities is impaired, or the government otherwise declines to do business with us, or significantly decreases the amount of business it is willing to do with us.

Federal government contracts contain provisions that may be unfavorable to us.

Federal government contracts contain provisions, and are subject to laws and regulations, that give the government rights and remedies not typically found in commercial contracts. These provisions may allow the government to terminate existing contracts for convenience, as well as for default, to reduce or modify contracts or subcontracts, to cancel multi-year contracts or related purchase orders if funds for contract performance for any subsequent year become unavailable, to decline to exercise an option to renew a multi-year contract or to decline to purchase product pursuant to an option afforded under a contract. If the government terminates a contract for convenience, we may recover only our incurred or committed costs, settlement expenses and profit on the work completed prior to the termination. If the government terminates a contract for default, we may not recover even those amounts, and instead
may be liable for excess costs incurred by the government in procuring undelivered items and services from another source.

**Unfavorable federal government audit results could subject us to penalties or sanctions and could impair our ability to win new contracts.**

The Defense Contract Audit Agency (“DCAA”) and other government agencies routinely audit and investigate government contracts and systems. These agencies review a contractor’s performance on its contract, cost structure and compliance with applicable laws, regulations and standards. The DCAA also reviews the adequacy of, and a contractor’s compliance with, its internal control systems and policies, including the contractor’s accounting, purchasing, property, estimating, compensation and managing information systems. Allegations of impropriety or deficient controls could harm our reputation and/or adversely influence the award of new contracts. Any costs found to be improperly allocated to a specific contract will not be reimbursed, while such costs already reimbursed must be refunded. Therefore, a DCAA audit could result in a substantial adjustment to our revenue earned from federal government contracts.

**The government may terminate our federal government contracts at any time.**

Federal government contracts may span one or more base years and one or more option years, and may provide the government with one or more options in respect of continued performance by us thereunder. For example, our contract with the DoD for the development and stockpiling of Prochymal for the treatment of ARS provides the DoD with successive options for the purchase of Prochymal, assuming receipt of FDA approval for its use in the treatment of ARS. Federal government agencies have no obligation to exercise these options unless determined to be in the best interest of the government. Additionally, federal government contracts typically contain provisions permitting the government to terminate the contract for its convenience. A decision not to exercise an option or a decision to terminate a contract could have a material adverse effect on our business and prospects.

**If we fail to comply with complex procurement laws and regulations, we could incur various penalties or sanctions.**

To the extent which we enter into contracts or other arrangements with the United States or other Allied governments, we must comply with the laws and regulations relating to the formation, administration and performance of those contracts. These laws and regulations affect how we conduct business with our government contracts. In complying with these laws and regulations, we may incur additional costs and delays, and non-compliance may also allow for the assignment of additional fines and penalties, including contractual damages. Among these laws and regulations are the Federal Acquisition Regulations, which comprehensively regulate the formation, administration and performance of United States federal government contracts, the Truth in Negotiations Act, which requires certification and disclosure of all costs and pricing data in connection with contract negotiations, and laws, regulations and executive orders restricting the use and dissemination of information classified for national security purposes, and restricting the export of certain products and technical data. We are subject to periodic review of our performance under and compliance with the terms of any federal government contracts to which we are a party. As a result of these reviews, we may learn that we are not in compliance with all of the terms of any such contracts and we could be subject to civil or criminal penalties or administrative sanctions for failure of compliance.
**Risks Related to Our Common Stock**

*The trading price of the shares of our common stock is highly volatile, and purchasers of our common stock could incur substantial losses.*

Our stock price is volatile. The stock market in general and the market for biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above the price they paid for it. The market price for our common stock may be influenced by many factors, including:

- results of clinical trials of our biologic drug candidates or those of our competitors;
- regulatory developments in the United States and foreign countries;
- variations in our financial results or those of companies that are perceived to be similar to us;
- changes in the structure of healthcare payment systems;
- announcements by us of significant acquisitions, strategic partnerships, joint ventures or capital commitments;
- market conditions in the pharmaceutical and biotechnology sectors and issuance of securities analysts’ reports or recommendations;
- sales of substantial amounts of our stock by existing stockholders;
- sales of our stock by insiders and 5% stockholders;
- general economic, industry and market conditions;
- additions or departures of key personnel;
- intellectual property, product liability or other litigation against us;
- expiration or termination of our relationships with our collaborators; and
- the other factors described in this “Risk Factors” section.

In addition, in the past, stockholders have initiated class action lawsuits against biotechnology and pharmaceutical companies following periods of volatility in the market prices of these companies’ stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management’s attention and resources, which could have a material adverse effect on our business, financial condition and results of operations.

**Concentration of ownership of our common stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions.**

Our executive officers, directors and beneficial owners of 5% or more of our common stock and their affiliates, in aggregate, beneficially own approximately 55% of our outstanding common stock as of December 31, 2009. These persons, acting together, will be able to significantly influence all matters requiring stockholder approval, including the election and removal of directors and any merger or other significant corporate transactions. The interests of this group of stockholders may not coincide with our interests or the interests of other stockholders.

Peter Friedli, our Chairman of the Board of Directors, and certain entities with which he is affiliated, beneficially own approximately 44% of our outstanding common stock as of December 31, 2009. Accordingly, Mr. Friedli currently has, and will continue to have, a significant influence over the outcome of all corporate actions requiring stockholder approval.
Certain provisions of Delaware law and of our charter and bylaws contain provisions that could delay and discourage takeover attempts and any attempts to replace our current management by stockholders.

Certain provisions of our certificate of incorporation and bylaws, and applicable provisions of Delaware corporate law, may make it more difficult for or prevent a third party from acquiring control of us or changing our Board of Directors and management. These provisions include:

- the ability of our Board of Directors to issue preferred stock with voting or other rights or preferences;
- the inability of stockholders to act by written consent;
- a classified Board of Directors with staggered three-year terms;
- requirements that special meetings of our stockholders may only be called by the chairman of our Board of Directors, upon request of stockholders holding at least 20% of our capital stock issued and outstanding, or upon a resolution adopted by, or an affirmative vote of, a majority of our Board of Directors; and
- requirements that our stockholders comply with advance notice procedures in order to nominate candidates for election to our Board of Directors or to place stockholders’ proposals on the agenda for consideration at meetings of stockholders.

We will also be afforded the protections of Section 203 of the Delaware General Corporation Law, which will prevent us from engaging in a business combination with a person who acquires at least 15% of our common stock for a period of three years from the date such person acquired such common stock, unless advance board or stockholder approval was obtained.

Any delay or prevention of a change of control transaction or changes in our Board of Directors or management could deter potential acquirers or prevent the completion of a transaction in which our stockholders could receive a substantial premium over the then current market price for their shares.

ITEM 1B. Unresolved Staff Comments.

Not Applicable.

ITEM 2. Properties.

Our corporate headquarters are located in Columbia, Maryland, where we lease approximately 61,000 square feet, currently at a rent of approximately $1.0 million per annum. This lease expires in July 2016, and includes options to extend the term of the lease for two additional five year periods. Previously, we had also leased approximately 126,000 square feet in Baltimore, Maryland where we housed our manufacturing operations. As planned, we vacated those facilities and consolidated our operations in our Columbia, Maryland location.

ITEM 3. Legal Proceedings.

From time to time in the ordinary course of business, we are subject to claims, asserted or unasserted, or named as a party to lawsuits, arbitrations, or investigations. Litigation, in general, and intellectual property and securities litigation in particular, can be expensive and disruptive to normal business operations. Moreover, the results of legal proceedings cannot be predicted with any certainty and in the case of more complex legal proceedings, such as intellectual property and securities litigation, the results are difficult to predict at all. We are not aware of any asserted or unasserted legal proceedings or claims that we believe would have a material adverse effect on our financial condition or results of our operations.

ITEM 4. Removed and Reserved.
PART II

ITEM 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Our common stock trades on the NASDAQ Global Market under the symbol “OSIR.” The following table lists the high and low sale prices per share for our common stock based on the closing sales prices as reported on the NASDAQ Global Market for the periods indicated.

<table>
<thead>
<tr>
<th>Quarter Ended</th>
<th>2009</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>High</td>
<td>Low</td>
</tr>
<tr>
<td>March 31</td>
<td>$21.01</td>
<td>12.62</td>
</tr>
<tr>
<td>June 30</td>
<td>14.59</td>
<td>11.60</td>
</tr>
<tr>
<td>September 30</td>
<td>15.20</td>
<td>6.46</td>
</tr>
<tr>
<td>December 31</td>
<td>7.53</td>
<td>5.35</td>
</tr>
</tbody>
</table>

Stockholders

As of March 1, 2010, there were approximately 206 stockholders of record of our common stock and, according to our estimates, approximately 5,044 beneficial owners of our common stock.

Dividends

We have not paid dividends to our stockholders since our inception and we do not plan to pay cash dividends in the foreseeable future. We currently intend to retain earnings, if any, to finance our growth.

Unregistered Sales of Securities

There were no issuances of unregistered securities during fiscal 2009.

Issuer Purchase of Equity Securities and Use of Proceeds

There were no repurchases by us of our securities during fiscal 2009 or 2008.
Stock Performance Graph

The following graph shows the cumulative total return, assuming the investment of $100 on August 4, 2006 (the date on which our initial public offering was declared effective and our common stock began trading on the NASDAQ Global Market), on an investment in each of our common stock, the NASDAQ Composite Index (U.S. and Foreign) and the NASDAQ Biotechnology Index. The comparisons in the table are required by the SEC and are not intended to forecast or be indicative of possible future performance of our common stock.

Securities Authorized for Issuance under Equity Compensation Plans

The information required by Item 201(d) of Regulation S-K, pursuant to paragraph (a) of this Item 5, is incorporated herein by reference to the information contained in the Company’s Proxy Statement for the 2010 Annual Meeting of Stockholders, which is anticipated to be filed pursuant to Regulation 14A no later than one hundred twenty (120) days following the end of the fiscal year reported on.

We derived the selected financial data presented below for the periods or dates indicated from our financial statements. Our financial statements for these periods were audited by an independent registered public accounting firm. You should read the data below in conjunction with our financial statements, related notes and other financial information appearing in “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Item 8. Financial Statements and Supplementary Data.” These historical results are not necessarily indicative of results that may be expected for future periods.

<table>
<thead>
<tr>
<th>Year Ended December 31,</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2009 (in thousands, except per share data)</td>
<td>2008</td>
<td>2007</td>
<td>2006</td>
<td>2005</td>
</tr>
<tr>
<td><strong>Statement of Operations Data:</strong></td>
<td>Revenue from collaborative research agreements, government contracts, and royalties</td>
<td>$44,533</td>
<td>$10,044</td>
<td>$2,048</td>
<td>$1,181</td>
</tr>
<tr>
<td></td>
<td>Operating expenses:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Research and development</td>
<td>63,266</td>
<td>69,897</td>
<td>47,140</td>
<td>37,590</td>
</tr>
<tr>
<td></td>
<td>General and administrative and other expenses</td>
<td>8,807</td>
<td>8,586</td>
<td>6,071</td>
<td>8,459</td>
</tr>
<tr>
<td></td>
<td>Total operating expenses</td>
<td>72,073</td>
<td>78,483</td>
<td>53,211</td>
<td>46,049</td>
</tr>
<tr>
<td></td>
<td>Loss from operations</td>
<td>(27,540)</td>
<td>(68,439)</td>
<td>(51,163)</td>
<td>(44,868)</td>
</tr>
<tr>
<td></td>
<td>Other income (expense), net</td>
<td>1,277</td>
<td>(978)</td>
<td>(6,695)</td>
<td>(4,685)</td>
</tr>
<tr>
<td></td>
<td>Loss from continuing operations, before income taxes</td>
<td>(26,263)</td>
<td>(69,417)</td>
<td>(57,858)</td>
<td>(49,553)</td>
</tr>
<tr>
<td></td>
<td>Income tax benefit</td>
<td>2,699</td>
<td>————</td>
<td>————</td>
<td>————</td>
</tr>
<tr>
<td></td>
<td>Loss from continuing operations</td>
<td>(23,564)</td>
<td>(69,417)</td>
<td>(57,858)</td>
<td>(49,553)</td>
</tr>
<tr>
<td></td>
<td>Income from discontinued operations, net of income taxes</td>
<td>38,136</td>
<td>35,925</td>
<td>3,937</td>
<td>4,594</td>
</tr>
<tr>
<td></td>
<td>Net income (loss)</td>
<td>$14,572</td>
<td>$(33,492)</td>
<td>$(53,921)</td>
<td>$(44,959)</td>
</tr>
<tr>
<td></td>
<td>Basic and diluted loss per share from continuing operations</td>
<td>$0.72</td>
<td>$(2.18)</td>
<td>$(2.03)</td>
<td>$(2.97)</td>
</tr>
<tr>
<td></td>
<td>Basic and diluted net income (loss) per share</td>
<td>$0.45</td>
<td>$(1.05)</td>
<td>$(1.89)</td>
<td>$(2.70)</td>
</tr>
<tr>
<td></td>
<td>Weighted average shares of common stock used in computing basic and diluted net loss per share</td>
<td>32,742</td>
<td>31,895</td>
<td>28,489</td>
<td>16,663</td>
</tr>
</tbody>
</table>
Balance Sheet Data:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and investments available for sale . . .</td>
<td>$100,715</td>
<td>$62,238</td>
<td>$18,164</td>
<td>$39,181</td>
<td>$43,471</td>
</tr>
<tr>
<td>Working capital(1)</td>
<td>52,362</td>
<td>70,599</td>
<td>7,247</td>
<td>33,166</td>
<td>38,103</td>
</tr>
<tr>
<td>Total assets</td>
<td>107,596</td>
<td>137,467</td>
<td>37,041</td>
<td>49,168</td>
<td>51,014</td>
</tr>
<tr>
<td>Notes payable, less current portion . . .</td>
<td>—</td>
<td>—</td>
<td>1,200</td>
<td>25,000</td>
<td>47,411</td>
</tr>
<tr>
<td>Mandatorily redeemable convertible preferred stock</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>64,267</td>
<td>—</td>
</tr>
<tr>
<td>Convertible preferred stock</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>32,746</td>
</tr>
<tr>
<td>Accumulated deficit</td>
<td>(260,344)</td>
<td>(274,916)</td>
<td>(241,424)</td>
<td>(187,503)</td>
<td>(142,544)</td>
</tr>
<tr>
<td>Total stockholders’ equity (deficit) . . .</td>
<td>12,560</td>
<td>(5,020)</td>
<td>14,336</td>
<td>11,287</td>
<td>(73,662)</td>
</tr>
</tbody>
</table>

(1) Working capital is computed as the excess of current assets over current liabilities.

ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

When reviewing the discussion below, you should keep in mind the substantial risks and uncertainties that characterize our business. In particular, we encourage you to review the risks and uncertainties described under “Risk Factors” included as Item 1A in this Annual Report on Form 10-K. These risks and uncertainties could cause actual results to differ materially from those forecasted in forward-looking statements or implied by past results and trends. Forward-looking statements are statements that attempt to project or anticipate future developments in our business; we encourage you to review the examples of forward-looking statements included in this Annual Report on Form 10-K under Item 1 at the beginning of this report. These statements, like all statements in this report, speak only as of the date of this report (unless another date is indicated), and we undertake no obligation to update or revise the statements in light of future developments.

The following is a discussion and analysis of our financial condition, results of operations, liquidity and capital resources for each of the three years in the period ended December 31, 2009 and significant factors that could affect our prospective financial condition and results of operations. You should read this discussion together with our financial statements and notes included in “—Item 8. Financial Statements and Supplementary Data.”

Business Overview

We are a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. Our biologic drug candidates utilize mesenchymal stem cells, or MSCs. We launched the only commercially available stem cell product in 2005, and sold that product line to NuVasive Inc. in 2008 for $85.0 million.

We believe cellular therapies have certain advantages over traditional medical approaches. For example, cell therapies can be targeted, avoiding many of the safety complications arising from systemic treatments. Cell therapies can also be responsive to their environment, turning on or off certain effects as conditions in the surrounding tissue change. Cell therapies can also be multifaceted. For example, the cells in Prochymal, our leading biologic drug candidate, have demonstrated the ability to not only down regulate inflammation, but also repair the damage caused by the inflammation.

We believe the combination of these unique properties will allow us to solve many of the more challenging questions facing medicine today. We have established ourselves as the leader in the emerging field of cell therapy. We are an industry leader in the field, having developed the only commercially available stem cell product on the market. We are continuing to make advances, with eight active clinical trials. Four of the trials have progressed to Phase III, each of which has been granted fast track status by the FDA.
We currently have eight clinical trials ongoing, including four Phase III clinical trials. We are conducting Phase III trials for Prochymal, our lead biologic drug candidate, for (1) the treatment of steroid refractory acute GvHD, (2) first line treatment of acute GvHD, (3) biologics refractory Crohn’s disease, and (4) acute radiation syndrome, which is under the Animal Rule.

We have received Fast Track Status from the FDA for each of these pivotal Phase III trials for Prochymal. We have initiated Phase II clinical trials for Prochymal for both type 1 diabetes and acute myocardial infarction.

We are a fully integrated company, having developed capabilities in research, development, manufacturing, marketing and distribution of stem cell products. We have developed an extensive intellectual property portfolio to protect our technology in the United States and a number of foreign countries, including 49 U.S. and 278 foreign patents owned or licensed. We believe that our biologic drug candidates have advantages over other stem cell therapeutics in development for at least the following reasons:

• **Stem Cell Source.** Our stem cells are obtained from adult bone marrow, a readily available source. The cells are drawn from the hips of volunteer donors between the ages of 18 and 30 years, using a simple needle and syringe aspiration. Because the cells are obtained from consenting adult donors, we are able to largely avoid the ethical controversy surrounding embryonic and fetal stem cell research.

• **Ability to Mass Produce.** Through our proprietary manufacturing methods, we can grow mesenchymal stem cells (“MSC”) in a controlled fashion to produce up to 10,000 treatments of our biologic drug candidates from a single bone marrow donation. Our ability to produce a large quantity of treatments from one donation provides us with manufacturing efficiencies and product consistency that are essential to commercialization.

• **Universal Compatibility.** Many stem cell therapies under development can elicit a rejection response in the recipient and therefore require donor-to-recipient matching or potentially harmful immunosuppression. This greatly reduces manufacturing efficiencies and creates a risk of mismatch which can result in an acute inflammatory response and, potentially, in death. Based on our clinical experience, we believe that our biologic drug candidates are not rejected by the patient’s immune system and so, like type O negative blood, do not require donor-to-recipient matching. This universal compatibility allows us to produce a standardized product available to all patients in almost any medical setting.

• **Treatment on Demand.** Our biologic drug candidates can be stored frozen at end-user medical facilities until they are needed. We anticipate that medical facilities will be able to prescribe and dispense these products in much the same way as conventional drugs. In contrast, other stem cell technologies under development require weeks to prepare after a patient’s need is identified. This is a key feature of our technology, as many patients in the critical care setting require prompt treatment.

On October 31, 2008, we entered into a Collaboration Agreement with Genzyme Corporation for the global development and commercialization of Prochymal and Chondrogen. Under the terms of the Collaboration Agreement, we retain the right to commercialize Prochymal and Chondrogen in the United States and Canada and Genzyme is granted the exclusive right and license to commercialize the products in all other countries (except with respect to GvHD in Japan where Prochymal has previously been licensed to another pharmaceutical company).

In July 2007, we separately partnered with Genzyme for the development of effective countermeasures to nuclear terrorism and other radiological emergencies. In January 2008, we were awarded a contract from the U.S. Department of Defense, pursuant to which we, in partnership with Genzyme, are seeking to develop and stockpile Prochymal for the repair of gastrointestinal injury.
resulting from acute radiation exposure. Additionally, we have partnered with the JDRF for the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes mellitus.

In April 2008, we committed to a plan to sell our assets related to Osteocel, a product that we have produced and marketed since July 2005, for regenerating bone in orthopedic indications. On May 8, 2008, we entered into an agreement to sell our entire Osteocel and Osteocel XO product line to NuVasive, Inc. The first of two scheduled closings in connection with this transaction, the "technology assets closing", occurred on July 24, 2008, at which time we received an initial payment of $35.0 million. The second and final closing, the "manufacturing assets closing," occurred on April 9, 2009. As of December 31, 2009, we have received the full $85.0 million proceeds from the sale of our Osteocel business. As a result, all of the activities related to our Osteocel product line have been reported as “discontinued operations” in the accompanying financial statements.

Financial Operations Overview

Revenue

In 2008, we entered into a Collaboration Agreement with Genzyme for the development and commercialization of Prochymal and Chondrogen that provides for non-contingent, non-refundable up front payments of $130.0 million and contingent milestone payments. This Collaboration Agreement has multiple deliverables, and consistent with our accounting policy for such transactions, we are amortizing these amounts into revenue on a straight-line basis over the estimated completion period of the deliverables, which extend through the first quarter of 2012. We recognized $40.0 million of revenue in fiscal 2009 and $6.7 million of revenue in fiscal 2008 related to this agreement. Contingent milestone payments earned and for which we have no continuing performance obligations, will be recognized as revenue upon achievement of the related milestone, while milestone payments for which we have a continuing performance obligation will be deferred when received and amortized to revenue over the term of the related performance obligations.

In 2007, we partnered with Genzyme to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. In the first quarter of 2008, we were awarded a contract from the United States Department of Defense ("DoD") pursuant to which we, in partnership with Genzyme, are seeking to develop and stockpile Prochymal for the repair of gastrointestinal injury resulting from acute radiation exposure. Under the terms of the contract, the DoD will provide funding to us, and if we are successful in obtaining FDA approval for acute radiation syndrome, the contract provides for the additional purchase of up to 20,000 doses of Prochymal, at $10,000 per dose. We recognized $2.9 million in revenue under the terms of this contract in fiscal 2009 and $2.5 million in revenue under the terms of this contract in fiscal 2008.

In prior years, we have entered into strategic agreements with other companies for the development and commercialization of select stem cell biologic drug candidates for specific indications and geographic markets. In 2007, we entered into a collaborative agreement with the Juvenile Diabetes Research Foundation ("JDRF") to conduct a Phase II clinical trial evaluating Prochymal as a treatment for type 1 diabetes mellitus. This collaborative agreement provides for JDRF to provide up to $4.0 million of contingent milestone funding to support the development of Prochymal for the preservation of insulin production in patients with newly diagnosed type 1 diabetes mellitus. The contingent milestone payments under the agreement are amortized into revenue on a straight line basis over the duration of our obligations under the collaborative agreement as they are earned. We received $1.5 million in milestone payment from JDRF in fiscal 2009 and recognized $1.2 million in revenue, and we received $2.0 million in milestone payments from JDRF in 2008 and recognized $0.6 million in revenue during 2008 under this agreement.
In 2003, we entered into an agreement with a foreign pharmaceutical company granting it exclusive rights to Prochymal for the treatment of GvHD in Japan. We recognized $0.5 million of revenue during 2007 related to this agreement.

Also in 2003 we entered into an agreement with a major pharmaceutical company relating to the development of our cardiac biologic drug candidate, and we received a $5.0 million fee for licensing the use of our technology. This agreement was terminated in 2007 and as a result we regained the worldwide rights to Prochymal for cardiac indications. We recognized $1.4 million in license fee revenue in 2007 related to this agreement.

Research and Development Costs

Our research and development costs consist of expenses incurred in identifying, developing and testing biologic drug candidates. These expenses consist primarily of salaries and related expenses for personnel, fees paid to professional service providers for independent monitoring and analysis of our clinical trials, costs of contract research and manufacturing, costs of facilities, and the costs of manufacturing clinical batches of biologic drug candidates, quality control supplies and material to expand biologic drug candidates.

Consistent with our focus on the development of biologic drug candidates with potential uses in multiple indications, many of our costs are not attributable to a specifically identified product. We use our employee and infrastructure resources across several projects. Accordingly, we do not account for internal research and development costs on a project-by-project basis. From inception through December 31, 2009, we incurred aggregate research and development costs of approximately $367 million.

We expect our research and development expenses to continue to be significant in the future, as we continue our clinical trial activity for our existing biologic drug candidates as they advance through the development cycle and as we invest in additional product opportunities and research programs. Clinical trials and preclinical studies are time-consuming and expensive. Our expenditures on current and future preclinical and clinical development programs are subject to many uncertainties. We test our products in several preclinical studies, and we then conduct clinical trials for those biologic drug candidates that we determine to be the most promising. As we obtain results from clinical trials, we may elect to discontinue or delay trials for some biologic drug candidates in order to focus our resources on more promising biologic drug candidates. Completion of clinical trials may take several years or more, but the length of time generally varies substantially according to the type, size of trial and intended use of a biologic drug candidate. The cost of clinical trials may vary significantly over the life of a project as a result of a variety of factors, including:

- the number of patients who participate in the trials;
- the number of sites included in the trials;
- the length of time required to enroll trial participants;
- the duration of patient treatment and follow-up;
- the costs of producing supplies of the biologic drug candidates needed for clinical trials and regulatory submissions;
- the efficacy and safety profile of the biologic drug candidate; and
- the costs and timing of, and the ability to secure, regulatory approvals.

As a result of these uncertainties, we are unable to determine with any significant degree of certainty the duration and completion costs of our research and development projects or when and to
what extent we will generate revenues from the commercialization and sale of any of our biologic drug candidates.

**General and Administrative Expenses**

General and administrative expenses consist primarily of the costs associated with our general management, including salaries, allocations of facilities and related costs, and professional fees such as legal and accounting expenses. We have increased our general and administrative expense for legal and accounting compliance costs, investor relations and other activities associated with operating as a publicly traded company and strengthened our administrative capabilities as we approach the commercial launch of Prochymal. Continued increases will also likely result from the hiring of additional operational, financial, accounting, facilities engineering and information systems personnel.

**Other Income (Expense), Net**

Investment income consists of interest earned on our cash and investments available for sale and realized gains and losses incurred on the sale of these investments. Interest expense consists of interest incurred on capital leases and other debt financings. We pay interest on our promissory notes, capital leases and convertible long-term debt. We do not expect to incur material interest expense in the future as we have extinguished all of our outstanding debt as of December 31, 2008, and have invested the excess in investments available for sale.

**Income Taxes**

We have not recognized any deferred tax assets or liabilities in our financial statements since we cannot assure their future realization. Because realization of deferred tax assets is dependent upon future earnings, a full valuation allowance has been recorded on the net deferred tax assets, which relate primarily to net operating loss and research and development carry-forwards. In the event that we become profitable within the next several years, we have net deferred tax assets (before a 100% valuation allowance) of approximately $65.3 million that may be utilized prior to us having to recognize any income tax expense or make payments to the taxing authorities other than the alternative minimum tax. In fiscal 2009, we recorded a provision for income taxes to recognize the U.S. Federal alternative minimum tax on our taxable income.

**Critical Accounting Policies**

**General**

Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, inventory valuation, deferred tax assets, share-based compensation, and contingencies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable. These results form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We believe that the following critical accounting policies reflect our more significant judgments and estimates used in the preparation of our financial statements.
Revenue Recognition

We generate revenues from collaborative agreements, research licenses, and a government contract. We evaluate revenues from agreements that have multiple elements to determine whether the components of the arrangement represent separate units of accounting. To recognize a delivered item in a multiple element arrangement, the delivered items must have value on a standalone basis, there must be objective and reliable evidence of fair value of the undelivered items, and the delivery or performance must be probable and within our control for any delivered items that have a right of return. The determination of whether multiple elements of a collaboration agreement meet the criteria for separate units of accounting requires us to exercise judgment.

Revenues from research licenses and government contracts are recognized as earned upon either the incurring of reimbursable expenses directly related to the particular research plan or the completion of certain development milestones as defined within the terms of the agreement. Payments received in advance of research performed are designated as deferred revenue. Non-refundable upfront license fees and certain other related fees are recognized on a straight-line basis over the development periods of the contract deliverables. Fees associated with substantive at risk, performance based milestones are recognized as revenue upon their completion, as defined in the respective agreements. Incidental assignment of technology rights is recognized as revenue as it is earned and received.

In October 2008, we entered into a Collaboration Agreement with Genzyme Corp. (“Genzyme”) for the development and commercialization of Prochymal and Chondrogen. Under this agreement, Genzyme agreed to pay to us non-contingent, non-refundable cash payments totaling $130.0 million, with $75.0 million paid during November 2008 and $55.0 million paid on July 1, 2009. The agreement provides Genzyme with certain rights to intellectual property developed by us, and requires that we continue to perform certain development work related to the subject biologic drug candidates. We have evaluated the deliverables related to these payments, and concluded that the various deliverables represent a single unit of accounting. For this reason, we have deferred the recognition of revenue related to the upfront payments, and are amortizing these amounts to revenue on a straight-line basis over the estimated delivery period of the required development services, which extend through the first quarter of 2012. Accordingly, we recognized $40.0 million and $6.7 million of revenue in the years ended December 31, 2009 and 2008, respectively, related to the amortization of the upfront payments. The balance of these payments has been recorded as $40.0 million of current deferred revenue and $43.3 million of long term deferred revenue as of December 31, 2009. The agreement also provides for contingent milestone payments of up to $1.25 billion in the aggregate, as well as royalties to be paid to us on any sales by Genzyme. Consistent with our revenue recognition policies, we will recognize revenue from these contingent milestone payments for which we have no continuing performance obligations upon achievement of the related milestone. For any milestone payments for which we have a continuing performance obligation, the milestone payments will be deferred and recognized as revenue over the term of the related performance obligations.

In 2007, we partnered with Genzyme to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. In January 2008, we were awarded a contract from the United States Department of Defense (“DoD”) pursuant to which we, in partnership with Genzyme, are seeking to develop and stockpile Prochymal for the repair of gastrointestinal injury resulting from acute radiation exposure. We began recognizing revenue under this contract during the first quarter of 2008. Contract revenue is recognized as the related costs are incurred, in accordance with the terms of the contract. We recognized $3.0 million and $2.5 million in revenue from the DoD contract during 2009 and 2008, respectively.

In October 2007, we entered into a collaborative agreement with the Juvenile Diabetes Research Foundation (“JDRF”) to conduct a Phase II clinical trial evaluating Prochymal as a treatment for type 1 diabetes mellitus. This collaborative agreement provides for JDRF to provide up to $4.0 million
of contingent milestone funding to support the development of Prochymal for the preservation of
insulin production in patients with newly diagnosed type 1 diabetes mellitus. The contingent milestone
payments under the agreement are amortized to revenue on a straight line basis over the duration of
our obligations under the collaborative agreement as they are earned. We have received $3.5 million of
the contingent milestones to date, and expect to receive the remaining $0.5 million in 2010. We began
amortizing the each payment as it was received, resulting in $1.2 million and $0.6 million of revenue
during 2009 and 2008, respectively under the agreement with JDRF. The remainder of the payments
received under this agreement has been recorded as $0.8 million of current deferred revenue and $0.8
million of long term deferred revenue as of December 31, 2009.

In July 2005, we launched our first commercial product, Osteocel. Revenues on Osteocel sales
were recognized when legal title to the product passed to the customer. In July 2008, we entered into
an Asset Purchase Agreement to sell our Osteocel business to NuVasive, Inc. and during 2008 and
2009, received $85.0 million in sales proceeds. Osteocel operations are accounted for as discontinued
operations in the accompanying financial statements, and the prior period financial statements have
been restated for comparative purposes.

We have entered into several strategic agreements with other pharmaceutical companies focusing
on the development and commercialization of our stem cell drug products. In 2003, we entered into
such an agreement with Boston Scientific Corporation pertaining to our cardiac drug development and
received a $5 million fee for licensing the use of our technology. We terminated the agreement with
Boston Scientific Corporation in 2007 and recognized the remaining unamortized license fee. Also in
2003, we entered into a similar agreement with JCR Pharmaceuticals Co., Ltd. pertaining to our
hematologic malignancies drugs for distribution in Japan, and recognize revenue upon the achievement
of milestone events specified in the agreement.

We also earn royalties on the sale of human MSCs sold for research purposes and recognize the
revenue on these sales as the sales are made.

Accounts Receivable

Accounts receivable are reported at their net realizable value. As of December 31, 2009 and 2008,
there was no allowance for doubtful accounts related to accounts receivable from continuing
operations, as we believe the reported amounts are fully collectible. Accounts receivable balances are
not collateralized.

Valuation of Long-lived Assets

We review long-lived assets for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset or group of assets may not be fully recoverable. These events or
changes in circumstances may include a significant deterioration of operating results, changes in
business plans, or changes in anticipated future cash flows. If an impairment indicator is present, we
evaluate recoverability by a comparison of the carrying amount of the assets to future undiscounted net
cash flows expected to be generated by the assets. Assets are grouped at the lowest level for which
there is identifiable cash flows that are largely independent of the cash flows generated by other asset
groups. If the total of the expected undiscounted future cash flows is less than the carrying amount of
the asset, an impairment loss is recognized for the difference between the fair value and carrying value
of assets. There were no impairment losses recognized during the years 2009, 2008 or 2007.

Assets to be disposed of are reported at the lower of carrying values or fair values, less estimated
costs of disposal.
Share-Based Compensation

We account for share-based payments using the fair value method.

We recognize all share-based payments to employees and non-employee directors in our financial statements based on their grant date fair values, calculated using the Black-Scholes option pricing model. Compensation expense related to share-based awards is recognized on a straight-line basis based on the value of share awards that are expected to vest during the requisite service period on the grant date, which is revised if actual forfeitures differ materially from original expectations.

Comprehensive Income

We disclose comprehensive income and its components in our statements of stockholders’ equity (deficit). Comprehensive income is comprised of net income (loss) and other comprehensive income (loss), which includes certain changes in equity that are excluded from net income (loss).

Recent Accounting Guidance Not Yet Adopted at December 31, 2009

In June 2009, the Financial Accounting Standards Board ("FASB") issued authoritative accounting guidance to improve financial reporting by companies involved with variable interest entities and to provide more relevant and reliable information to users of financial statements. The new guidance requires revised evaluations of whether entities represent variable interest entities, ongoing assessments of control over such entities, and additional disclosures of variable interests. This guidance is effective for fiscal years beginning after November 15, 2009. We adopted this guidance January 1, 2010, and since we are not involved with any variable interest entities, we do not expect the adoption to have a material impact on our financial statements.

In September 2009, ASU 2009-13, Revenue Recognition (Topic 605)—Multiple-Deliverable Revenue Arrangements ("ASU 2009-13") was issued and will change the accounting for multiple-deliverable arrangements to enable vendors to account for products or services (deliverables) separately rather than as a combined unit. Specifically, this guidance amends the criteria in Subtopic 605-25, Revenue Recognition—Multiple-Element Arrangements, for separating consideration in multiple-deliverable arrangements. This guidance establishes a selling price hierarchy for determining the selling price of a deliverable, which is based on: (a) vendor-specific objective evidence; (b) third-party evidence; or (c) estimates. This guidance also eliminates the residual method of allocation and requires that arrangement consideration be allocated at the inception of the arrangement to all deliverables using the relative selling price method. In addition, this guidance significantly expands required disclosures related to a vendor’s multiple-deliverable revenue arrangements. ASU 2009-13 is effective prospectively for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010 with early adoption permitted. The impact of ASU 2009-13 on our financial statements will depend on the nature and terms of revenue arrangements that we enter into or materially modify after the adoption date. However, based on our current customer arrangements, we do not believe the adoption of this ASU will have a material impact on our financial statements.

In January 2010, the Financial Accounting Standards Board issued ASU 2010-06, Fair Value Measurements and Disclosures (Topic 820)—Improving Disclosures about Fair Value Measurements ("ASU 2010-06"), which amends Topic 820 to add new requirements for disclosures about transfers into and out of Levels 1 and 2 and separate disclosures about purchases, sales, issuances, and settlements related to Level 3 measurements. ASU 2010-06 also clarifies existing fair value disclosures about the level of disaggregation and about inputs and valuation techniques used to measure fair value. The ASU is effective for the first reporting period beginning after December 15, 2009, except for the requirements to provide the Level 3 activity of purchases, sales, issuances, and settlements on a gross basis, which will be effective for fiscal years beginning after December 15, 2010, and for interim periods...
within those fiscal years. Early adoption is permitted. We believe the adoption of this amendment will not have a material effect on our financial position or results of operations.

Results of Operations

Year ended December 31, 2009 compared to December 31, 2008

Revenue

Total revenues increased to $44.5 million for the fiscal year ended December 31, 2009 from $10.0 million in fiscal 2008. In fiscal 2009, we recognized $40.0 million in revenue from the Genzyme Collaboration Agreement, $3.0 million from our contract with DoD and $1.2 million from the JDRF agreement. Revenues in 2008 included $6.7 million from the Genzyme agreement, $2.5 million from the DoD contract and $600,000 from the JDRF agreement.

Research and Development Expenses

Research and Development expenses were $63.3 million in fiscal 2009 compared to $69.9 million in the prior year. In the second half of fiscal 2009, we completed substantially all the patient treatment in our Phase III GvHD trials and began to experience reductions in our R&D expenses. R&D expenses will continue to be substantial as we treat patients in our Phase II cardiac trial and complete our Biologics License Application for submission to the FDA for the market approval of Prochymal.

General and Administrative Expenses

General and administrative expenses were $8.8 million in fiscal 2009 compared to $8.6 million in the prior year. Share-based payments included in G&A were $1.5 million in fiscal 2009 compared to $1.0 million in the prior year.

Board Compensation

We pay fees to members of our Board of Directors through awards of our common stock and/or a combination of stock and cash. In 2009, we issued 25,000 shares of common stock for services on the Board and valued these shares at the then current closing price of our stock on the NASDAQ Global Market, resulting in a $0.4 million charge.

Other Income (Expense), Net

Other income (expense) primarily consists of investment income, which is made up of interest paid to us on our investments available for sale and the realized gains and losses recognized upon sale, net of interest expense. In fiscal 2009, we recognized investment income of $1.3 million, which included $900,000 of gains realized upon the sale of shares of NuVasive, Inc. common stock that was paid to us in connection with the sale of our Osteocel business. In fiscal 2008, we recognized $416,000 of investment income. We incurred $8,000 of interest expense on our capital equipment leases during fiscal 2009 compared to $1.4 million in interest expense in fiscal 2008, including $508,000 paid to related parties, on debt that was retired during fiscal 2008.

Year ended December 31, 2008 compared to December 31, 2007

Revenue

Total revenues increased to $10.0 million for the twelve months ended December 31, 2008 from $2.0 million in the corresponding period in 2007. The increase is the result of the Genzyme Collaboration Agreement and the DoD contract, each of which was entered during 2008, and the JDRF agreement entered into in 2007. Revenues in 2007 included $1.3 million of unamortized license
fees that was recognized in 2007 upon the termination of the agreement with Boston Scientific Corporation in December 2007.

**Research and Development Expenses**

Research and development expenses were $69.9 million for the twelve months ended December 31, 2008 compared to $47.1 million in the prior year. The increase in research and development expenses in 2008 reflects the increased number of clinical trials in process versus the prior year and the resulting increases in clinical doses of our drug candidates. We also incurred additional research and development costs in connection with the development of our Biologics License Application (“BLA”) as we approach the commercialization of Prochymal.

**General and Administrative Expenses**

General and administrative expenses were $8.3 million for the twelve months ended December 31, 2008 compared to $6.0 million in the prior year. The increase was attributable to additional personnel and related costs to support our expanded operations as we approach the anticipated commercialization of Prochymal.

**Board Compensation**

In 2008, we issued 21,500 shares of common stock for services on the Board and valued these shares at the then current closing price of our stock on the NASDAQ Global Market, resulting in a $0.3 million charge.

**Other Income (Expense), Net**

Other Income expense, net was $1.0 million for the twelve months ended December 31, 2008 compared to $6.7 million in the prior year. Interest expense decreased significantly in 2008 due to a reduced amount of debt outstanding throughout the year. We did not have any debt outstanding as of December 31, 2008. Interest expense in 2007 also includes a non-cash charge of $4.8 million resulting from the induced conversion of $18.8 million of our convertible promissory notes into common stock and $0.3 million of previously deferred debt financing fees.

**Liquidity and Capital Resources**

**Liquidity**

At December 31, 2009, we had $1.3 million in cash and $99.4 million in investments available for sale. In addition, we did not have any outstanding debt at any time during fiscal 2009, or at year end.

During the fiscal year ended December 31, 2008, we generated cash from operating activities for the first time since our inception, as a result of the $75.0 million portion of the up front fees received under the Collaboration Agreement with Genzyme. We generated a further $55.0 million of cash in up front fees during fiscal 2009. We used a portion of these proceeds to completely extinguish our debt during 2008, and have since consistently made purchases of investments available for sale with our excess cash. Although there can be no assurances, we believe that we have sufficient liquidity on hand as of December 31, 2009 to fund our operations through the commercialization of our first biological drug candidate. Prior to 2008, we had historically financed our research and development activities through cash flows provided by financing activities.
Cash Flow

The following table sets forth a summary of our cash flows for each of our three most recently completed fiscal years:

<table>
<thead>
<tr>
<th></th>
<th>Years Ended December 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2009</td>
</tr>
<tr>
<td>Net cash (used in) provided by operating activities</td>
<td>$(12,113)</td>
</tr>
<tr>
<td>Net cash provided by (used in) investing activities</td>
<td>12,447</td>
</tr>
<tr>
<td>Net cash provided by financing activities</td>
<td>32</td>
</tr>
</tbody>
</table>

We had a net use of cash by our operating activities during fiscal 2009, primarily as the result of our receiving an aggregate of $40.0 million from the sale of our Osteocel asset group through the delivery of shares of NuVasive common stock, as provided for under the Asset Purchase Agreement. Comprising this amount, payments of $12.5 million were made to us on June 30, 2009 and September 30, 2009, and a payment of $15.0 million was made to us in October 2009, all through the delivery of shares of NuVasive common stock having equivalent value. Cumulatively, we received 1,001,422 shares of NuVasive common stock, of which we had sold 986,122 for total cash proceeds of approximately $40.3 million, as of December 31, 2009. We sold the remaining shares of NuVasive common stock in February 2010 and realized approximately $598,000 of additional proceeds. The cash proceeds from these shares are reported as cash generated by our financing activities. Had these payments been received in cash instead of shares of stock to be subsequently sold, the cash flow would have been reported as cash provided by operating activities, resulting in net cash provided by operating activities during 2009.

Net cash used in operating activities was $12.1 million for the twelve months ended December 31, 2009. During that period, our continuing operations used $5.5 million of cash, primarily reflecting our loss from continuing operations and cash used to fund operating assets, which was partially offset by the $55.0 million installment of up front payments received from Genzyme on July 1, 2009. Net cash used by discontinued operations was $6.6 million for the year ended December 31, 2009, which was the result of $40.0 million of the payments for the sale of our Osteocel line of business being received in shares of stock as discussed above. Net cash provided by operating activities was $10.2 million for the twelve months ended December 31, 2008. During that period, our continuing operations used $2.7 million of cash, primarily reflecting our loss from continuing operations partially offset by the $75.0 million installment of up front payments received from Genzyme, and net cash provided by discontinued operations was $13.0 million due primarily to the cash portion of the income from discontinued operations.

Net cash provided by investing activities was $12.4 million for the twelve months ended December 31, 2009, all of which was attributable to our continuing operations. During that period, we generated $9.7 million of cash from the sale of our Osteocel asset group and had $54.2 million of proceeds from the sale of investments available for sale, primarily representing the sale of the NuVasive shares of common stock we received as partial payment for the Osteocel line of business, as described above. These cash inflows were partially offset by $50.2 million of purchases of investments available for sale with our excess cash on hand during the year. Net cash used in investing activities was $13.1 million for the twelve months ended December 31, 2008. During that period, the investing activities of our continuing operations used $10.3 million of cash, utilizing our excess cash resources to make net purchases of investments available for sale, which was partially offset by the net proceeds from the sale of the Osteocel business. Investing activities of discontinued operations used $2.8 million of cash for the purchases property and equipment during the period.

Net cash provided by financing activities was insignificant for the twelve months ended December 31, 2009, as we had no debt outstanding at any time during the year. The cash that we
received from the exercise of options to purchase shares of our common stock was offset by an increase in restricted cash to support an increased letter of credit for the direct lease of our office facilities that we assumed during the year. Net cash provided by financing activities was $3.1 million for the twelve months ended December 31, 2008, all representing net proceeds realized on the issuance and subsequent redemption of convertible and short-term notes during the period.

**Capital Resources.**

Our future capital requirements will depend on many factors, including:

- the scope and results of our research and preclinical development programs;
- the scope and results of our clinical trials, particularly regarding the number of patients required for our Phase III trials;
- the timing of and the costs involved in obtaining regulatory approvals for our biologic drug candidates, which could be more lengthy or complex than obtaining approval for a new conventional drug, given the FDA’s limited experience with late-stage clinical trials and marketing approval for stem cell therapeutics;
- the timing and achievement of contingent milestone payments under the Genzyme collaboration agreement;
- the costs of maintaining, expanding and protecting our intellectual property portfolio, including possible litigation costs and liabilities; and
- the costs of enlarging our work force consistent with expanding our business and operations and status as a public company.

We did not have any outstanding debt at any time during 2009. As a result of our financial position and forecasts as of December 31, 2009, we believe that we have sufficient liquidity on hand as of that date to fund our operations through the initial commercialization of our biological drug candidate.

**Off-Balance Sheet Arrangements.**

We have no off-balance sheet financing arrangements and we have not entered into any transactions involving unconsolidated subsidiaries or special purpose entities.

**Future Contractual Obligations**

The following table sets forth our estimates as to the amounts and timing of contractual payments for our most significant contractual obligations at December 31, 2009. The information in the table reflects future unconditional payments and is based on the terms of the relevant agreements, appropriate classification of item under accounting principles generally accepted in the United States and certain assumptions. Future events could cause actual payments to differ from these amounts.

<table>
<thead>
<tr>
<th>Contractual Obligations</th>
<th>Total (amounts in thousands)</th>
<th>Less Than 1-Year</th>
<th>Years 1-3</th>
<th>Years 4-5</th>
<th>More Than 5-Years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operating lease—facilities</td>
<td>$7,349</td>
<td>$1,056</td>
<td>2,191</td>
<td>$2,302</td>
<td>$1,800</td>
</tr>
<tr>
<td>Contract Research Organizations</td>
<td>15,636</td>
<td>8,610</td>
<td>7,026</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Capital leases—equipment</td>
<td>3</td>
<td>3</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Total contractual cash obligations</td>
<td>$22,988</td>
<td>$9,669</td>
<td>$9,217</td>
<td>$2,302</td>
<td>$1,800</td>
</tr>
</tbody>
</table>

63
**Contract Research Organizations.** We utilize independent contract research organizations ("CROs") to perform the clinical trials of our biological drug candidates. Under the terms of these agreements, we design the protocol regarding the testing to be performed, and the CRO enrolls the patients and testing sites, administers the trial, performs statistical analysis of the results, and compiles the final report.

We pay fees directly to the CROs for their professional services, which may be payable upon specified trial milestones or as they provide services, depending on the structure of the contract. We are also responsible for reimbursing the CROs for certain pass-through expenses they incur in administering the trial. The timing of our payments to the CROs is dependent upon the progress of the various trials, which is highly variable dependent upon the speed with which the CROs are able to enroll patients and testing sites. As such, we are unable to specifically predict the timing of future payments to CROs.

As of December 31, 2009, we had active contracts with CROs related to four on-going clinical trials which were in varying stages of completion. The total contracted payments to CROs under these agreements were $29.6 million, of which we had incurred approximately $14.0 million as of that date. Although we cannot directly control the timing of the remaining payments, based on our estimates and assumptions as of December 31, 2009, we currently expect to make payments to the CROs through 2012 as detailed above.

**Clinical Manufacturing Services Agreement.** We have contracted for lot screening services for the isolation, growth, and differentiation of the MSCs to be used in our biological drug candidates. Due to the long production cycle for MSCs, we are obligated to provide a twelve month future forecast production plan, under which the counterparty will produce our required MSC doses for a fixed price per dose. The term of the agreement is five years, provided that we continue to provide a forecast production plan. We have the right to terminate the contract with thirty days written notice. In the event we terminate the contract, we are obligated for any in-process production as of the termination date that has been initiated according to our production forecast. Accordingly, our minimum contractual commitment under this contract is limited to in-process production at any given time. Our obligation would not extend for a period longer than twelve months, the maximum outlook of the production forecast. Based on our current forecast production plan, we do not have a future minimum contractual commitment under this contract.

**Leases.** During 2006, we entered into a sublease agreement for approximately 61,000 square feet of laboratory, production, warehouse and office space in Columbia, Maryland. We also entered into a direct lease with the owner of this facility that was effective as of June 1, 2009 upon the expiration of the sublease and expires in July 2016. During 2009, following the expiration of the sublease agreement, we increased the amount of an outstanding letter of credit, which was used in lieu of a security deposit for this lease, to $591,000 according to the terms of the direct lease with the owner of the facility. This letter of credit remained outstanding as of December 31, 2009, and is fully collateralized by restricted cash.

As of December 31, 2008, NuVasive had agreed to assume the lease to our Columbia, Maryland facility concurrent with the manufacturing asset closing under the Asset Purchase Agreement, which was to occur during 2009. As previously discussed, the Asset Purchase Agreement was amended during the first quarter of 2009 such that we relieved NuVasive of its obligation to assume the lease for our Columbia, Maryland facility. Accordingly, we have retained all of the privileges and obligations under this contract.
**Effect of Inflation.**

Inflation and changing prices are not generally a material factor affecting our business. General operating expenses such as salaries, employee benefits and lease costs are, however, subject to normal inflationary pressures.

**ITEM 7A. Quantitative and Qualitative Disclosures about Market Risk.**

**Interest Rate Risk**

Due to the short duration of our investment portfolio and the high quality of our investments, an immediate 10% change in interest rates would not have a material effect on the value of our portfolio. Therefore, we would not expect our operating results or cash flows to be affected to any material degree by the effect of a sudden change in market interest rates on our securities portfolio.

We believe that the interest rate risk related to our accounts receivable is not significant. We manage the risk associated with these accounts through periodic reviews of the carrying value for non-collectability and establishment of appropriate allowances in connection with our internal controls and policies.

**Foreign Current Exchange Rate Risk**

We conduct clinical trial activities in areas that operate in a functional currency other than the United States dollar (USD). As a result, when the USD rises and falls against the functional currencies of these other nations, our costs will either increase or decrease by the relative change in the exchange rate. Foreign currency gains and losses were not significant during the three years ended December 31, 2009, and at the present time, we have elected not to hedge our exposure to foreign currency fluctuations.

**Derivative Instruments**

We do not enter into hedging or derivative instrument arrangements.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
OSIRIS THERAPEUTICS, INC.
FINANCIAL STATEMENTS
INDEX

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Management’s Report on Internal Control Over Financial Reporting</td>
<td>67</td>
</tr>
<tr>
<td>Report of Independent Registered Public Accounting Firm on Fiscal 2009</td>
<td>68</td>
</tr>
<tr>
<td>Report of Independent Registered Public Accounting Firm on Fiscal 2008 and 2007</td>
<td>70</td>
</tr>
<tr>
<td>Balance Sheets at December 31, 2009 and 2008</td>
<td>71</td>
</tr>
<tr>
<td>Statements of Operations for the years ended December 31, 2009, 2008 and 2007</td>
<td>72</td>
</tr>
<tr>
<td>Statements of Stockholders’ Equity (Deficit) for the years ended December 31, 2009, 2008 and 2007</td>
<td>73</td>
</tr>
<tr>
<td>Statements of Cash Flows for the years ended December 31, 2009, 2008 and 2007</td>
<td>74</td>
</tr>
<tr>
<td>Notes to Financial Statements</td>
<td>75</td>
</tr>
</tbody>
</table>
REPORT OF MANAGEMENT

Management’s Report on Financial Statements

Our management is responsible for the preparation, integrity and fair presentation of information in our financial statements, including estimates and judgments. The financial statements presented in this Annual Report on Form 10-K have been prepared in accordance with accounting principles generally accepted in the United States of America. Our management believes the financial statements and other financial information included in this Annual Report on Form 10-K fairly present, in all material respects, our financial condition, results of operations and cash flows as of and for the periods presented in this Annual Report on Form 10-K. The financial statements for fiscal 2009 have been audited by Grant Thornton LLP, an independent registered public accounting firm, as stated in their report, which is included herein. The financial statements for fiscal 2008 and 2007 have been audited by Stegman & Company, an independent registered public accounting firm, as stated in their report, which is included herein.

Management’s Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.

Our internal control over financial reporting includes those policies and procedures that:

- pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets;

- provide reasonable assurance that our transactions are recorded as necessary to permit preparation of our financial statements in accordance with accounting principles generally accepted in the United States of America, and that our receipts and expenditures are being made only in accordance with authorization of our management and our directors; and

- provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the consolidated financial statements.

Because of its inherent limitations, internal control over financial reporting can provide only reasonable assurance and may not prevent or detect misstatements. Also, projections of any evaluation of the effectiveness of such controls in future periods are subject to the risk that the controls may become inadequate because of changes in conditions or that the degree of compliance with the policies and procedures may deteriorate.

Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2009. In making this assessment, our management used the criteria set forth in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on its assessment, our management concluded that, as of December 31, 2009, our internal control over financial reporting was effective based on those criteria.

Grant Thornton LLP has issued an attestation report on our internal control over financial reporting. This report is included in the Report of Independent Public Accounting Firm in Item 15.
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Board of Directors and Shareholders of Osiris Therapeutics, Inc.

We have audited the accompanying balance sheet of Osiris Therapeutics, Inc. (a Delaware corporation) as of December 31, 2009, and the related statements of operations, stockholders’ equity, and cash flows for year then ended. We also have audited Osiris Therapeutics, Inc.’s internal control over financial reporting as of December 31, 2009, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Osiris Therapeutics, Inc.’s management is responsible for these financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on these financial statements and an opinion on Osiris Therapeutics, Inc.’s internal control over financial reporting based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement and whether effective internal control over financial reporting was maintained in all material respects. Our audit of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Osiris Therapeutics, Inc. as of December 31, 2009, and the results of its operations and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, Osiris Therapeutics, Inc. maintained, in
all material respects, effective internal control over financial reporting as of December 31, 2009, based on criteria established in Internal Control—Integrated Framework issued by COSO.

/s/ Grant Thornton LLP
Baltimore, Maryland
March 12, 2010
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders
Osiris Therapeutics, Inc.
Columbia, Maryland

We have audited the accompanying balance sheet of Osiris Therapeutics, Inc. as of December 31, 2008, and the related statements of operations, stockholders’ equity (deficit) and cash flows for each of the years in the two-year period ended December 31, 2008. Osiris Therapeutics, Inc.’s management is responsible for these financial statements. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Osiris Therapeutics, Inc. as of December 31, 2008, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2008 in conformity with accounting principles generally accepted in the United States of America.

/s/ STEGMAN & COMPANY

Baltimore, Maryland
March 14, 2009
## OSIRIS THERAPEUTICS, INC.
### BALANCE SHEETS
(amounts in thousands)

<table>
<thead>
<tr>
<th>December 31, 2009</th>
<th>December 31, 2008</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASSETS</strong></td>
<td></td>
</tr>
<tr>
<td>Current assets:</td>
<td></td>
</tr>
<tr>
<td>Cash</td>
<td>$ 1,306</td>
</tr>
<tr>
<td>Investments available for sale</td>
<td>99,409</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>1,138</td>
</tr>
<tr>
<td>Prepaid expenses and other current assets</td>
<td>948</td>
</tr>
<tr>
<td>Current assets of discontinued operations</td>
<td>—</td>
</tr>
<tr>
<td>Total current assets</td>
<td>102,801</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>3,734</td>
</tr>
<tr>
<td>Restricted cash</td>
<td>666</td>
</tr>
<tr>
<td>Other assets</td>
<td>395</td>
</tr>
<tr>
<td>Long-term assets of discontinued operations</td>
<td>—</td>
</tr>
<tr>
<td>Total assets</td>
<td>$ 107,596</td>
</tr>
<tr>
<td><strong>LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</strong></td>
<td></td>
</tr>
<tr>
<td>Current liabilities:</td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$ 9,013</td>
</tr>
<tr>
<td>Deferred revenue, current portion</td>
<td>41,011</td>
</tr>
<tr>
<td>Capital lease obligations, current portion</td>
<td>3</td>
</tr>
<tr>
<td>Current liabilities of discontinued operations</td>
<td>412</td>
</tr>
<tr>
<td>Total current liabilities</td>
<td>50,439</td>
</tr>
<tr>
<td>Deferred revenue, net of current portion</td>
<td>44,173</td>
</tr>
<tr>
<td>Other long-term liabilities</td>
<td>424</td>
</tr>
<tr>
<td>Total liabilities</td>
<td>95,036</td>
</tr>
<tr>
<td>Stockholders’ equity (deficit):</td>
<td></td>
</tr>
<tr>
<td>Common stock, $.001 par value, 90,000 shares authorized, 32,773 and 32,676 shares outstanding in 2009 and 2008</td>
<td>33</td>
</tr>
<tr>
<td>Additional paid-in-capital</td>
<td>272,959</td>
</tr>
<tr>
<td>Accumulated other comprehensive income (loss)</td>
<td>(88)</td>
</tr>
<tr>
<td>Accumulated deficit</td>
<td>(260,344)</td>
</tr>
<tr>
<td>Total stockholders’ equity (deficit)</td>
<td>12,560</td>
</tr>
<tr>
<td>Total liabilities and stockholders’ equity (deficit)</td>
<td>$ 107,596</td>
</tr>
</tbody>
</table>

The accompanying notes are an integral part of these financial statements.
OSIRIS THERAPEUTICS, INC.
STATEMENTS OF OPERATIONS
(amounts in thousands, except per share data)

<table>
<thead>
<tr>
<th>Years ended December 31,</th>
<th>2009</th>
<th>2008</th>
<th>2007</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue from collaborative research agreements, government contract, and royalties</td>
<td>$44,533</td>
<td>$10,044</td>
<td>$2,048</td>
</tr>
<tr>
<td>Operating expenses:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research and development</td>
<td>63,266</td>
<td>69,897</td>
<td>47,140</td>
</tr>
<tr>
<td>General and administrative</td>
<td>8,312</td>
<td>8,328</td>
<td>5,953</td>
</tr>
<tr>
<td>Fees paid to related parties</td>
<td>95</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Share based payments to related parties</td>
<td>400</td>
<td>258</td>
<td>118</td>
</tr>
<tr>
<td>Total operating expenses</td>
<td>72,073</td>
<td>78,483</td>
<td>53,211</td>
</tr>
<tr>
<td>Loss from operations</td>
<td>(27,540)</td>
<td>(68,439)</td>
<td>(51,163)</td>
</tr>
<tr>
<td>Other income (expense):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investment income</td>
<td>1,285</td>
<td>416</td>
<td>1,321</td>
</tr>
<tr>
<td>Interest paid to related parties</td>
<td>—</td>
<td>(508)</td>
<td>—</td>
</tr>
<tr>
<td>Interest expense</td>
<td>(8)</td>
<td>(886)</td>
<td>(8,016)</td>
</tr>
<tr>
<td>Total other income (expense), net</td>
<td>1,277</td>
<td>(978)</td>
<td>(6,695)</td>
</tr>
<tr>
<td>Loss from continuing operations, before income taxes</td>
<td>(26,263)</td>
<td>(69,417)</td>
<td>(57,858)</td>
</tr>
<tr>
<td>Income tax benefit</td>
<td>2,699</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Loss from continuing operations</td>
<td>(23,564)</td>
<td>(69,417)</td>
<td>(57,858)</td>
</tr>
<tr>
<td>Discontinued operations:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Income from discontinued operations, net of income taxes of $120 in 2009</td>
<td>1,084</td>
<td>5,525</td>
<td>3,937</td>
</tr>
<tr>
<td>Gain from sale of discontinued operations, net of income taxes of $4,121 in 2009</td>
<td>37,052</td>
<td>30,400</td>
<td>—</td>
</tr>
<tr>
<td>Income from discontinued operations</td>
<td>38,136</td>
<td>35,925</td>
<td>3,937</td>
</tr>
<tr>
<td>Net income (loss)</td>
<td>$14,572</td>
<td>$(33,492)</td>
<td>$(53,921)</td>
</tr>
<tr>
<td>Basic and diluted net income (loss) per share:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loss from continuing operations</td>
<td>(0.72)</td>
<td>(2.18)</td>
<td>(2.03)</td>
</tr>
<tr>
<td>Income from discontinued operations</td>
<td>1.16</td>
<td>1.13</td>
<td>0.14</td>
</tr>
<tr>
<td>Net income (loss)</td>
<td>0.45</td>
<td>(1.05)</td>
<td>(1.89)</td>
</tr>
<tr>
<td>Weighted average number of common shares outstanding (basic and diluted)</td>
<td>32,742</td>
<td>31,895</td>
<td>28,489</td>
</tr>
</tbody>
</table>

The accompanying notes are an integral part of these financial statements.
OSIRIS THERAPEUTICS, INC.
STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
(amounts in thousands, except for share data)

<table>
<thead>
<tr>
<th></th>
<th>Common Stock Shares</th>
<th>Additional Paid-in Capital</th>
<th>Accumulated Other Comprehensive Income</th>
<th>Accumulated Deficit</th>
<th>Total Stockholders’ Equity (Deficit)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Balance at January 1, 2007</strong></td>
<td>27,321,319</td>
<td>27</td>
<td>198,763</td>
<td>(187,503)</td>
<td>11,287</td>
</tr>
<tr>
<td>Exercise of options to purchase common stock ($0.40-$6.84 per share)</td>
<td>141,312</td>
<td>—</td>
<td>60</td>
<td>—</td>
<td>60</td>
</tr>
<tr>
<td>Share-based payment—director services ($23.62 per share)</td>
<td>12,500</td>
<td>—</td>
<td>295</td>
<td>—</td>
<td>295</td>
</tr>
<tr>
<td>Issuance of common stock in private placements to overseas investors ($11.38-$12.37 per share)</td>
<td>2,707,469</td>
<td>3</td>
<td>31,698</td>
<td>—</td>
<td>31,701</td>
</tr>
<tr>
<td>Induced conversion of convertible notes payable into common stock ($13.00 per share)</td>
<td>1,465,837</td>
<td>2</td>
<td>23,867</td>
<td>—</td>
<td>23,869</td>
</tr>
<tr>
<td>Share-based payment—employee compensation</td>
<td>—</td>
<td>—</td>
<td>1,045</td>
<td>—</td>
<td>1,045</td>
</tr>
<tr>
<td>Net loss</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>(53,921)</td>
</tr>
<tr>
<td><strong>Balance at December 31, 2007</strong></td>
<td>31,648,437</td>
<td>32</td>
<td>255,728</td>
<td>(241,424)</td>
<td>14,336</td>
</tr>
<tr>
<td>Exercise of options to purchase common stock ($0.40-$12.50 per share)</td>
<td>66,545</td>
<td>—</td>
<td>289</td>
<td>—</td>
<td>289</td>
</tr>
<tr>
<td>Share-based payment—director services ($12.01 per share)</td>
<td>21,500</td>
<td>—</td>
<td>258</td>
<td>—</td>
<td>258</td>
</tr>
<tr>
<td>Conversion of convertible notes payable into common stock ($12.04-$13.18 per share)</td>
<td>851,914</td>
<td>1</td>
<td>10,499</td>
<td>—</td>
<td>10,500</td>
</tr>
<tr>
<td>Induced conversion of convertible notes payable into common stock ($14.00 per share)</td>
<td>87,524</td>
<td>—</td>
<td>1,500</td>
<td>—</td>
<td>1,500</td>
</tr>
<tr>
<td>Share-based payment—employee compensation</td>
<td>—</td>
<td>—</td>
<td>1,556</td>
<td>—</td>
<td>1,556</td>
</tr>
<tr>
<td><strong>Comprehensive loss:</strong></td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>(33,492)</td>
</tr>
<tr>
<td>Net loss</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>33</td>
</tr>
<tr>
<td>Unrealized gain on investments available for sale</td>
<td>—</td>
<td>—</td>
<td>33</td>
<td>—</td>
<td>33</td>
</tr>
<tr>
<td><strong>Total comprehensive loss</strong></td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>(33,459)</td>
</tr>
<tr>
<td><strong>Balance at December 31, 2008</strong></td>
<td>32,675,920</td>
<td>$33</td>
<td>$269,830</td>
<td>$ 33</td>
<td>$274,916</td>
</tr>
<tr>
<td>Exercise of options to purchase common stock ($0.40-$13.33 per share)</td>
<td>75,911</td>
<td>—</td>
<td>575</td>
<td>—</td>
<td>575</td>
</tr>
<tr>
<td>Share-based payment—director services ($18.60 per share)</td>
<td>21,500</td>
<td>—</td>
<td>400</td>
<td>—</td>
<td>400</td>
</tr>
<tr>
<td>Share-based payment—employee compensation</td>
<td>—</td>
<td>—</td>
<td>2,154</td>
<td>—</td>
<td>2,154</td>
</tr>
<tr>
<td><strong>Comprehensive income:</strong></td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>14,572</td>
</tr>
<tr>
<td>Net income</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>14,572</td>
</tr>
<tr>
<td>Unrealized loss on investments available for sale</td>
<td>—</td>
<td>—</td>
<td>(121)</td>
<td>—</td>
<td>(121)</td>
</tr>
<tr>
<td><strong>Total comprehensive income</strong></td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>14,451</td>
</tr>
<tr>
<td><strong>Balance at December 31, 2009</strong></td>
<td>32,773,331</td>
<td>$33</td>
<td>$272,959</td>
<td>$ (88)</td>
<td>$260,344</td>
</tr>
</tbody>
</table>

The accompanying notes are an integral part of these financial statements.
OSIRIS THERAPEUTICS, INC.

STATEMENTS OF CASH FLOWS

(amounts in thousands)

<table>
<thead>
<tr>
<th>Years Ended December 31,</th>
<th>2009</th>
<th>2008</th>
<th>2007</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash flows from operating activities:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Continuing Operations</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loss from continuing operations</td>
<td>$(23,564)</td>
<td>$(69,417)</td>
<td>$(57,858)</td>
</tr>
<tr>
<td>Adjustments to reconcile loss from continuing operations to net cash used in continuing operations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>665</td>
<td>1,633</td>
<td>1,928</td>
</tr>
<tr>
<td>Non cash share-based payments</td>
<td>2,456</td>
<td>1,627</td>
<td>1,271</td>
</tr>
<tr>
<td>Non cash interest expense</td>
<td>—</td>
<td>130</td>
<td>6,881</td>
</tr>
<tr>
<td>Changes in operating assets and liabilities:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>55,149</td>
<td>(60,738)</td>
<td>(422)</td>
</tr>
<tr>
<td>Prepaid expenses and other current assets</td>
<td>1,112</td>
<td>(477)</td>
<td>(618)</td>
</tr>
<tr>
<td>Other assets</td>
<td>220</td>
<td>784</td>
<td>663</td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>(1,950)</td>
<td>124,746</td>
<td>(1,349)</td>
</tr>
<tr>
<td>Long-term interest and other liabilities</td>
<td>—</td>
<td>—</td>
<td>(1,120)</td>
</tr>
<tr>
<td>Net cash used in continuing operations</td>
<td>$(5,474)</td>
<td>(2,734)</td>
<td>(47,362)</td>
</tr>
<tr>
<td><em>Discontinued Operations</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Income from discontinued operations</td>
<td>38,136</td>
<td>35,925</td>
<td>3,937</td>
</tr>
<tr>
<td>Adjustments to reconcile loss from discontinued operations to net cash (used in) provided by discontinued operations:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non cash impact of the sale of discontinued operations</td>
<td>(44,788)</td>
<td>(30,400)</td>
<td>—</td>
</tr>
<tr>
<td>Depreciation &amp; amortization</td>
<td>210</td>
<td>562</td>
<td>105</td>
</tr>
<tr>
<td>Provision for bad debts</td>
<td>45</td>
<td>29</td>
<td>—</td>
</tr>
<tr>
<td>Non cash share-based payments</td>
<td>98</td>
<td>187</td>
<td>69</td>
</tr>
<tr>
<td>Changes in operating assets and liabilities:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>1,516</td>
<td>2,779</td>
<td>(2,855)</td>
</tr>
<tr>
<td>Inventory and other current assets</td>
<td>1,707</td>
<td>1,821</td>
<td>(2,228)</td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>(3,563)</td>
<td>2,053</td>
<td>1,816</td>
</tr>
<tr>
<td>Net cash (used in) provided by discontinued operations</td>
<td>$(6,639)</td>
<td>12,956</td>
<td>844</td>
</tr>
<tr>
<td>Net cash (used in) provided by operating activities</td>
<td>$(12,113)</td>
<td>10,222</td>
<td>(46,518)</td>
</tr>
<tr>
<td>Cash flows from investing activities:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investing activities of continuing operations:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purchases of property and equipment</td>
<td>(304)</td>
<td>(166)</td>
<td>(798)</td>
</tr>
<tr>
<td>Proceeds from the sale of property and equipment</td>
<td>17</td>
<td>104</td>
<td>—</td>
</tr>
<tr>
<td>Proceeds from sale of discontinued operations, net</td>
<td>9,736</td>
<td>33,607</td>
<td>—</td>
</tr>
<tr>
<td>Proceeds from sale of investments available for sale</td>
<td>54,185</td>
<td>16,195</td>
<td>50,900</td>
</tr>
<tr>
<td>Purchases of investments available for sale</td>
<td>(51,187)</td>
<td>(60,000)</td>
<td>(29,893)</td>
</tr>
<tr>
<td>Net cash provided by (used in) investing activities of continuing operations</td>
<td>12,447</td>
<td>(10,260)</td>
<td>20,209</td>
</tr>
<tr>
<td>Investing activities of discontinued operations:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purchases of property and equipment of discontinued operations</td>
<td>—</td>
<td>(2,808)</td>
<td>(3,904)</td>
</tr>
<tr>
<td>Net cash used in discontinued operations</td>
<td>—</td>
<td>(2,808)</td>
<td>(3,904)</td>
</tr>
<tr>
<td>Net cash provided by (used in) investing activities</td>
<td>12,447</td>
<td>(13,068)</td>
<td>16,305</td>
</tr>
<tr>
<td>Cash flows from financing activities:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Principal payments on capital lease obligations and notes payable</td>
<td>(7)</td>
<td>(14,357)</td>
<td>(1,115)</td>
</tr>
<tr>
<td>Restricted cash</td>
<td>(536)</td>
<td>150</td>
<td>17</td>
</tr>
<tr>
<td>Proceeds from convertible and short-term notes payable</td>
<td>575</td>
<td>289</td>
<td>31,701</td>
</tr>
<tr>
<td>Proceeds from the issuance of preferred and common stock, net</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Payment of debt financing fees</td>
<td>—</td>
<td>—</td>
<td>(400)</td>
</tr>
<tr>
<td>Net cash provided by financing activities</td>
<td>32</td>
<td>3,082</td>
<td>30,203</td>
</tr>
<tr>
<td>Net increase (decrease) in cash and cash equivalents</td>
<td>366</td>
<td>236</td>
<td>(10)</td>
</tr>
<tr>
<td>Cash and cash equivalents at beginning of period</td>
<td>940</td>
<td>704</td>
<td>714</td>
</tr>
<tr>
<td>Cash and cash equivalents at end of period</td>
<td>1,306</td>
<td>940</td>
<td>704</td>
</tr>
</tbody>
</table>

Supplemental disclosure of cash flows information:

<table>
<thead>
<tr>
<th></th>
<th>2009</th>
<th>2008</th>
<th>2007</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash paid for interest</td>
<td>$8</td>
<td>$1,264</td>
<td>$1,450</td>
</tr>
<tr>
<td>Supplemental schedule of non cash investing and financing activities:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conversion of notes payable to common stock</td>
<td>—</td>
<td>11,700</td>
<td>18,800</td>
</tr>
<tr>
<td>Conversion of accrued interest into common stock</td>
<td>—</td>
<td>300</td>
<td>5,069</td>
</tr>
<tr>
<td>Transfer of fixed assets from discontinued operations</td>
<td>3,581</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

The accompanying notes are an integral part of these financial statements.
OSIRIS THERAPEUTICS, INC.
NOTES TO FINANCIAL STATEMENTS

1. Description of Business and Significant Accounting Policies

Description of Business

Osiris Therapeutics, Inc. (“we,” “our,” or the “Company”) is a Delaware corporation headquartered in Columbia, Maryland. We began operations on December 23, 1992. We are a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas. Our biologic drug candidates utilize adult human mesenchymal stem cells (“MSCs”), which can selectively differentiate, based on the tissue environment, into various tissue lineages, such as muscle, bone, cartilage, marrow stroma, tendon or fat. In addition, MSCs have anti-inflammatory properties and can prevent fibrosis or scarring, which gives MSCs the potential to treat a wide variety of medical conditions. Our operations consist primarily of research, development and clinical activities to bring our biologic drug candidates to the marketplace. We have several research collaboration agreements and a government contract for additional product development.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Due to the inherent uncertainty involved in making those assumptions, actual results could differ from those estimates. We believe that the most significant estimates that affect the accompanying financial statements are those that relate to the progress and timing of our clinical trials, inventory valuation, deferred tax assets, and share-based compensation.

Investments Available for Sale and Other Comprehensive Income

Investments available for sale consist primarily of marketable securities with maturities varying between three months and one year. Investments available for sale are valued at their fair value, with unrealized gains and losses reported as a separate component of stockholders’ equity in accumulated other comprehensive income. All realized gains and losses on our investments available for sale are recognized in results of operations as investment income.

Investments available for sale are evaluated periodically to determine whether a decline in their value is “other than temporary.” Management reviews criteria such as the magnitude and duration of the decline, as well as the reasons for the decline, to predict whether the loss in value is other than temporary. If a decline in value is determined to be other than temporary, the value of the security is reduced and a corresponding charge to earnings is recognized.

Restricted Cash

We periodically are required under the terms of various agreements to provide letters of credit which are collateralized by cash deposits. The majority of the restricted cash balance relates to a letter of credit that we caused to be issued in lieu of a security deposit under the operating lease for our Columbia, Maryland facility.
Accounts Receivable

Accounts receivable are reported at their net realizable value. We charge off uncollectible receivables when the likelihood of collection is remote. We consider receivables outstanding more than 45-days to be past due. As of December 31, 2009 and 2008, there was no allowance for doubtful accounts related to accounts receivable from continuing operations, as we believe the reported amounts are fully collectible. Accounts receivable balances are not collateralized.

Property and Equipment

Property and equipment, including improvements that extend useful lives, are valued at cost, while maintenance and repairs are charged to operations as incurred. Depreciation is calculated using the straight-line method based on estimated useful lives ranging from three to seven years for furniture, equipment and internal use software. Leasehold improvements and assets under capital leases are amortized over the shorter of the estimated useful life of the asset or the original term of the lease.

Valuation of Long-lived Assets

We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable. These events or changes in circumstances may include a significant deterioration of operating results, changes in business plans, or changes in anticipated future cash flows. If an impairment indicator is present, we evaluate recoverability by a comparison of the carrying amount of the assets to future undiscounted net cash flows expected to be generated by the assets. Assets are grouped at the lowest level for which there is identifiable cash flows that are largely independent of the cash flows generated by other asset groups. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset, an impairment loss is recognized for the difference between the fair value and carrying value of assets. Fair value is generally determined by estimates of discounted cash flows. The discount rate used in any estimate of discounted cash flows would be the rate required for a similar investment of like risk. There were no impairment losses recognized during the years 2009, 2008 or 2007.

Assets to be disposed of are reported at the lower of carrying values or fair values, less estimated costs of disposal.

Revenue Recognition

We generate revenues from collaborative agreements, research licenses, and a government contract. We evaluate revenues from agreements that have multiple elements to determine whether the components of the arrangement represent separate units of accounting. To recognize a delivered item in a multiple element arrangement, the delivered items must have value on a stand alone basis, there must be objective and reliable evidence of fair value of the undelivered items, and the delivery or performance must be probable and within our control for any delivered items that have a right of return. The determination of whether multiple elements of a collaboration agreement meet the criteria for separate units of accounting requires us to exercise judgment.

Revenues from research licenses and government contracts are recognized as earned upon either the incurring of reimbursable expenses directly related to the particular research plan or the completion
1. Description of Business and Significant Accounting Policies (Continued)

of certain development milestones as defined within the terms of the agreement. Payments received in advance of research performed are designated as deferred revenue. Non-refundable upfront license fees and certain other related fees are recognized on a straight-line basis over the development periods of the contract deliverables. Fees associated with substantive at risk performance based milestones are recognized as revenue upon their completion, as defined in the respective agreements. Incidental assignment of technology rights is recognized as revenue as it is earned and received.

In October 2008, we entered into a Collaboration Agreement with Genzyme Corp. (“Genzyme”) for the development and commercialization of Prochymal and Chondrogen. Under this agreement, Genzyme agreed to pay to us non-contingent, non-refundable cash payments totaling $130.0 million, with $75.0 million paid during November 2008 and $55.0 million paid on July 1, 2009. The agreement provides Genzyme with certain rights to intellectual property developed by us, and requires that we continue to perform certain development work related to the subject biologic drug candidates. We have evaluated the deliverables related to these payments, and concluded that the various deliverables represent a single unit of accounting. For this reason, we have deferred the recognition of revenue related to the upfront payments, and are amortizing these amounts to revenue on a straight-line basis over the estimated delivery period of the required development services, which extend through the first quarter of 2012. Accordingly, we recognized $40.0 million and $6.7 million of revenue in the years ended December 31, 2009 and 2008, respectively, related to the amortization of the upfront payments. The balance of these payments has been recorded as $40.0 million of current deferred revenue and $43.3 million of long term deferred revenue as of December 31, 2009. The agreement also provides for contingent milestone payments of up to $1.25 billion in the aggregate, as well as royalties to be paid to us on any sales by Genzyme. Consistent with our revenue recognition policies, we will recognize revenue from these contingent milestone payments for which we have no continuing performance obligations upon achievement of the related milestone. For any milestone payments for which we have a continuing performance obligation, the milestone payments will be deferred and recognized as revenue over the term of the related performance obligations.

In 2007, we partnered with Genzyme to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. In January 2008, we were awarded a contract from the United States Department of Defense (“DoD”) pursuant to which we, in partnership with Genzyme, are seeking to develop and stockpile Prochymal for the repair of gastrointestinal injury resulting from acute radiation exposure. We began recognizing revenue under this contract during the first quarter of 2008. Contract revenue is recognized as the related costs are incurred, in accordance with the terms of the contract. We recognized $3.0 million and $2.5 million in revenue from the DoD contract during 2009 and 2008, respectively.

In October 2007, we entered into a collaborative agreement with the Juvenile Diabetes Research Foundation (“JDRF”) to conduct a Phase II clinical trial evaluating Prochymal as a treatment for type 1 diabetes mellitus. This collaborative agreement provides for JDRF to provide up to $4.0 million of contingent milestone funding to support the development of Prochymal for the preservation of insulin production in patients with newly diagnosed type 1 diabetes mellitus. The contingent milestone payments under the agreement are amortized to revenue on a straight line basis over the duration of our obligations under the collaborative agreement as they are earned. We have received $3.5 million of the contingent milestones to date, and expect to receive the remaining $0.5 million in 2010.
1. Description of Business and Significant Accounting Policies (Continued)

amortizing the each payment as it was received, resulting in $1.2 million and $0.6 million of revenue during 2009 and 2008, respectively under the agreement with JDRF. The remainder of the payments received under this agreement has been recorded as $0.8 million of current deferred revenue and $0.8 million of long term deferred revenue as of December 31, 2009.

We also earn royalties on the sale of human mesenchymal stem cells sold for research purposes and recognize the revenue on these sales as the sales are made. Revenues include $0.3 million of royalty revenue during 2009 and $0.2 million of royalty revenue during each of the years 2008 and 2007.

Research and Development Costs

We expense internal and external research and development (“R&D”) costs, including costs of funded R&D arrangements and the manufacture of clinical batches of our biologic drug candidates used in clinical trials, in the period incurred.

Income Taxes

Deferred tax liabilities and assets are recognized for the estimated future tax consequences of temporary differences, income tax credits and net operating loss carry-forwards. Temporary differences are primarily the result of the differences between the tax bases of assets and liabilities and their financial reporting values. Deferred tax liabilities and assets are measured by applying the enacted statutory tax rates applicable to the future years in which deferred tax liabilities or assets are expected to be settled or realized. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense, if any, consists of the taxes payable for the current period and the change during the period in deferred tax assets and liabilities. For all periods presented, valuation allowances have been provided for the full amount of net deferred tax assets.

On January 1, 2007, we adopted a new financial pronouncement that gives guidance related to the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and requires that we recognize in our financial statements the impact of a tax position, if that position is more likely than not to be sustained upon an examination, based on the technical merits of the position. Interest and penalties related to income tax matters are recorded as income tax expense. At December 31, 2009 and 2008, we had no accruals for interest or penalties related to income tax matters.

Income (Loss) per Common Share

Basic income (loss) per common share is calculated by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted income (loss) per common share refers to the adjustment to basic income (loss) per share for the potentially dilutive effects of shares issuable under stock option plans and the conversion of preferred stock and convertible debt using the treasury stock method. We did not have any preferred stock or convertible debt outstanding as of either December 31, 2009 or 2008. Diluted income (loss) per common share excludes 1,000,762, 1,211,177, and 880,410 options for the years ended December 31, 2009, 2008, and 2007, respectively as
1. Description of Business and Significant Accounting Policies (Continued)

their effect is anti-dilutive. Similarly, the 1,000,000 shares issuable upon the assumed exercise of our outstanding warrant, discussed in Note 8 below, has also been excluded from the calculation for all periods presented as the effect is anti-dilutive. As a result of the anti-dilutive nature of the options and outstanding warrants, basic and diluted income (loss) per share are identical.

Share-Based Compensation

We account for share-based payments using the fair value method.

We recognize all share-based payments to employees and non-employee directors in our financial statements based on their grant date fair values, calculated using the Black-Scholes option pricing model. Compensation expense related to share-based awards is recognized on a straight-line basis based on the value of share awards that are expected to vest during the requisite service period on the grant date, which is revised if actual forfeitures differs materially from original expectations.

Comprehensive Income

We disclose comprehensive income and its components in our statements of stockholders’ equity (deficit). Comprehensive income is comprised of net income (loss) and other comprehensive income (loss), which includes certain changes in equity that are excluded from net income (loss).

Concentration of Risk

We maintain cash and short-term investment balances in accounts that exceed federally insured limits, although we have not experienced any losses on such accounts. We also invest excess cash in investment grade securities, generally with maturities of three months or less.

We have historically provided credit in the normal course of business to contract counterparties and to the distributors of our product. Accounts receivable in the accompanying balance sheets consists primarily of amounts due from four contract counterparties. We expect all of our receivables to be fully collected. Receivables from distributors of the Osteocel product line have been classified as a portion of current assets of discontinued operations.

Recent Accounting Guidance Not Yet Adopted at December 31, 2009

In June 2009, the Financial Accounting Standards Board (“FASB”) issued authoritative accounting guidance to improve financial reporting by companies involved with variable interest entities and to provide more relevant and reliable information to users of financial statements. The new guidance requires revised evaluations of whether entities represent variable interest entities, ongoing assessments of control over such entities, and additional disclosures of variable interests. This guidance is effective for fiscal years beginning after November 15, 2009. We adopted this guidance as of January 1, 2010, and since we are not involved with any variable interest entities, we do not expect the adoption to have a material impact on our financial statements.

In September 2009, ASU 2009-13, Revenue Recognition (Topic 605)—Multiple-Deliverable Revenue Arrangements (“ASU 2009-13”) was issued and will change the accounting for multiple-deliverable arrangements to enable vendors to account for products or services (deliverables) separately rather than
1. Description of Business and Significant Accounting Policies (Continued)

as a combined unit. Specifically, this guidance amends the criteria in Subtopic 605-25, Revenue Recognition—Multiple-Element Arrangements, for separating consideration in multiple-deliverable arrangements. This guidance establishes a selling price hierarchy for determining the selling price of a deliverable, which is based on: (a) vendor-specific objective evidence; (b) third-party evidence; or (c) estimates. This guidance also eliminates the residual method of allocation and requires that arrangement consideration be allocated at the inception of the arrangement to all deliverables using the relative selling price method. In addition, this guidance significantly expands required disclosures related to a vendor’s multiple-deliverable revenue arrangements. ASU 2009-13 is effective prospectively for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010 with early adoption permitted. The impact of ASU 2009-13 on our financial statements will depend on the nature and terms of revenue arrangements that we enter into or materially modify after the adoption date. However, based on our current customer arrangements, we do not believe the adoption of this ASU will have a material impact on our financial statements.

In January 2010, the Financial Accounting Standards Board issued ASU 2010-06, Fair Value Measurements and Disclosures (Topic 820)—Improving Disclosures about Fair Value Measurements (“ASU 2010-06”), which amends Topic 820 to add new requirements for disclosures about transfers into and out of Levels 1 and 2 and separate disclosures about purchases, sales, issuances, and settlements related to Level 3 measurements. ASU 2010-06 also clarifies existing fair value disclosures about the level of disaggregation and about inputs and valuation techniques used to measure fair value. The ASU is effective for the first reporting period beginning after December 15, 2009, except for the requirements to provide the Level 3 activity of purchases, sales, issuances, and settlements on a gross basis, which will be effective for fiscal years beginning after December 15, 2010, and for interim periods within those fiscal years. Early adoption is permitted. We believe the adoption of this amendment will not have a material effect on our financial position or results of operations.

2. Collaboration Agreements and Government Contract

Following is a detailed discussion of each of our material collaborative agreements and contracts. The accounting policies related to each of these contracts, including material impact on our financial statements, is included above under the “Revenue Recognition” section of Note 1, Description of Business and Significant Accounting Policies.

Collaboration Agreement with Genzyme Corporation. On October 31, 2008, we entered into a Collaboration Agreement with Genzyme for the development and commercialization of Prochymal and Chondrogen. Under the terms of the agreement, we will retain the rights to commercialize Prochymal and Chondrogen in the United States and Canada, and Genzyme has been granted the exclusive right and license to commercialize Prochymal and Chondrogen in all other countries (the “Genzyme Territory”), except with respect to Prochymal for Graft vs. Host Disease (“GvHD”) in Japan, which has previously been licensed to another pharmaceutical company. Genzyme has the right to “opt-out” of any further Chondrogen development following receipt of the results of the planned Phase II/III clinical trial for Chondrogen. If Genzyme opts-out, all rights to Chondrogen will revert to us with no further obligations between the companies with regard to Chondrogen. In the event that Genzyme does not opt-out but instead participates in the future development efforts for Chondrogen, Genzyme would be entitled to retain rights and licenses to our intellectual property related to Chondrogen in all countries outside the United States and Canada.
2. Collaboration Agreements and Government Contract (Continued)

As partial consideration for the grant of these rights, the Collaboration Agreement provides for a non-contingent, non-refundable cash payment to us of $130.0 million from Genzyme, with $75.0 million paid in November 2008 and $55.0 million paid on July 1, 2009. The Collaboration Agreement also provides for contingent milestone payments of up to $1.25 billion in the aggregate, in addition to royalties on any sales by Genzyme, to be paid by Genzyme to us, as follows:

**Prochymal**: As respects Prochymal, we are eligible to receive up to $500.0 million in development and regulatory milestone payments and up to $250.0 million in sales based milestone payments, as follows:

- Total development milestones related to GvHD of up to $50.0 million, with $25.0 million payable upon marketing approval from the United States Food & Drug Administration (“FDA”), and $25.0 million payable upon marketing approval from the European Medicines Agency (“EMEA”).
- Total development milestones of up to $180.0 million related to Crohn’s disease and Ulcerative Colitis, with $50.0 million payable upon achieving statistically significant endpoint(s) in a Phase III clinical trial for Crohn’s disease, $100.0 million payable upon marketing approval by the EMEA for Crohn’s disease, $10.0 million payable upon achieving statistically significant endpoint(s) in a Phase II or Phase III clinical trial for Ulcerative Colitis, and $20.0 million payable upon achieving marketing approval for Ulcerative Colitis by the EMEA.
- Total development milestones of up to $270.0 million related to the development of follow-on indications for Prochymal, with $20.0 million payable upon each success in a Phase II clinical trial for acute myocardial infarction, type 1 diabetes or other follow-on indications, as agreed to by the Company and Genzyme, and $40.0 million payable upon receipt of each marketing approval by the EMEA for Prochymal for chronic obstructive pulmonary disease (“COPD”), acute myocardial infarction, type 1 diabetes mellitus or other follow-on indications, as agreed to by the Company and Genzyme.
- Total sales based milestones of up to $250.0 million for Prochymal, with $100.0 million payable when annual Prochymal sales reach $500.0 million in the Genzyme Territory, and $150.0 million payable when annual Prochymal sales reach $1.0 billion in the Genzyme Territory.

**Chondrogen**: Upon receipt of the results of the planned Phase II/III clinical trial of Chondrogen, Genzyme may elect to opt-out of any further Chondrogen development, at which point all rights to Chondrogen will revert to us with no further obligations between the companies with regard to Chondrogen. If Genzyme does not opt-out, we are eligible to receive up to $500.0 million in development, regulatory and sales based milestone payments for Chondrogen, as follows:

- Total development and regulatory milestones of up to $100.0 million, with $10.0 million payable if Genzyme does not opt-out, $10.0 million payable upon demonstration of disease modification in the current clinical trial program, $40.0 million payable upon marketing approval by either the FDA or EMEA for a pain reduction indication, and $40.0 million payable upon marketing approval by either the FDA or EMEA for a disease modification indication.
2. Collaboration Agreements and Government Contract (Continued)

- Total sales milestones of up to $400.0 million, with $100.0 million payable when annual Chondrogen sales reach $500.0 million in the Genzyme Territory, $150.0 million payable when annual Chondrogen sales reach $1.0 billion in the Genzyme territory, and $150.0 million payable when annual Chondrogen sales reach $2.0 billion in the Genzyme Territory.

We will be solely responsible for ongoing clinical trial costs and future clinical trial costs with respect to both Prochymal and Chondrogen through Phase II clinical trials. We will share with Genzyme all costs of future Phase III and Phase IV clinical trials for agreed-upon indications (assuming in the case of Chondrogen that Genzyme does not opt-out), with us being responsible for 60% of such costs and Genzyme responsible for 40% of such costs.

Assuming successful development and marketing approval (and assuming in the case of Chondrogen that Genzyme does not opt-out), we will be entitled to receive escalating royalties on sales of Prochymal and Chondrogen within the Genzyme Territory.

**Genzyme Partnership and the United States Department of Defense Contract.** In 2007, we partnered with Genzyme to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. In January 2008, we were awarded a contract from the DoD pursuant to which we, in partnership with Genzyme, are seeking to develop and stockpile Prochymal for the repair of gastrointestinal injury resulting from acute radiation exposure. Under the terms of the contract, the DoD will provide funding to us for the development of Prochymal for acute radiation syndrome (“ARS”). If we are successful in obtaining FDA approval for ARS, the contract provides for the purchase by the DoD of up to 20,000 doses of Prochymal, at $10,000 per dose, in four 5,000 dose increments. Under the terms of our partnership with Genzyme, we will contribute Prochymal and corresponding safety and efficacy data to the effort and Genzyme will lend its vast product development and large-scale commercialization expertise. The agreement provides for Genzyme to receive a royalty of 15% on sales of Prochymal, limited to those sales made under contract to U.S. or Allied governmental agencies for emergency preparedness.

**Juvenile Diabetes Research Foundation Agreement.** In 2007, we entered into a collaborative agreement with the JDRF which provides funding to support the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes mellitus. This collaborative agreement provides for JDRF to provide up to $4.0 million of contingent milestone funding. We initiated a Phase II clinical trial evaluating Prochymal as a treatment for type 1 diabetes in the fourth quarter of 2007, and earned $2.0 million of the contingent milestones during 2008 and $1.5 million in 2009. We expect to earn the remaining $0.5 million contingent milestone in 2010. Consistent with our revenue recognition policies for such contingent milestones, we began amortizing each milestone payment as it was received and will continue to amortize the payments over the remaining term of our obligations under the agreement. Future milestone payments received will be similarly amortized over the term of our obligations beginning upon their receipt.

**JCR Pharmaceuticals Agreement.** In 2003, we entered into a strategic alliance with JCR Pharmaceuticals Co. Ltd. (“JCR”). Under the JCR agreement, we have granted to JCR the exclusive right in Japan to use our technology in conjunction with the treatment of hematologic malignancies using hematopoietic stem cell transplants. The JCR agreement entitles us to a licensing fee and to royalties on any resulting revenue. Upon commencement of the agreement, JCR purchased 545,454
2. Collaboration Agreements and Government Contract (Continued)

shares of our Series B Convertible Preferred Stock for $3.0 million. These shares were converted into 136,363 shares of our common stock concurrent with our initial public offering in August 2006. They have also paid us a total of $4.0 million in licensing fees under the agreement. The JCR agreement also provides for additional contingent milestone payments totaling $3.0 million, which will be recorded as revenue if and when the milestone events occur.

3. Segment Reporting, Discontinued Operations & Gain on Sale of Discontinued Operations

In 2007, we began to manage our business in two reportable operating segments: the Biologic Drug Candidates segment and the Biologic Tissue Product segment. Our Biologic Drug Candidates segment focuses on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. Its operations have focused on clinical trials and discovery efforts to identify additional medical indications. Our Biologic Drug Candidates segment generates revenues from license fees, government contracts, and royalties from collaborative agreements.

Our Biologic Tissue Product segment included the manufacture and sale of Osteocel, which we launched in July 2005 and is currently being used by orthopedic surgeons for focal bone repair. In April 2008, we committed to a plan to sell our biologic tissue product segment, including our entire product line relating to the processing, manufacturing, marketing and selling of Osteocel® and Osteocel® XO, an allograft material containing cancellous bone, used in spinal fusion and other surgical procedures. We refer to these assets as our Osteocel asset disposal group, and on May 2, 2008, we entered into an Asset Purchase Agreement to sell these assets to NuVasive, Inc., a Delaware corporation. Not included among the Osteocel asset disposal group is Osteocel® XC, our second generation product candidate under development for bone repair, utilizing culture expanded mesenchymal stem cells to create a synthetic version of Osteocel.

We eliminated the Osteocel asset disposal group from our ongoing operations as a result of the disposal transaction and have presented the results of the group’s operations as a discontinued operation for all periods. Accordingly, our continuing operations now represent the business that was previously referred to as the Biologic Drug Candidates segment. Substantially all of our revenues and assets are attributed to and are received from entities located in the United States.

The Asset Purchase Agreement to sell the Osteocel asset disposal group to NuVasive provides for two closings—a technology assets closing, at which technology and certain other business assets were transferred, and a manufacturing assets closing, at which manufacturing assets and facilities were transferred. On July 24, 2008, we held a Special Meeting of Stockholders at which our stockholders overwhelmingly approved the sale of the Osteocel business. The technology assets closing also occurred on that date, at which time we received an initial payment of $35.0 million. Concurrent with the technology assets closing, we entered into a Manufacturing Agreement with NuVasive, under which we continued to manufacture Osteocel and sold 100% of the product to NuVasive at specified prices. In December 2008, we earned another $5.0 million in additional purchase price through the achievement of a production milestone. The agreements with NuVasive were amended several times during 2008, all without altering the potential purchase price.

We recognized a gain on the technology assets closing of $25.5 million in the third quarter of 2008. We incurred transaction costs of $1.4 million, including legal, accounting and advisory fees. At that
3. Segment Reporting, Discontinued Operations & Gain on Sale of Discontinued Operations (Continued)

time, we also established reserves totaling $8.1 million to recognize the concessionary pricing of Osteocel that we produced under the Manufacturing Agreement. The reserves were amortized into the income (loss) from operations of discontinued operations beginning in the fourth quarter of 2008 as we fulfilled our obligations under the Manufacturing Agreement. We earned the first $5.0 million contingent milestone payment during December 2008. This milestone, net of $0.1 million of additional expenses, was recorded as an increase to the gain from the sale of discontinued operations during the fourth quarter of 2008. At December 31, 2008, $3.6 million of the concessionary pricing reserves remained unamortized, and were included in current liabilities of discontinued operations as of that date.

In March 2009, we entered into further amendments to the Asset Purchase Agreement and the related Manufacturing Agreement, as a result of which the manufacturing assets closing was accelerated and all performance conditions to receipt, by us, of $30.0 million of contingent milestone payments were removed. As a result, those payments became payable at specified dates, without regard to other conditions, either in cash or in shares of NuVasive stock, at the option of NuVasive.

The Asset Purchase Agreement, as amended, provided for up to $85.0 million of total purchase price, as follows:

<table>
<thead>
<tr>
<th>Payments</th>
<th>Amount (000)</th>
<th>Payment Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial cash payment</td>
<td>35,000</td>
<td>July 2008</td>
</tr>
<tr>
<td>Cumulative sales to NuVasive of 75,000 ccs of Osteocel, paid in cash</td>
<td>5,000</td>
<td>January 2009</td>
</tr>
<tr>
<td>Accelerated Manufacturing Assets Closing, paid in cash</td>
<td>5,000</td>
<td>March 2009</td>
</tr>
<tr>
<td>Installment paid in stock</td>
<td>12,500</td>
<td>June 2009</td>
</tr>
<tr>
<td>Installment paid in stock</td>
<td>12,500</td>
<td>September 2009</td>
</tr>
<tr>
<td>Milestone payment due upon NuVasive achieving at least $35.0 million in cumulative sales of Osteocel, paid in stock</td>
<td>15,000</td>
<td>November 2009</td>
</tr>
<tr>
<td><strong>Total possible purchase price</strong></td>
<td><strong>85,000</strong></td>
<td></td>
</tr>
</tbody>
</table>

The $30.0 million of payments that became payable at specified dates (March, June and September 2009, respectively) as a result of the March 2009 amendments, net of direct expenses of approximately $0.2 million, were recorded as a component of the gain on the sale of discontinued operations in the first quarter of 2009. The $12.5 million payments due June 30, 2009 and September 30, 2009, as well as the final $15.0 million milestone achieved in October 2009, were paid in shares of common stock issued by NuVasive. Cumulatively, we have received 1,001,422 shares of NuVasive common stock, of which we have sold 986,122 for total cash proceeds of approximately $40.3 million at December 31, 2009. At December 31, 2009, we had the remaining 15,300 shares, with a fair value of $489,000, included on our balance sheet as a component of Investments Available for Sale. Title to the fixed assets transferred to NuVasive passed on April 9, 2009.

Concurrent with the March 2009 amendments to the Asset Purchase Agreement with NuVasive, we executed a Supply Agreement with AlloSource to facilitate the complete transfer of the Osteocel business, pursuant to which we transferred to AlloSource our entire Osteocel work-in-process inventory.
OSIRIS THERAPEUTICS, INC.
NOTES TO FINANCIAL STATEMENTS (Continued)

3. Segment Reporting, Discontinued Operations & Gain on Sale of Discontinued Operations (Continued)

at specified prices on the date of the manufacturing assets closing with NuVasive. The aggregate purchase price for the Osteocel work-in-process inventory was approximately $3.7 million, paid by AlloSource in cash installments over the 90-days following the execution of the Supply Agreement.

As stipulated under the March 2009 amendments, we ceased manufacturing Osteocel on March 28, 2009. As a result of this cessation of manufacturing, we committed to a workforce reduction of the approximately 80 employees involved in the Osteocel business. Employees directly affected by the workforce reduction received notification on March 30, 2009, and the workforce reduction was substantially completed in the second quarter of 2009. All of the affected employees received severance benefits, comprised principally of severance, benefits continuation costs and outplacement services. Total one-time termination benefits for the reduction in force totaled approximately $1.4 million, which was recorded as a component of the gain on the sale of discontinued operations in the first quarter of 2009.

Also in connection with the March 2009 amendments, we relieved NuVasive of its obligation to assume the lease for our Columbia, Maryland facility. As a result of the combination of our cessation of Osteocel manufacturing and retaining the lease obligations for the Columbia, Maryland facility, we conducted an analysis of our future minimum lease payments for the facility, related to unutilized space, and recorded an impairment charge of approximately $3.2 million related to our future minimum lease payments. Additionally, we recorded an impairment of the leasehold improvements specifically related to Osteocel production of approximately $3.0 million.

At the end of the third quarter of 2009, we created a new Biosurgery Division, focused on developing high-end biologic products for use in surgical procedures. This new Biosurgery Division will utilize the facilities previously used to manufacture Osteocel. As a result, we updated our analysis of the lease impairment charge and reversed the $2.8 million impairment that remained unamortized at that time. Both of these impairments charges were recorded as components of the gain on the sale of discontinued operations in 2009.

Also as a result of acceleration of the manufacturing assets closing, during the first quarter of 2009 we reversed approximately $2.5 million of concessionary pricing reserves for future Osteocel production that had been established under the original Manufacturing Agreement.

The fair value of the property that we transferred on the date of the manufacturing assets closing in April 2009, including both the manufacturing assets transferred to NuVasive and the inventory transferred to AlloSource, was approximately $5.1 million.

We recognized a gain of approximately $37.1 million, net of income taxes, on the sale of discontinued operations for the year ended December 31, 2009. In connection with this transaction, we
3. Segment Reporting, Discontinued Operations & Gain on Sale of Discontinued Operations (Continued)

recognized a gain on the sale of discontinued operations of $30.4 million during the fiscal year ended December 31, 2008. These gains are summarized as follows:

<table>
<thead>
<tr>
<th>Description</th>
<th>2009 ($000)</th>
<th>2008 ($000)</th>
<th>2007 ($000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial purchase price and milestone payments earned under the Asset Purchase Agreement</td>
<td>$45,000</td>
<td>$40,000</td>
<td>$—</td>
</tr>
<tr>
<td>Direct expenses related to the sale</td>
<td>(259)</td>
<td>(1,443)</td>
<td>—</td>
</tr>
<tr>
<td>Concessionary pricing and inventory adjustments</td>
<td>2,549</td>
<td>(8,097)</td>
<td>—</td>
</tr>
<tr>
<td>Employee related costs</td>
<td>(1,397)</td>
<td>(60)</td>
<td>—</td>
</tr>
<tr>
<td>Impairment of long lived assets and manufacturing facilities</td>
<td>(4,720)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Pretax gain on sale</td>
<td>41,173</td>
<td>30,400</td>
<td>—</td>
</tr>
<tr>
<td>Income tax expense</td>
<td>(4,121)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Gain from sale of discontinued operations, net</td>
<td>$37,052</td>
<td>$30,400</td>
<td>$—</td>
</tr>
</tbody>
</table>

We eliminated the Osteocel asset disposal group from our ongoing operations as a result of the disposal transaction and have presented the group’s assets, liabilities, and the results of the group’s operations as a discontinued operation for all periods.

The net assets allocable to the Osteocel asset disposal group at December 31, 2009 and 2008 were as follows:

<table>
<thead>
<tr>
<th>Description</th>
<th>2009 ($000)</th>
<th>2008 ($000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts receivable</td>
<td>$—</td>
<td>$1,516</td>
</tr>
<tr>
<td>Inventory</td>
<td>—</td>
<td>1,502</td>
</tr>
<tr>
<td>Other current assets</td>
<td>—</td>
<td>205</td>
</tr>
<tr>
<td>Current assets of discontinued operations</td>
<td>—</td>
<td>3,223</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>—</td>
<td>7,520</td>
</tr>
<tr>
<td>Current liabilities of discontinued operations</td>
<td>(412)</td>
<td>(7,219)</td>
</tr>
<tr>
<td>Net assets of discontinued operations</td>
<td>$(412)</td>
<td>$3,524</td>
</tr>
</tbody>
</table>
3. Segment Reporting, Discontinued Operations & Gain on Sale of Discontinued Operations
(Continued)

Summarized operating results of the Osteocel asset disposal group for the years ended December 31, 2009, 2008, and 2007 are as follows:

<table>
<thead>
<tr>
<th></th>
<th>2009 ($000)</th>
<th>2008 ($000)</th>
<th>2007 ($000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product sales</td>
<td>$6,295</td>
<td>$24,670</td>
<td>$15,240</td>
</tr>
<tr>
<td>Cost of goods sold</td>
<td>$4,967</td>
<td>$17,455</td>
<td>$6,955</td>
</tr>
<tr>
<td>Gross profit</td>
<td>$1,328</td>
<td>$7,215</td>
<td>$8,285</td>
</tr>
<tr>
<td>Operating expenses</td>
<td>$124</td>
<td>$1,690</td>
<td>$4,348</td>
</tr>
<tr>
<td>Income from operations</td>
<td>$1,084</td>
<td>$5,525</td>
<td>$3,937</td>
</tr>
<tr>
<td>before income taxes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Income tax expense</td>
<td>$120</td>
<td>$—</td>
<td>$—</td>
</tr>
<tr>
<td>Income from operations</td>
<td>$1,064</td>
<td>$5,525</td>
<td>$3,937</td>
</tr>
</tbody>
</table>

Inventory consists of tissue products in process and available for distribution, and is valued using the first-in, first-out method. Due to the nature of the Osteocel product, all of the costs to manufacture the product are incurred prior to completing the extensive testing and evaluation necessary to determine if the product can be released. Accordingly, we estimate the reserve for work-in-process inventory based upon historical experience.

Revenues on Osteocel sales were recognized when legal title to the product passed to the customer. Costs of goods sold related to the Osteocel product consist primarily of the costs to obtain the tissue and other chemicals and supplies, quality and sterility testing, plus labor and allocated overhead costs and the costs of operating the clean-room facilities.

Operating expenses for the year ended December 31, 2007 were unusually high due to costs associated with the expansion of the Osteocel manufacturing facility, as we experienced failed production qualification runs while expanding our capacity. The production issues were subsequently resolved in late March 2007.

Prior to the execution of the Asset Purchase Agreement and related Manufacturing Agreement with NuVasive, we sold Osteocel primarily to two customers, each of which represented greater than ten percent of our consolidated revenues for the year ended December 31, 2007.
4. Property and Equipment

Property and equipment consist of the following at December 31,

<table>
<thead>
<tr>
<th>Description</th>
<th>2009 ($000)</th>
<th>2008 ($000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laboratory and manufacturing equipment</td>
<td>$338</td>
<td>$212</td>
</tr>
<tr>
<td>Computer hardware, furniture and fixtures</td>
<td>$477</td>
<td>$289</td>
</tr>
<tr>
<td>Leased assets</td>
<td>$26</td>
<td>$26</td>
</tr>
<tr>
<td>Leasehold improvements</td>
<td>$4,162</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>$5,003</td>
<td>$527</td>
</tr>
<tr>
<td>Accumulated depreciation and amortization</td>
<td>$(1,269)</td>
<td>$(133)</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>$3,734</td>
<td>$394</td>
</tr>
</tbody>
</table>

During the third quarter of 2008, we consolidated all of our corporate activities, including the production of Osteocel, in our Columbia, Maryland facility. Prior to that time, we had leased approximately 126,000 square feet of laboratory, production, warehouse and office space in Baltimore, Maryland under a lease agreement that expired in September 2008 which had originally been arranged by the Maryland Economic Development Corporation and the City of Baltimore. Upon the expiration of the Baltimore lease, we vacated that location and consolidated our operations in our Columbia facility.

As detailed in Note 3—Segment Reporting, Discontinued Operations & Gain on Sale of Discontinued Operations, in connection with the March 2009 amendments to the Asset Purchase Agreement, we relieved NuVasive of its obligation to assume the lease for our Columbia, Maryland facility. As a result, we retained title to a portion of the property and equipment that had been allocated to the Osteocel disposal group as of December 31, 2008, and those assets have been included in the table above as assets of our continuing operations as of December 31, 2009.

5. Notes Payable and Capital Lease Obligations

In 2004, we borrowed $5.0 million on the $50.0 million line-of-credit entered into with Boston Scientific Corporation which was part of a collaborative arrangement for the development of our biologic drug candidate for cardiac indications. Under the terms of the original line-of-credit, this loan was to be repaid from the proceeds of future sales. In December 2007, the collaborative agreement was terminated. The line-of-credit was cancelled and the outstanding principal, together with accrued interest, was converted into a one-year term note, bearing interest at 8% and payable in quarterly installments starting in January 2008. We repaid this note, including accrued interest, during 2008.

In October 2006, we issued $20.0 million in convertible promissory notes in a private placement to several Swiss investors. The notes accrued interest at a rate of 10%, with semi-annual payments of accrued interest becoming due and payable on April 30 and October 30 of each calendar year, until maturity on April 30, 2009. The notes were convertible at the option of the respective holders at any time after February 9, 2007, into shares of common stock at the conversion price of $18.00 per share. The notes initially provided for automatic conversion into common stock at the same conversion price, if at any time after February 9, 2007, the closing price of the our common stock on the NASDAQ Global Market closed for ten consecutive trading days at $25.00 per share or greater. The notes also
5. Notes Payable and Capital Lease Obligations (Continued)

provided for redemption at any time at our option, with 30-day written notice. In December 2007, we
induced the conversion of $18.8 million of the notes, together with accrued interest into 1,465,837
shares of common stock. In connection with this induced conversion, we recorded a non-cash charge of
$4.8 million as interest expense. In January 2008, we induced the conversion the remaining $1.2 million
of these notes, together with accrued interest into 87,524 shares of common stock at the conversion
price of $14.00 per share, which resulted in a non cash charge of $248,000 as interest expense.

In March and May 2008, we issued an aggregate of $10.5 million in convertible promissory notes
to several non-U.S. investors pursuant to a private placement intended to qualify under Regulation S
and Section 4(2) of the Securities Act of 1933, as amended. Three of these notes with an aggregate
principal amount of $8.0 million bore interest at 2% and were due and payable on November 30, 2008.
The fourth note with a principal amount of $2.5 million bore interest at 4% and was due and payable
on November 30, 2009. The notes were convertible at the option of the respective holders at any time,
into shares of our common stock at conversion prices ranging from $12.04 to $13.18 per share (the
respective closing prices on the NASDAQ Global Market on the dates of the definitive agreements).
The notes provided for redemption at any time at our option, with 30-days prior written notice. These
notes, together with accrued interest, were converted into shares of our common stock at their
respective conversion rates during the fourth quarter of 2008.

In June 2008, we issued an aggregate of $5.5 million in short-term notes, and in July 2008, we
issued an aggregate of $1.0 million in short-term notes to several non-U.S. investors pursuant to a
private placement intended to qualify under Regulation S and Section 4(2) of the Securities Act of
1933, as amended. These notes bore interest at 10% semi-annually and became due and payable in
December 2008. In the third quarter of 2008, we repaid $2.5 million of these notes together with
accrued interest, and repaid the remaining $4.0 million, with accrued interest, during the fourth quarter
of 2008.

Accordingly, there were no notes payables outstanding at either December 31, 2009 or 2008.

**Maturities of Capital Lease Obligations**

The following table sets forth the maturities of our capital lease obligations for the fiscal years
ending December 31, as indicated:

<table>
<thead>
<tr>
<th></th>
<th>2009 (Email)</th>
<th>2008 (Email)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total capital lease obligations</td>
<td>$3</td>
<td>$9</td>
</tr>
<tr>
<td>Less current portion</td>
<td>(3)</td>
<td>(6)</td>
</tr>
<tr>
<td>Capital lease obligations, long-term</td>
<td>$—</td>
<td>$3</td>
</tr>
</tbody>
</table>

As of December 31, 2009, the remaining payments on our capital lease obligations are due in 2010.

6. Share-Based Compensation

In April 2006, we adopted our 2006 Omnibus Plan. We amended and restated this plan in 2008 to,
among other things, increase the number of shares available for grant. In addition, we had previously
established our Amended and Restated 1994 Stock Incentive Plan. Both Plans authorize the issuance of various forms of stock-based awards, including incentive and non-qualified stock options, stock purchase rights, stock appreciation rights and restricted and unrestricted stock awards. A total of 1,450,000 shares of our common stock have been reserved for issuance under the Amended and Restated 2006 Omnibus Plan, and 736,378 shares were reserved under our Amended and Restated 1994 Stock Incentive Plan. We ceased all grants under the Amended and Restated 1994 Stock Incentive Plan concurrent with our initial public offering in August 2006. As a result, no shares are currently available for future awards under the Amended and Restated 1994 Stock Incentive Plan. At December 31, 2009, there were 676,448 shares available for future awards under the Amended and Restated 2006 Omnibus Plan.

We generally issue stock option awards that vest over four years and have a ten-year life. We estimate the fair value of stock options using the Black-Scholes option-pricing model. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards. The fair value of stock options granted during each of the periods was estimated using the following assumptions:

<table>
<thead>
<tr>
<th>Years ended December 31,</th>
<th>2009</th>
<th>2008</th>
<th>2007</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assumptions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weighted average risk-free interest rate . . . .</td>
<td>2.20%</td>
<td>3.83%</td>
<td>4.61%</td>
</tr>
<tr>
<td>Dividend yield . . . . . . . . . . .</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Expected life of option grants . . . . . . .</td>
<td>5.0-years</td>
<td>6.25-years</td>
<td>4.5-years</td>
</tr>
<tr>
<td>Weighted average expected stock price volatility .</td>
<td>55-59%</td>
<td>67%</td>
<td>67%</td>
</tr>
</tbody>
</table>

The expected life of stock options granted was based on the Company’s historical option exercise experience and post vesting forfeiture experience using the historical expected term from the vesting date. The expected volatility of the options granted was determined using historical volatilities based on stock prices over a look-back period corresponding to the expected life. The risk-free interest rate was determined using the yield available for zero-coupon United States government issues with a remaining term approximating the expected life of the options. The forfeiture rate was determined using historical pre-vesting forfeiture rates since the inception of the plans. We have never paid a dividend, and as such, the dividend yield is zero.

In connection with the stock options exercised during the year ended December 31, 2009, we received cash proceeds of $575,000. At December 31, 2009, there was $1.7 million of total unrecognized compensation costs related to non-vested stock options, which is expected to be recognized over a weighted average period of 1.5 years.
6. Share-Based Compensation (Continued)

A summary of stock option activity for the years ended December 31, 2009, 2008 and 2007 is as follows:

<table>
<thead>
<tr>
<th></th>
<th>Number of Shares</th>
<th>Weighted Average Exercise Price</th>
<th>Weighted Average Remaining Contractual Life</th>
<th>Aggregate Intrinsic Value (in thousands)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outstanding at January 1, 2007</td>
<td>695,915</td>
<td>$2.05</td>
<td>8.3-years</td>
<td></td>
</tr>
<tr>
<td>Granted</td>
<td>373,500</td>
<td>$18.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exercised</td>
<td>(141,312)</td>
<td>$(0.42)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Forfeited or canceled</td>
<td>(47,693)</td>
<td>$(12.49)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Balance, December 31, 2007</td>
<td>880,410</td>
<td>$8.64</td>
<td>8.3-years</td>
<td>$2,174</td>
</tr>
<tr>
<td>Granted</td>
<td>552,000</td>
<td>$13.56</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exercised</td>
<td>(66,545)</td>
<td>$(4.36)</td>
<td>$663</td>
<td></td>
</tr>
<tr>
<td>Forfeited or canceled</td>
<td>(154,688)</td>
<td>$(12.23)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Balance, December 31, 2008</td>
<td>1,211,177</td>
<td>$10.66</td>
<td>8.0-years</td>
<td>$2,187</td>
</tr>
<tr>
<td>Granted</td>
<td>164,750</td>
<td>$17.75</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exercised</td>
<td>(75,911)</td>
<td>$(7.57)</td>
<td>$497</td>
<td></td>
</tr>
<tr>
<td>Forfeited or canceled</td>
<td>(299,254)</td>
<td>$(14.96)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Balance, December 31, 2009</td>
<td>1,000,762</td>
<td>$10.78</td>
<td>7.0-years</td>
<td>$2,179</td>
</tr>
<tr>
<td>Exercisable at December 31, 2009</td>
<td>521,948</td>
<td>$6.24</td>
<td>6.0-years</td>
<td></td>
</tr>
</tbody>
</table>

A summary of stock options outstanding at December 31, 2009, by price range is as follows:

<table>
<thead>
<tr>
<th>Range of Exercise Prices</th>
<th>Number Outstanding</th>
<th>Weighted-Average Remaining Contractual Life (in years)</th>
<th>Weighted-Average Exercise Price</th>
<th>Number Outstanding</th>
<th>Weighted-Average Exercise Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ 0.40 to $ 1.00</td>
<td>322,762</td>
<td>5.1</td>
<td>$0.40</td>
<td>322,574</td>
<td>$0.40</td>
</tr>
<tr>
<td>1.01 to 6.75</td>
<td>1,000</td>
<td>9.8</td>
<td>6.51</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.76 to 10.00</td>
<td>38,250</td>
<td>6.6</td>
<td>6.84</td>
<td>18,750</td>
<td>6.84</td>
</tr>
<tr>
<td>10.01 to 12.50</td>
<td>255,000</td>
<td>7.9</td>
<td>12.07</td>
<td>83,249</td>
<td>12.05</td>
</tr>
<tr>
<td>12.51 to 15.00</td>
<td>61,500</td>
<td>8.0</td>
<td>13.54</td>
<td>18,125</td>
<td>13.86</td>
</tr>
<tr>
<td>15.01 to 17.50</td>
<td>72,500</td>
<td>8.5</td>
<td>17.03</td>
<td>18,500</td>
<td>17.03</td>
</tr>
<tr>
<td>17.51 to 20.00</td>
<td>129,250</td>
<td>8.9</td>
<td>18.56</td>
<td>500</td>
<td>19.55</td>
</tr>
<tr>
<td>$20.01 to $24.00</td>
<td>120,500</td>
<td>7.1</td>
<td>23.59</td>
<td>60,250</td>
<td>23.59</td>
</tr>
<tr>
<td></td>
<td>1,000,762</td>
<td>7.0</td>
<td>10.78</td>
<td>521,948</td>
<td>6.24</td>
</tr>
</tbody>
</table>

The weighted fair value of options granted during the years ended December 31, 2009, 2008 and 2007 were $9.26, $8.77, and $10.61, respectively.

The table below reflects the total share-based compensation expense recognized in our income statements for the years ended December 31, 2009, 2008 and 2007. Accounting standards require
6. Share-Based Compensation (Continued)

Forfeitures to be estimated at the time an award is granted and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Pre-vesting forfeitures were estimated to be between 0% and 20% based on historical experience. For the years ended December 31, 2009, 2008 and 2007, share-based compensation expense is based on awards ultimately expected to vest and has been reduced for estimated forfeitures.

<table>
<thead>
<tr>
<th>Year ended December 31,</th>
<th>2009 (S000)</th>
<th>2008 (S000)</th>
<th>2007 (S000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research and development</td>
<td>$ 959</td>
<td>$ 652</td>
<td>$ 608</td>
</tr>
<tr>
<td>General and administrative</td>
<td>1,497</td>
<td>975</td>
<td>663</td>
</tr>
<tr>
<td>Discontinued operations</td>
<td>98</td>
<td>187</td>
<td>69</td>
</tr>
<tr>
<td>Share-based compensation</td>
<td>$2,554</td>
<td>$1,814</td>
<td>$1,340</td>
</tr>
</tbody>
</table>

7. Related Party Transactions

**Peter Friedli.** Peter Friedli, the Chairman of our Board of Directors, or entities with which he is affiliated, have been responsible for procuring since 1993, an aggregate of approximately $270 million in debt and equity financing for us and our predecessor company. Mr. Friedli is the beneficial owner of approximately 44% of our common stock as of December 31, 2009. Of the shares beneficially owned by Mr. Friedli at December 31, 2009, 45,000 shares were received by him as Board compensation since 1996, 12,500 shares and warrants for 1,000,000 shares were granted in recognition of his fundraising efforts, as discussed below, and the remaining shares were acquired through investment or through purchase from third parties.

**Private Placement Financings During the Three Years Ended December 31, 2009.** Freidli Corporate Finance, Inc, or FCF, has served as our agent in Europe in connection with the fundraising efforts described below. Mr. Friedli is the sole owner of FCF.

- the issuance and sale in 2006 of $20 million of our Convertible Notes to non-U.S. investors, which were converted into an aggregate of 1,553,361 shares of our common stock in December 2007 and January 2008, at prices above the NASDAQ closing price on the dates of conversion. Mr. Friedli and an entity affiliated with Mr. Friedli purchased $8.5 million of these Notes, and the Notes acquired by the affiliated entity were subsequently purchased by Mr. Friedli in a separate transaction between those parties;
- the issuance and sale in June 2007 of 1,757,469 shares of our common stock in a private placement to non-U.S. investors at a purchase price of $11.38 per share, which represented the NASDAQ closing price on the date of the transaction, representing gross proceeds of $20.0 million. Mr. Friedli purchased 1,230,299 shares of our common stock issued in this private placement, representing gross proceeds of $14 million;
- the issuance and sale in December 2007 of 950,000 shares of our common stock in a private placement to non-U.S. investors at a purchase price of $12.37 per share, which represented the NASDAQ closing price on the date of the transaction, representing gross proceeds of
$11.8 million. Mr. Friedli purchased 100,000 shares of our common stock issued in this private placement, representing aggregate proceeds of $1.2 million;

- the issuance and sale during 2008 of $10.5 million of Convertible Notes to non-U.S. investors bearing interest at between 2% and 4%, which were converted into an aggregate of 851,914 shares of our common stock in November 2008, at prices equal to the NASDAQ closing price on the dates the definitive agreements were entered into. Mr. Friedli and an entity affiliated with Mr. Friedli purchased $5 million of these Notes which were converted into an aggregate of 395,104 shares of our common stock. Prior to conversion of these Notes, an aggregate of $147,000 in interest was paid to the holders of the Notes, including $32,000 in interest paid to Mr. Friedli; and

- the issuance and sale during 2008 of $6.5 million of Short-term Promissory Notes to non-US investors bearing interest at 10% semi-annually, which were redeemed during November 2008. Mr. Friedli purchased $4 million of these Notes. Prior to redemption of these Notes, an aggregate of $434,000 in interest was paid to the holders of the Notes, including $326,000 in interest paid to Mr. Friedli.

In October 2007, we also obtained a $30.0 million financing commitment from FCF. This financing commitment was for a twelve month term and provided for financing through the issuance by us of common stock at a price determined as the basis of market value, or the issuance by us of three-year promissory notes bearing interest at LIBOR plus 4%. We did not incur any fees in connection with the establishment of this financing commitment, nor did we draw any funds on this financing comment, which has since expired.

Our Board of Directors, including all of our independent directors, but with Mr. Friedli abstaining, together with the audit committee for all transactions occurring following our initial public offering, unanimously approved each of these financings, including the participation of Mr. Friedli and entities affiliated with Mr. Friedli and the arrangements with FCF.

We did not pay any fees for any of the financings arranged in 2007 through Mr. Friedli or entities with which he is affiliated. In 2008, we accrued $150,000 for fees payable to Mr. Friedli or entities with which he is affiliated in connection with the $17 million of financing provided by him during 2008. These fees are classified as Interest Paid to Related Parties in the accompanying statement of operations. We did not pay any cash fees to Mr. Friedli during 2009.

To facilitate borrowings and other financings prior to our initial public offering, and for commitments of consideration in respect of yet additional financing if needed, we issued warrants for an aggregate of 1,250,000 shares at an exercise price of $0.40 per share. Mr. Friedli subsequently arranged for the acquisition of those warrants and they have since been cancelled. In recognition of his efforts in procuring financing over the years and the cancellation of all of these warrants, in 2006, we issued a new warrant to Mr. Friedli, exercisable for up to 1,000,000 shares of our common stock at $11.00 per share, the price for which shares were sold in the initial public offering. This warrant expires in May 2011.

**Lockup Agreement.** On October 30, 2006, we entered into a Lockup Agreement with Mr. Friedli, Venturetec, Inc. and U.S. Venture 05, Inc. Pursuant to the Lockup Agreement, Mr. Friedli and such
7. Related Party Transactions (Continued)

entities initially agreed with us, subject to limited exceptions, not to transfer our securities held by them
without our approval, until January 30, 2008. The Lockup Agreement was amended in September 2007,
by an Amendment to Lockup Agreement, pursuant to which Mr. Friedli and Venturetec, Inc agreed to
extend the term of the Lockup Agreement as applicable to them, until January 30, 2009. The term of
the Amended Lockup Agreement expired on January 30, 2009.

8. Warrants

At December 31, 2009, we had an outstanding warrant to purchase 1,000,000 shares of our
common stock at an exercise price of $11.00 per share. As of December 31, 2009, a summary of the
status of the warrant is as follows:

<table>
<thead>
<tr>
<th>Warrant Price</th>
<th>Common Shares</th>
<th>Weighted Average Remaining Contractual Life</th>
<th>Intrinsic Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>$11.00</td>
<td>1,000,000</td>
<td>1.5 years</td>
<td>$—</td>
</tr>
</tbody>
</table>

The warrant was issued during 2006 prior to our IPO, and has an exercise price of $11.00. We
computed the value of this warrant using the Black-Scholes option pricing method, using a risk free
interest rate of 4.80%, the expected life of 2.5-years and a stock volatility factor of 44.66%. Since the
Company just recently completed its initial public offering at the time of the valuation, and previously
its stock did not trade, we determined the volatility by selecting a comparable public company in the
biotech industry and tracking its stock prices over the past 2.5-years. The value of this warrant was
determined to be $3.5 million, which was expensed during 2006.

9. Income Taxes

The provision for income taxes in 2009 represents the U.S. Federal alternative minimum tax of
$1.6 million on our taxable income. Our 2009 total tax expense comprises of the income tax benefit of
$(2.6) million from our continuing operations and the tax expense of $4.2 million on the gain from the
discontinued operations. We did not incur any income taxes on our net losses during 2008 or 2007.

The effective tax rate varies from the U.S. Federal Statutory tax rate principally due to the
following:

<table>
<thead>
<tr>
<th>Tax Component</th>
<th>2009</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S. Federal Statutory tax rate</td>
<td>35.0%</td>
<td>35.0%</td>
</tr>
<tr>
<td>State taxes, net of federal benefits</td>
<td>5.4</td>
<td>5.4</td>
</tr>
<tr>
<td>Non-deductible expenses</td>
<td>45.3</td>
<td>—</td>
</tr>
<tr>
<td>Change in Valuation Allowance</td>
<td>(75.7)</td>
<td>(40.4)</td>
</tr>
<tr>
<td>Valuation allowance</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Other</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Effective tax rate</td>
<td>10.0%</td>
<td>—%</td>
</tr>
</tbody>
</table>

Non-deductible expenses represent primarily research and development expenses for which we claimed
the orphan drug credit for 2009.
9. Income Taxes (Continued)

The components of our net deferred tax assets and liabilities at December 31 are as follows:

<table>
<thead>
<tr>
<th></th>
<th>2009 ($000)</th>
<th>2008 ($000)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Deferred Tax Assets:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net operating loss carry-forwards</td>
<td>$ 2,106</td>
<td>$ 30,047</td>
</tr>
<tr>
<td>Research and orphan drug credit carry-forwards</td>
<td>74,879</td>
<td>54,677</td>
</tr>
<tr>
<td>Alternative minimum tax credit carry-forwards</td>
<td>1,613</td>
<td>—</td>
</tr>
<tr>
<td><strong>Total Deferred Tax Assets:</strong></td>
<td>$ 78,598</td>
<td>$ 84,724</td>
</tr>
<tr>
<td>Valuation allowance</td>
<td>(65,263)</td>
<td>(84,724)</td>
</tr>
<tr>
<td><strong>Net deferred tax assets:</strong></td>
<td>$ 13,335</td>
<td>$ —</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2009 ($000)</th>
<th>2008 ($000)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Deferred Tax Liabilities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>$ 13,335</td>
<td>$ —</td>
</tr>
</tbody>
</table>

Our deferred tax assets have been fully reserved in both 2009 and 2008 since their ultimate future realization cannot be assured. We presently have available for federal income tax purposes, approximately $5.2 million of net operating loss carry-forwards and $74.9 million of research and experimentation credit carry-forwards, which expire beginning in 2025 through 2029. In 2009, we were subject to the alternative minimum tax and in the future, we may continue to be subject to the alternative minimum tax regardless of our net operating loss carry-forwards.

During 2009, we amended our federal income tax returns for the years ended December 31, 2006 and December 31, 2007 to revise the amount of net operating losses and tax credits generated in those years and available as carryover deferred tax assets at December 31, 2009. Our deferred tax assets at December 31, 2009 include the additional tax credit carryovers as a result of the amended federal income tax returns.

Generally, corporations with tax attribute carryovers such as net operating losses and tax credits (“Loss Corporations”) may become subject to an annual limitation as to the amount of tax attributes that may be available for use for federal income tax purposes. In general, Sections 382 and 383 of the Internal Revenue Code generally limit the annual amount of net operating loss and credit carryovers of Loss Corporations when such Loss Corporations experience an ownership change. An ownership change occurs if one or more “5-percent shareholders” increase their ownership in the Loss Corporation stock, in the aggregate, by more than 50 percentage points during a 3-year “testing period.” The regulations governing the determination of a corporation’s 5-percent shareholders attempt to identify the individuals who, directly or pursuant to certain attribution rules, are the beneficial owners of the Loss Corporation stock and, correspondingly, benefit from the use its tax attribute carryovers. Generally, the annual limitations are determined with reference to the value of the underlying corporation.

We performed a limited period analysis from February 21, 2003 to December 31, 2008 and determined that we had experienced three ownership changes during this period. Accordingly, the majority of our net operating losses and all of our tax credits that were generated from our inception through February 11, 2005, the date of the last ownership change, are expected to expire unused.
9. Income Taxes (Continued)

Notwithstanding the net operating losses used to offset our taxable income for the year ended December 31, 2009, we maintain a full valuation allowance on its deferred tax assets after taking into account available sources of taxable income in accordance with the accounting for income taxes.

Effective January 1, 2007, we adopted the provisions of the accounting pronouncement clarifying the accounting for uncertain tax positions. The pronouncement prescribes a recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The pronouncement also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. We have evaluated our tax positions in the tax returns filed, as well as un-filed tax positions and the amounts comprising our deferred tax assets. We have determined that the pronouncement does not have a material impact on our financial condition, results of operations or cash flows.

10. Defined Contribution Plan

We have a 401(k) plan that is available to all employees. Employee contributions are voluntary and are determined on an individual basis up to the amount allowable under federal regulations. Employer contributions to the plan are at the discretion of the Board of Directors and vest over a seven year period beginning after the third year of eligibility. No employer contributions have been made to date.

11. Commitments and Contingencies

Contract Research Organizations. We utilize independent contract research organizations ("CROs") to perform the clinical trials of our biological drug candidates to utilize their testing expertise and to ensure the objectivity of the clinical results. Under the terms of these agreements, we design the protocol regarding the testing to be performed, and the CRO enrolls the patients and testing sites, administers the trial, performs statistical analysis of the results, and compiles the final report.

We pay fees directly to the CROs for their professional services, which may be payable upon specified trial milestones or as they provide services, depending on the structure of the contract. We are also responsible for reimbursing the CROs for certain pass thru expenses they incur in administering the trial. The timing of our payments to the CROs is dependent upon the progress of the various trials, which is highly variable dependent upon the speed with which the CROs are able to enroll patients and testing sites. As such, we are unable to specifically predict the timing of future payments to CROs.

As of December 31, 2009, we had active contracts with CROs related to four on-going clinical trials which were in varying stages of completion. The total contracted payments to CROs under these agreements were $29.6 million, of which we had incurred approximately $14.0 million as of that date.
11. Commitments and Contingencies (Continued)

Although we cannot directly control the timing of the remaining payments, based on our estimates and assumptions as of December 31, 2009, we expect to make payments to CROs as follows:

<table>
<thead>
<tr>
<th>Estimated CRO Payments ($000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
</tr>
<tr>
<td>2011</td>
</tr>
<tr>
<td>2012</td>
</tr>
<tr>
<td><strong>Total</strong></td>
</tr>
</tbody>
</table>

**Clinical Manufacturing Services Agreement.** In 2005, we contracted with Lonza Walkersville, Inc. ("Lonza") to provide lot screening services for the isolation, growth, and differentiation of the MSCs to be used in our biological drug candidates. Due to the long production cycle for MSCs, we are obligated to provide Lonza a twelve month future forecast production plan for our MSC requirements. Lonza then produces the MSC doses according to our production plan at a fixed price per dose. The price per dose is based upon our volume commitment level.

In June 2008, the Clinical Manufacturing Services Agreement with Lonza was amended such that the term of the agreement is five years, provided that we continue to provide a forecast production plan to Lonza. We have the right to terminate the contract with thirty days written notice. In the event we terminate the contract, we are obligated for any in-process production as of the termination date that has been initiated according to our production forecast. Accordingly, our minimum contractual commitment under this contract is limited to in-process production at any given time. Our obligation would not extend for a period longer than twelve months, which is the maximum outlook of the production forecast that we provide to Lonza.

Our expenses under this agreement were $19.7 million and $15.6 million during the years ended December 31, 2009 and 2008, respectively. Based on our current forecast production plan, we do not have a future minimum contractual commitment under this contract for 2010.

**Leases.** During 2006, we entered into a sublease agreement for approximately 61,000 square feet of laboratory, production, warehouse and office space in Columbia, Maryland. We have also entered into a direct lease with the owner of this facility that was effective as of June 1, 2009 upon the expiration of the sublease and expires in July 2016. During 2009, following the expiration of the sublease agreement, we increased an outstanding letter of credit, which was used in lieu of a security deposit for this lease, to $591,000 according to the terms of the direct lease with the owner of the facility. This letter of credit remained outstanding as of December 31, 2009, and has been fully collateralized by restricted cash.
11. Commitments and Contingencies (Continued)

The future minimum lease payments due under the operating lease for this facility are as follows:

<table>
<thead>
<tr>
<th>Year</th>
<th>Columbia Facility ($000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>$1,056</td>
</tr>
<tr>
<td>2011</td>
<td>1,082</td>
</tr>
<tr>
<td>2012</td>
<td>1,109</td>
</tr>
<tr>
<td>2013</td>
<td>1,137</td>
</tr>
<tr>
<td>2014 - 2016</td>
<td>2,965</td>
</tr>
<tr>
<td></td>
<td><strong>$7,349</strong></td>
</tr>
</tbody>
</table>

Payments under these leases were $957,000, $827,000, and $822,000 during 2009, 2008, and 2007, respectively:

We also have entered into various financing arrangements to lease laboratory and other equipment. The terms of these facilities and equipment leases are considered capitalized leases, and the following amounts are included in our balance sheets at December 31, 2009 and 2008:

<table>
<thead>
<tr>
<th></th>
<th>2009 ($000)</th>
<th>2008 ($000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Facilities leases</td>
<td>$—</td>
<td>$—</td>
</tr>
<tr>
<td>Equipment leases</td>
<td>26</td>
<td>26</td>
</tr>
<tr>
<td>Less—accumulated amortization</td>
<td>(20)</td>
<td>(17)</td>
</tr>
<tr>
<td>Leased property and equipment, net</td>
<td>$6</td>
<td>$9</td>
</tr>
</tbody>
</table>

Future minimum lease payments under these capitalized facilities and equipment arrangements as of December 31, 2009 are $3,000, all of which will be made during 2010.

**Technology Transfer and License Agreement.** In 1994, we entered into a Technology Transfer and License Agreement with Case Western Reserve University (“CWRU”) under which we purchased rights to certain mesenchymal stem cell and related technology and patents. We are required to pay royalties on revenues related to CWRU developed technology, with minimum royalties of $50,000 per year. We paid CWRU $50,000 in 2009, $64,000 in 2008 and $50,000 in 2007 under this agreement.

**Legal.** We are subject to certain litigation, claims and assessments which occur in the normal course of business. Based on consultation with our legal counsel, management is of the opinion that such matters, when resolved, will not have a material impact on our consolidated results of operations, financial position or cash flows.

12. Investments Available for Sale

As discussed above in Note 3—Segment Reporting, Discontinued Operations, & Gain on Sale of Discontinued Operations, NuVasive, Inc. paid us a total of $40.0 million in freely tradable shares of its
12. Investments Available for Sale (Continued)

common stock, as provided for under the amended Asset Purchase Agreement. Comprising this amount, the $12.5 million payments due June 30, 2009 and September 30, 2009, as well as the final $15.0 million milestone achieved in October 2009, were paid in shares of common stock issued by NuVasive. The number of shares delivered to us at each payment date was determined based upon the average closing price of NuVasive’s common stock over a ten-day period.

Cumulatively, we have received 1,001,422 shares of NuVasive common stock, of which we have sold 986,122 for total cash proceeds of approximately $40.3 million, which as been invested in accordance with our Investment Policy. At December 31, 2009, we had the remaining 15,300 shares, with a fair value of $489,000, included as a component of Investments Available for Sale on our balance sheet.

As a result of these transactions, we recognized approximately $0.9 million in gains on the sale of the NuVasive shares and had recorded an unrealized loss of approximately $0.1 million at December 31, 2009, as a component of Other Comprehensive Loss.

Investments available for sale consisted of the following as of December 31, 2009 and 2008:

<table>
<thead>
<tr>
<th></th>
<th>2009 ($000)</th>
<th>2008 ($000)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cost</td>
<td>Fair Value</td>
</tr>
<tr>
<td><strong>Cash equivalents:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Money market funds &amp; certificates of deposit</td>
<td>$23,706</td>
<td>$23,707</td>
</tr>
<tr>
<td>Commercial paper</td>
<td>19,393</td>
<td>19,393</td>
</tr>
<tr>
<td><strong>Total cash equivalents:</strong></td>
<td>43,099</td>
<td>43,100</td>
</tr>
<tr>
<td><strong>Short term investments:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Auction rate certificates</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Common stock</td>
<td>573</td>
<td>489</td>
</tr>
<tr>
<td>Corporate notes and bonds</td>
<td>42,586</td>
<td>42,577</td>
</tr>
<tr>
<td>US government agencies</td>
<td>13,239</td>
<td>13,243</td>
</tr>
<tr>
<td><strong>Total short term investments:</strong></td>
<td>56,398</td>
<td>56,309</td>
</tr>
<tr>
<td><strong>Total investments available for sale:</strong></td>
<td>$99,497</td>
<td>$99,409</td>
</tr>
</tbody>
</table>

The following table summarizes maturities of our investments available for sale as of December 31, 2009 and 2008:

<table>
<thead>
<tr>
<th></th>
<th>2009 ($000)</th>
<th>2008 ($000)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cost</td>
<td>Fair Value</td>
</tr>
<tr>
<td><strong>Maturities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Within 3-months</td>
<td>$28,330</td>
<td>$28,240</td>
</tr>
<tr>
<td>Between 3 - 12 months</td>
<td>65,824</td>
<td>65,819</td>
</tr>
<tr>
<td>Between 1 - 2 years</td>
<td>5,343</td>
<td>5,350</td>
</tr>
<tr>
<td><strong>Total investments available for sale:</strong></td>
<td>$99,497</td>
<td>$99,409</td>
</tr>
</tbody>
</table>
13. Fair Value

Fair value is defined as the price at which an asset could be exchanged or a liability transferred (an exit price) in an orderly transaction between knowledgeable, willing parties in the principal or most advantageous market for the asset or liability. Where available, fair value is based on observable market prices or parameters or derived from such prices or parameters. Where observable prices or inputs are not available, valuation models are applied.

Financial assets recorded at fair value in the accompanying financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, and are as follows:

Level 1 Inputs are unadjusted, quoted prices in active markets for identical assets at the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.

The fair valued assets we hold that are generally included in this category are money market securities where fair value is based on publicly quoted prices.

Level 2 Inputs are other than quoted prices included in Level 1, which are either directly or indirectly observable for the asset or liability through correlation with market data at the reporting date and for the duration of the instrument’s anticipated life.

The fair valued assets we hold that are generally included in this category are investment grade short-term securities.

Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities and which reflect management’s best estimate of what market participants would use in pricing the asset or liability at the reporting date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

We carry no investments classified as Level 3.

Assets and liabilities measured at fair value on a recurring basis are summarized below as of December 31, 2009 and 2008:

<table>
<thead>
<tr>
<th></th>
<th>2009 ($000)</th>
<th></th>
<th></th>
<th>2008 ($000)</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Level 1</td>
<td>Level 2</td>
<td>Total</td>
<td>Level 1</td>
<td>Level 2</td>
<td>Total</td>
</tr>
<tr>
<td>Assets:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overnight securities included in Cash . . . .</td>
<td>$ —</td>
<td>$ —</td>
<td>$ —</td>
<td>$ 929</td>
<td>$ —</td>
<td>$ 929</td>
</tr>
<tr>
<td>Investments available for sale . . . . . . .</td>
<td>30,313</td>
<td>69,096</td>
<td>99,409</td>
<td>61,298</td>
<td>—</td>
<td>61,298</td>
</tr>
<tr>
<td>Total assets . . . . . . . . . . . . . . . .</td>
<td>$30,313</td>
<td>$69,096</td>
<td>$99,409</td>
<td>$62,227</td>
<td>$ —</td>
<td>$62,227</td>
</tr>
</tbody>
</table>
14. Quarterly Financial Data (Unaudited)

Following is a summary of our unaudited quarterly results for the years ended December 31, 2009 and 2008:

<table>
<thead>
<tr>
<th>Year</th>
<th>First Quarter</th>
<th>Second Quarter</th>
<th>Third Quarter</th>
<th>Fourth Quarter</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenues</td>
<td>$12,726</td>
<td>$10,469</td>
<td>$10,584</td>
<td>$10,754</td>
</tr>
<tr>
<td>Research and development expenses</td>
<td>18,567</td>
<td>18,540</td>
<td>16,247</td>
<td>9,912</td>
</tr>
<tr>
<td>General and administrative expenses and fees</td>
<td>2,913</td>
<td>2,321</td>
<td>1,511</td>
<td>2,062</td>
</tr>
<tr>
<td>Loss from continuing operations</td>
<td>(7,908)</td>
<td>(8,587)</td>
<td>(6,802)</td>
<td>(267)</td>
</tr>
<tr>
<td>Income (loss) from discontinued operations</td>
<td>22,667</td>
<td>(1,094)</td>
<td>608</td>
<td>15,955</td>
</tr>
<tr>
<td>Net income (loss)</td>
<td>14,759</td>
<td>(9,681)</td>
<td>(6,194)</td>
<td>15,688</td>
</tr>
</tbody>
</table>

** Loss per share from continuing operations, basic and diluted **  
**Income per share from discontinued operations, basic and diluted **  
**Net income (loss) per share, basic and diluted **

2008

<table>
<thead>
<tr>
<th>Year</th>
<th>First Quarter</th>
<th>Second Quarter</th>
<th>Third Quarter</th>
<th>Fourth Quarter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td>$ 362</td>
<td>$ 2,530</td>
<td>$ 995</td>
<td>$ 6,157</td>
</tr>
<tr>
<td>Research and development expenses</td>
<td>16,694</td>
<td>19,048</td>
<td>18,592</td>
<td>15,563</td>
</tr>
<tr>
<td>General and administrative expenses and fees</td>
<td>2,608</td>
<td>1,782</td>
<td>1,887</td>
<td>2,309</td>
</tr>
<tr>
<td>Loss from continuing operations</td>
<td>(19,149)</td>
<td>(18,472)</td>
<td>(19,903)</td>
<td>(11,893)</td>
</tr>
<tr>
<td>Income (loss) from discontinued operations</td>
<td>3,549</td>
<td>3,104</td>
<td>25,155</td>
<td>4,117</td>
</tr>
<tr>
<td>Net (loss) income</td>
<td>(15,600)</td>
<td>(15,368)</td>
<td>5,252</td>
<td>(7,776)</td>
</tr>
</tbody>
</table>

** Loss per share is calculated on a quarterly basis and may not be additive to year-to-date amounts.

15. Subsequent Events

We evaluated our December 31, 2009 financial statements for subsequent events through the date the financial statements were available for issuance. We are not aware of any subsequent events which would require recognition or disclosure in the financial statements.

None.

ITEM 9A. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures. An evaluation of the effectiveness of the design and operation of our “disclosure controls and procedures” (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended), as of the end of the period covered by this Annual Report on Form 10-K was made under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures (a) are effective to ensure that information required to be disclosed by us in reports filed or submitted under the Securities Exchange Act of 1934 is timely recorded, processed, summarized and reported and (b) include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed or submitted under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.


Changes in Internal Control over Financial Reporting. There have not been any changes in our internal control over financial reporting that occurred during the fourth quarter of the fiscal year ended December 31, 2009 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

ITEM 9B. Other Information.

None.

PART III

Certain information required in Part III is omitted from this report, but is incorporated by reference from our definitive proxy statement for the 2010 Annual Meeting of Stockholders anticipated to be filed within 120 days after the end of our fiscal year ended December 31, 2009, pursuant to Regulation 14A with the Securities and Exchange Commission.

ITEM 10. Directors, Executive Officers and Corporate Governance.

The information required by this item and not set forth below is incorporated herein by reference to the information contained in the Proxy Statement.

We have adopted the Osiris Therapeutics, Inc. Code of Business Conduct & Ethics for Members of the Board of Directors and Executive Officers and the Osiris Therapeutics, Inc. Code of Conduct which applies to all our employees and members of the Board of Directors. These policies are publicly available on our website at http://www/investor.osiris.com/documents.cfm.

ITEM 11. Executive Compensation.

The information required by this item is incorporated herein by reference to the information contained in the Proxy Statement.

The information required by this item is incorporated herein by reference to the information contained in the Proxy Statement.

ITEM 13. Certain Relationships and Related Transactions, and Director Independence.

The information required by this item is incorporated herein by reference to the information contained in the Proxy Statement.

ITEM 14. Principal Accounting Fees and Services.

The information required by this item is incorporated herein by reference to the information contained in the Proxy Statement.

PART IV


(a) The following documents are filed as part of this report:

1. The following financial statements are included in Item 8 of this Annual Report:
   
   Management’s Report on Internal Control over Financial Reporting
   Report of Independent Registered Public Accounting Firm on Fiscal 2009
   Balance Sheets as of December 31, 2009 and 2008
   Statements of Operations for the years ended December 31, 2009, 2008 and 2007
   Statements of Stockholders’ Equity (Deficit) for the years ended December 31, 2009, 2008 and 2007
   Notes to Financial Statements

   Schedules not listed above have been omitted because the information required to be set forth therein is not applicable.

2. Exhibits:

<table>
<thead>
<tr>
<th>Exhibit Number</th>
<th>Description of Exhibit</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.1†</td>
<td>Amended and Restated Certificate of Incorporation of the Registrant.</td>
</tr>
<tr>
<td>3.2†</td>
<td>Amended and Restated Bylaws of the Registrant.</td>
</tr>
<tr>
<td>4.†</td>
<td>Form of Common Stock Certificate.</td>
</tr>
<tr>
<td>10.1†</td>
<td>Amended and Restated 1994 Stock Incentive Plan, as amended.</td>
</tr>
<tr>
<td>10.2</td>
<td>Amended and Restated 2006 Omnibus Plan. (Incorporated herein by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed by the Registrant with the SEC on August 11, 2008).</td>
</tr>
<tr>
<td>10.3†</td>
<td>Director Compensation Policy.</td>
</tr>
<tr>
<td>10.4†</td>
<td>Employment Agreement by and between the Registrant and C. Randal Mills, Ph.D., dated as of May 15, 2004.</td>
</tr>
<tr>
<td>Exhibit Number</td>
<td>Description of Exhibit</td>
</tr>
<tr>
<td>----------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>10.5†</td>
<td>Investor Rights Agreement by and between the Registrant and JCR Pharmaceuticals, Inc. dated August 26, 2003.</td>
</tr>
<tr>
<td>10.6†*</td>
<td>License Agreement by and between the Registrant and JCR Pharmaceuticals, Inc. dated August 26, 2003.</td>
</tr>
<tr>
<td>10.7†</td>
<td>Technology Transfer and License Agreement by and between the Registrant and Case Western University, dated as of January 1, 1993, as amended.</td>
</tr>
<tr>
<td>10.8†</td>
<td>Warrant to Purchase up to 1,000,000 shares of Common Stock granted by Registrant to Peter Friedli, dated May 24, 2006.</td>
</tr>
<tr>
<td>10.9†</td>
<td>Employment Agreement, dated July 31, 2006, by and between the Registrant and Lode Debrabandere.</td>
</tr>
<tr>
<td>10.11</td>
<td>Form of Subscription Agreements, entered into on March 19 and March 24, 2008, by and between the Registrant and certain non-U.S. Purchasers in connection with the issuance and sale of $8.0 million in Convertible Promissory Notes in the aggregate (Incorporated herein by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed by the Registrant with the SEC on May 12, 2008).</td>
</tr>
<tr>
<td>10.12</td>
<td>Form of 2% Convertible Promissory Notes of the Registrant, dated March 19 and March 24, 2008, issued in the aggregate principal amount of $8 million to certain non-U.S. Purchasers (Incorporated herein by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q filed by the Registrant with the SEC on May 12, 2008).</td>
</tr>
<tr>
<td>10.13</td>
<td>Asset Purchase Agreement, dated May 8, 2008, by and between the Registrant and NuVasive, Inc. (Incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Registrant with the SEC on May 12, 2008).</td>
</tr>
<tr>
<td>10.15</td>
<td>Form of Subscription Agreements, dated June 12, 2008 and June 30, 2008, respectively, by and between the Registrant and certain non-U.S. purchasers in connection with the issuance and sale of Promissory Notes in the aggregate principal amount of $5.5 million (Incorporated herein by reference to Exhibit 10.4 to the Quarterly Report on Form 10-Q filed by the Registrant with the SEC on August 11, 2008).</td>
</tr>
<tr>
<td>10.16</td>
<td>Form of Promissory Notes of the Registrant, dated June 12, 2008 and June 30, 2008, issued to certain non-U.S. purchasers in the aggregate principal amount of $5.5 million (Incorporated herein by reference to Exhibit 10.5 to the Quarterly Report on Form 10-Q filed by the Registrant with the SEC on August 11, 2008).</td>
</tr>
<tr>
<td>10.17**</td>
<td>Manufacturing Agreement, dated as of July 24, 2008, by and between the Registrant and NuVasive, Inc. (Incorporated herein by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed by the Registrant with the SEC on November 10, 2008).</td>
</tr>
<tr>
<td>Exhibit Number</td>
<td>Description of Exhibit</td>
</tr>
<tr>
<td>----------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>10.18**</td>
<td>Amendment to Manufacturing Agreement, dated as of September 30, 2008, by and between Registrant and NuVasive, Inc. (Incorporated herein by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q filed by the Registrant with the SEC on November 10, 2008).</td>
</tr>
<tr>
<td>10.19**</td>
<td>Amendment to Asset Purchase Agreement, dated as of September 30, 2008, by and between Registrant and NuVasive, Inc. (Incorporated herein by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q filed by the Registrant with the SEC on November, 2008).</td>
</tr>
<tr>
<td>10.20</td>
<td>Employment Agreement by and between Osiris Therapeutics, Inc. and Richard W. Hunt entered into as of July 23, 2008 (Incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Registrant with the SEC on July 29, 2008).</td>
</tr>
<tr>
<td>10.22</td>
<td>Amendment No. 3 to Manufacturing Agreement, dated as of March 25, 2009, by and between Osiris Therapeutics, Inc. and NuVasive, Inc. (Incorporated herein by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed by the Registrant with the SEC on May 11, 2009).</td>
</tr>
<tr>
<td>10.23</td>
<td>Amendment No. 2 to Asset Purchase Agreement, dated as of March 25, 2009, by and between Osiris Therapeutics, Inc. and NuVasive, Inc. (Incorporated herein by reference to Exhibit 10.2 to Quarterly Report on Form 10-Q filed by the Registrant with the SEC on May 11, 2009).</td>
</tr>
<tr>
<td>10.24****</td>
<td>Supply Agreement, dated as of March 25, 2009, by and between Osiris Therapeutics, Inc. and AlloSource. (Incorporated herein by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q filed by the Registrant with the SEC on May 11, 2009).</td>
</tr>
<tr>
<td>10.26†</td>
<td>Lease Agreement by and between Gateway S-8, LLLP and Nova Telecommunications, Inc., dated August 11, 1998, as amended</td>
</tr>
<tr>
<td>10.27†</td>
<td>Agreement of Lease by and between the Registrant and Columbia Gateway S-28, L.L.C., dated June 6, 2006</td>
</tr>
<tr>
<td>11.1.1</td>
<td>Statement re: Computation of Per Share Loss (included in Note 2 to Financial Statements included in Part II Item 8 herein).</td>
</tr>
<tr>
<td>23.1.1</td>
<td>Consent of Grant Thornton LLP (filed herewith).</td>
</tr>
<tr>
<td>23.1.2</td>
<td>Consent of Stegman &amp; Company (filed herewith).</td>
</tr>
<tr>
<td>31.1.1</td>
<td>Rule 15d-14(a) Certification of C. Randal Mills, President and Chief Executive Officer (filed herewith).</td>
</tr>
<tr>
<td>31.2.1</td>
<td>Rule 15d-14(a) Certification of Philip R. Jacoby, Jr., Chief Financial Officer (filed herewith).</td>
</tr>
<tr>
<td>Exhibit Number</td>
<td>Description of Exhibit</td>
</tr>
<tr>
<td>---------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>32.1.1</td>
<td>Section 1350 Certification of C. Randal Mills, Chief Executive Officer, and Philip R. Jacoby, Jr., Chief Financial Officer (filed herewith).</td>
</tr>
</tbody>
</table>

† Incorporated herein by reference to corresponding Exhibit to the Registrant’s Registration Statement on Form S-1, which was declared effective by the SEC on August 3, 2006.

* Confidential treatment has been granted for certain portions thereof pursuant to an order of the United States Securities and Exchange Commission issued in response to a Confidential Treatment Application filed by the Registrant in connection with its Registration Statement on Form S-1, declared effective on August 3, 2006.

** Confidential treatment has been granted for certain portions thereof pursuant to an order of the United States Securities and Exchange Commission issued in response to a Confidential Treatment Application filed by the Registrant in connection with its Quarterly Report on Form 10-Q, for the quarterly period ended September 30, 2008.

*** Confidential treatment has been granted for certain portions thereof pursuant to an order of the United States Securities and Exchange Commission issued in response to a Confidential Treatment Application filed by the Registrant in connection with its Annual Report on Form 10-K for the annual period ended December 31, 2008.

**** Confidential treatment has been granted for certain portions thereof pursuant to an order of the United States Securities and Exchange Commission issued in response to a Confidential Treatment Application filed by the Registrant in connection with its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2009.
Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

OSIRIS THERAPEUTICS, INC.

March 12, 2010

By: /s/ C. RANDAL MILLS
C. Randal Mills, Ph.D.
President & Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

/s/ C. RANDAL MILLS
C. Randal Mills, Ph.D. President and Chief Executive Officer (principal executive officer) March 12, 2010

/s/ PHILIP R. JACOBY, JR.
Philip R. Jacoby, Jr. Chief Financial Officer (principal financial officer) March 12, 2010

/s/ MATTHEW NEUMAYER
Matthew Neumayer Corporate Controller (Principal Accounting Officer) March 12, 2010

/s/ GREGORY H. BARNHILL
Gregory H. Barnhill Director March 12, 2010

/s/ PETER FRIEDLI
Peter Friedli Director March 12, 2010

/s/ FELIX GUTZWILLER
Felix Gutzwiller Director March 12, 2010

/s/ JAY M. MOYES
Jay M. Moyes Director March 12, 2010
Certification of Principal Executive Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, C. Randal Mills, certify that:

1. I have reviewed this Annual Report on Form 10-K of Osiris Therapeutics, Inc., the Registrant;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
   (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
   (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
   (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
   (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 12, 2010

/s/ C. RANDAL MILLS
C. Randal Mills, Ph.D., Chief Executive Officer
Exhibit 31.2.1

Certification of Principal Financial Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Philip R. Jacoby, Jr., certify that:

1. I have reviewed this Annual Report on Form 10-K of Osiris Therapeutics, Inc., the Registrant;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
   (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
   (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
   (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
   (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 12, 2010

/s/ PHILIP R. JACOBY, JR.
Philip R. Jacoby, Jr., Chief Financial Officer
Certification

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Osiris Therapeutics, Inc., (the “Company”), does hereby certify, to the best of each officer’s knowledge that:

The Annual Report on Form 10-K for the year ended December 31, 2009 (the “Form 10-K”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 12, 2010
/s/ C. RANDAL MILLS

C. Randal Mills, Ph.D.
Chief Executive Officer

Date: March 12, 2010
/s/ PHILIP R. JACOBY, JR.

Philip R. Jacoby, Jr.
Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. This certification “accompanies” the Form 10-K to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.
FORWARD-LOOKING STATEMENTS
This Annual Report to Shareholders may contain forward-looking statements which include statements about our expectations, beliefs, plans, objectives, intentions, assumptions, and other statements that are not historical facts. Words or phrases such as “anticipate,” “believe,” “continue,” “ongoing,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project” or similar words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Specific examples of forward-looking statements are given under the heading “Cautionary Statements About Forward-looking Information” in our Annual Report on Form 10-k for fiscal year 2009, as filed with the United States Securities and Exchange Commission, a copy of which is included in this Annual Report to Shareholders. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions. Accordingly, our actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in the section entitled “Risk Factors” in our Annual Report on Form 10-K. Consequently, the reader is cautioned to consider all forward-looking statements in light of the risks to which they are subject.